id	sid	tid	token	lemma	pos
ijpds-3747	1	1	maryam	maryam	PROPN
ijpds-3747	1	2	and	and	CCONJ
ijpds-3747	1	3	ahmad	ahmad	PROPN
ijpds-3747	1	4	safety	safety	PROPN
ijpds-3747	1	5	comparison	comparison	NOUN
ijpds-3747	1	6	of	of	ADP
ijpds-3747	1	7	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	1	8	and	and	CCONJ
ijpds-3747	1	9	belimumab	belimumab	NOUN
ijpds-3747	1	10	vol	vol	NOUN
ijpds-3747	1	11	2	2	NUM
ijpds-3747	1	12	|	|	NOUN
ijpds-3747	1	13	issue	issue	NOUN
ijpds-3747	1	14	1	1	NUM
ijpds-3747	1	15	|	|	ADV
ijpds-3747	1	16	jan	jan	PROPN
ijpds-3747	1	17	–	–	PUNCT
ijpds-3747	1	18	mar	mar	PROPN
ijpds-3747	1	19	2023	2023	NUM
ijpds-3747	1	20	indian	indian	PROPN
ijpds-3747	1	21	j	j	PROPN
ijpds-3747	1	22	pharm	pharm	PROPN
ijpds-3747	1	23	drug	drug	PROPN
ijpds-3747	1	24	studies	study	NOUN
ijpds-3747	1	25	|	|	ADV
ijpds-3747	1	26	5	5	NUM
ijpds-3747	1	27	review	review	NOUN
ijpds-3747	1	28	article	article	NOUN
ijpds-3747	1	29	comprehensive	comprehensive	ADJ
ijpds-3747	1	30	analysis	analysis	NOUN
ijpds-3747	1	31	and	and	CCONJ
ijpds-3747	1	32	critical	critical	ADJ
ijpds-3747	1	33	review	review	NOUN
ijpds-3747	1	34	of	of	ADP
ijpds-3747	1	35	randomized	randomized	ADJ
ijpds-3747	1	36	clinical	clinical	ADJ
ijpds-3747	1	37	trials	trial	NOUN
ijpds-3747	1	38	on	on	ADP
ijpds-3747	1	39	safety	safety	NOUN
ijpds-3747	1	40	profiling	profiling	NOUN
ijpds-3747	1	41	of	of	ADP
ijpds-3747	1	42	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	1	43	and	and	CCONJ
ijpds-3747	1	44	belimumab	belimumab	NOUN
ijpds-3747	1	45	zahra	zahra	PROPN
ijpds-3747	1	46	maryam1	maryam1	PROPN
ijpds-3747	1	47	,	,	PUNCT
ijpds-3747	1	48	ausaf	ausaf	PROPN
ijpds-3747	1	49	ahmad2	ahmad2	PROPN
ijpds-3747	1	50	from	from	ADP
ijpds-3747	1	51	,	,	PUNCT
ijpds-3747	1	52	1	1	NUM
ijpds-3747	1	53	m	m	NOUN
ijpds-3747	1	54	s	s	NOUN
ijpds-3747	1	55	scholar	scholar	NOUN
ijpds-3747	1	56	,	,	PUNCT
ijpds-3747	1	57	department	department	NOUN
ijpds-3747	1	58	of	of	ADP
ijpds-3747	1	59	pharmaceutical	pharmaceutical	ADJ
ijpds-3747	1	60	chemistry	chemistry	NOUN
ijpds-3747	1	61	,	,	PUNCT
ijpds-3747	1	62	faculty	faculty	NOUN
ijpds-3747	1	63	of	of	ADP
ijpds-3747	1	64	pharmacy	pharmacy	NOUN
ijpds-3747	1	65	,	,	PUNCT
ijpds-3747	1	66	anadolou	anadolou	PROPN
ijpds-3747	1	67	university	university	PROPN
ijpds-3747	1	68	,	,	PUNCT
ijpds-3747	1	69	turkey	turkey	PROPN
ijpds-3747	1	70	,	,	PUNCT
ijpds-3747	1	71	2ms	2ms	ADJ
ijpds-3747	1	72	scholar	scholar	NOUN
ijpds-3747	1	73	,	,	PUNCT
ijpds-3747	1	74	school	school	NOUN
ijpds-3747	1	75	of	of	ADP
ijpds-3747	1	76	life	life	NOUN
ijpds-3747	1	77	and	and	CCONJ
ijpds-3747	1	78	medical	medical	ADJ
ijpds-3747	1	79	sciences	science	NOUN
ijpds-3747	1	80	.	.	PUNCT
ijpds-3747	2	1	university	university	NOUN
ijpds-3747	2	2	of	of	ADP
ijpds-3747	2	3	hertfordshire	hertfordshire	PROPN
ijpds-3747	2	4	,	,	PUNCT
ijpds-3747	2	5	uk	uk	PROPN
ijpds-3747	2	6	.	.	PROPN
ijpds-3747	2	7	correspondence	correspondence	NOUN
ijpds-3747	2	8	to	to	ADP
ijpds-3747	2	9	:	:	PUNCT
ijpds-3747	2	10	zahra	zahra	PROPN
ijpds-3747	2	11	maryam	maryam	PROPN
ijpds-3747	2	12	,	,	PUNCT
ijpds-3747	2	13	m	m	PROPN
ijpds-3747	2	14	s	s	NOUN
ijpds-3747	2	15	scholar	scholar	NOUN
ijpds-3747	2	16	,	,	PUNCT
ijpds-3747	2	17	department	department	NOUN
ijpds-3747	2	18	of	of	ADP
ijpds-3747	2	19	pharmaceutical	pharmaceutical	ADJ
ijpds-3747	2	20	chemistry	chemistry	NOUN
ijpds-3747	2	21	,	,	PUNCT
ijpds-3747	2	22	faculty	faculty	NOUN
ijpds-3747	2	23	of	of	ADP
ijpds-3747	2	24	pharmacy	pharmacy	NOUN
ijpds-3747	2	25	,	,	PUNCT
ijpds-3747	2	26	anadolu	anadolu	PROPN
ijpds-3747	2	27	university	university	NOUN
ijpds-3747	2	28	,	,	PUNCT
ijpds-3747	2	29	eskişehir	eskişehir	NOUN
ijpds-3747	2	30	26470	26470	NUM
ijpds-3747	2	31	,	,	PUNCT
ijpds-3747	2	32	turkey	turkey	PROPN
ijpds-3747	2	33	.	.	PUNCT
ijpds-3747	3	1	email	email	NOUN
ijpds-3747	3	2	:	:	PUNCT
ijpds-3747	4	1	zahra.maryam489@gmail.com	zahra.maryam489@gmail.com	X
ijpds-3747	4	2	abstract	abstract	ADJ
ijpds-3747	4	3	systemic	systemic	ADJ
ijpds-3747	4	4	lupus	lupus	PROPN
ijpds-3747	4	5	erythematosus	erythematosus	NOUN
ijpds-3747	4	6	(	(	PUNCT
ijpds-3747	4	7	sle	sle	PROPN
ijpds-3747	4	8	)	)	PUNCT
ijpds-3747	4	9	,	,	PUNCT
ijpds-3747	4	10	an	an	DET
ijpds-3747	4	11	autoimmune	autoimmune	ADJ
ijpds-3747	4	12	disorder	disorder	NOUN
ijpds-3747	4	13	is	be	AUX
ijpds-3747	4	14	characterized	characterize	VERB
ijpds-3747	4	15	by	by	ADP
ijpds-3747	4	16	multiorgan	multiorgan	NOUN
ijpds-3747	4	17	damage	damage	NOUN
ijpds-3747	4	18	,	,	PUNCT
ijpds-3747	4	19	flares	flare	NOUN
ijpds-3747	4	20	,	,	PUNCT
ijpds-3747	4	21	and	and	CCONJ
ijpds-3747	4	22	heterogeneity	heterogeneity	NOUN
ijpds-3747	4	23	in	in	ADP
ijpds-3747	4	24	its	its	PRON
ijpds-3747	4	25	clinical	clinical	ADJ
ijpds-3747	4	26	symptoms	symptom	NOUN
ijpds-3747	4	27	.	.	PUNCT
ijpds-3747	5	1	the	the	DET
ijpds-3747	5	2	treatment	treatment	NOUN
ijpds-3747	5	3	strategy	strategy	NOUN
ijpds-3747	5	4	for	for	ADP
ijpds-3747	5	5	this	this	DET
ijpds-3747	5	6	notorious	notorious	ADJ
ijpds-3747	5	7	disease	disease	NOUN
ijpds-3747	5	8	focuses	focus	VERB
ijpds-3747	5	9	on	on	ADP
ijpds-3747	5	10	long	long	ADJ
ijpds-3747	5	11	-	-	PUNCT
ijpds-3747	5	12	term	term	NOUN
ijpds-3747	5	13	antisle	antisle	NOUN
ijpds-3747	5	14	treatment	treatment	NOUN
ijpds-3747	5	15	to	to	PART
ijpds-3747	5	16	improve	improve	VERB
ijpds-3747	5	17	the	the	DET
ijpds-3747	5	18	quality	quality	NOUN
ijpds-3747	5	19	of	of	ADP
ijpds-3747	5	20	life	life	NOUN
ijpds-3747	5	21	,	,	PUNCT
ijpds-3747	5	22	prevent	prevent	VERB
ijpds-3747	5	23	flares	flare	NOUN
ijpds-3747	5	24	,	,	PUNCT
ijpds-3747	5	25	and	and	CCONJ
ijpds-3747	5	26	suppress	suppress	VERB
ijpds-3747	5	27	the	the	DET
ijpds-3747	5	28	immune	immune	ADJ
ijpds-3747	5	29	system	system	NOUN
ijpds-3747	5	30	.	.	PUNCT
ijpds-3747	6	1	thus	thus	ADV
ijpds-3747	6	2	,	,	PUNCT
ijpds-3747	6	3	the	the	DET
ijpds-3747	6	4	chronic	chronic	ADJ
ijpds-3747	6	5	use	use	NOUN
ijpds-3747	6	6	of	of	ADP
ijpds-3747	6	7	sle	sle	PROPN
ijpds-3747	6	8	medicines	medicine	NOUN
ijpds-3747	6	9	makes	make	VERB
ijpds-3747	6	10	it	it	PRON
ijpds-3747	6	11	inevitable	inevitable	ADJ
ijpds-3747	6	12	to	to	PART
ijpds-3747	6	13	study	study	VERB
ijpds-3747	6	14	the	the	DET
ijpds-3747	6	15	safety	safety	NOUN
ijpds-3747	6	16	and	and	CCONJ
ijpds-3747	6	17	tolerability	tolerability	NOUN
ijpds-3747	6	18	of	of	ADP
ijpds-3747	6	19	drugs	drug	NOUN
ijpds-3747	6	20	in	in	ADP
ijpds-3747	6	21	large	large	ADJ
ijpds-3747	6	22	populations	population	NOUN
ijpds-3747	6	23	.	.	PUNCT
ijpds-3747	7	1	in	in	ADP
ijpds-3747	7	2	this	this	DET
ijpds-3747	7	3	comprehensive	comprehensive	ADJ
ijpds-3747	7	4	analytical	analytical	ADJ
ijpds-3747	7	5	study	study	NOUN
ijpds-3747	7	6	,	,	PUNCT
ijpds-3747	7	7	hydroxychloroquine	hydroxychloroquine	PROPN
ijpds-3747	7	8	(	(	PUNCT
ijpds-3747	7	9	hcq	hcq	PROPN
ijpds-3747	7	10	)	)	PUNCT
ijpds-3747	7	11	,	,	PUNCT
ijpds-3747	7	12	which	which	PRON
ijpds-3747	7	13	is	be	AUX
ijpds-3747	7	14	known	know	VERB
ijpds-3747	7	15	for	for	ADP
ijpds-3747	7	16	its	its	PRON
ijpds-3747	7	17	safe	safe	ADJ
ijpds-3747	7	18	use	use	NOUN
ijpds-3747	7	19	in	in	ADP
ijpds-3747	7	20	sle	sle	PROPN
ijpds-3747	7	21	,	,	PUNCT
ijpds-3747	7	22	and	and	CCONJ
ijpds-3747	7	23	belimumab	belimumab	NOUN
ijpds-3747	7	24	,	,	PUNCT
ijpds-3747	7	25	which	which	PRON
ijpds-3747	7	26	is	be	AUX
ijpds-3747	7	27	comparatively	comparatively	ADV
ijpds-3747	7	28	a	a	DET
ijpds-3747	7	29	novel	novel	ADJ
ijpds-3747	7	30	monoclonal	monoclonal	NOUN
ijpds-3747	7	31	antibody	antibody	NOUN
ijpds-3747	7	32	were	be	AUX
ijpds-3747	7	33	critically	critically	ADV
ijpds-3747	7	34	analyzed	analyze	VERB
ijpds-3747	7	35	for	for	ADP
ijpds-3747	7	36	their	their	PRON
ijpds-3747	7	37	adverse	adverse	ADJ
ijpds-3747	7	38	events	event	NOUN
ijpds-3747	7	39	.	.	PUNCT
ijpds-3747	8	1	we	we	PRON
ijpds-3747	8	2	performed	perform	VERB
ijpds-3747	8	3	the	the	DET
ijpds-3747	8	4	absolute	absolute	ADJ
ijpds-3747	8	5	risk	risk	NOUN
ijpds-3747	8	6	,	,	PUNCT
ijpds-3747	8	7	relative	relative	ADJ
ijpds-3747	8	8	risk	risk	NOUN
ijpds-3747	8	9	ratio	ratio	NOUN
ijpds-3747	8	10	,	,	PUNCT
ijpds-3747	8	11	and	and	CCONJ
ijpds-3747	8	12	odds	odd	VERB
ijpds-3747	8	13	ratio	ratio	NOUN
ijpds-3747	8	14	analysis	analysis	NOUN
ijpds-3747	8	15	after	after	SCONJ
ijpds-3747	8	16	critically	critically	ADV
ijpds-3747	8	17	scru	scru	ADJ
ijpds-3747	8	18	tinizing	tinize	VERB
ijpds-3747	8	19	the	the	DET
ijpds-3747	8	20	clinical	clinical	ADJ
ijpds-3747	8	21	trials	trial	NOUN
ijpds-3747	8	22	for	for	ADP
ijpds-3747	8	23	significant	significant	ADJ
ijpds-3747	8	24	adverse	adverse	ADJ
ijpds-3747	8	25	effects	effect	NOUN
ijpds-3747	8	26	.	.	PUNCT
ijpds-3747	9	1	hcq	hcq	PROPN
ijpds-3747	9	2	showed	show	VERB
ijpds-3747	9	3	major	major	ADJ
ijpds-3747	9	4	effects	effect	NOUN
ijpds-3747	9	5	on	on	ADP
ijpds-3747	9	6	the	the	DET
ijpds-3747	9	7	eye	eye	NOUN
ijpds-3747	9	8	and	and	CCONJ
ijpds-3747	9	9	heart	heart	NOUN
ijpds-3747	9	10	.	.	PUNCT
ijpds-3747	10	1	however	however	ADV
ijpds-3747	10	2	,	,	PUNCT
ijpds-3747	10	3	based	base	VERB
ijpds-3747	10	4	on	on	ADP
ijpds-3747	10	5	the	the	DET
ijpds-3747	10	6	results	result	NOUN
ijpds-3747	10	7	,	,	PUNCT
ijpds-3747	10	8	hcq	hcq	PROPN
ijpds-3747	10	9	was	be	AUX
ijpds-3747	10	10	found	find	VERB
ijpds-3747	10	11	to	to	PART
ijpds-3747	10	12	be	be	AUX
ijpds-3747	10	13	safer	safe	ADJ
ijpds-3747	10	14	than	than	ADP
ijpds-3747	10	15	belimumab	belimumab	NOUN
ijpds-3747	10	16	,	,	PUNCT
ijpds-3747	10	17	as	as	SCONJ
ijpds-3747	10	18	a	a	DET
ijpds-3747	10	19	few	few	ADJ
ijpds-3747	10	20	serious	serious	ADJ
ijpds-3747	10	21	complications	complication	NOUN
ijpds-3747	10	22	were	be	AUX
ijpds-3747	10	23	found	find	VERB
ijpds-3747	10	24	associated	associate	VERB
ijpds-3747	10	25	with	with	ADP
ijpds-3747	10	26	belimumab	belimumab	NOUN
ijpds-3747	10	27	.	.	PUNCT
ijpds-3747	11	1	our	our	PRON
ijpds-3747	11	2	results	result	NOUN
ijpds-3747	11	3	were	be	AUX
ijpds-3747	11	4	found	find	VERB
ijpds-3747	11	5	to	to	PART
ijpds-3747	11	6	be	be	AUX
ijpds-3747	11	7	as	as	ADP
ijpds-3747	11	8	per	per	ADP
ijpds-3747	11	9	the	the	DET
ijpds-3747	11	10	previous	previous	ADJ
ijpds-3747	11	11	metaanalysis	metaanalysis	NOUN
ijpds-3747	11	12	.	.	PUNCT
ijpds-3747	12	1	this	this	DET
ijpds-3747	12	2	comprehensive	comprehensive	ADJ
ijpds-3747	12	3	review	review	NOUN
ijpds-3747	12	4	is	be	AUX
ijpds-3747	12	5	aimed	aim	VERB
ijpds-3747	12	6	at	at	ADP
ijpds-3747	12	7	analyzing	analyze	VERB
ijpds-3747	12	8	the	the	DET
ijpds-3747	12	9	safety	safety	NOUN
ijpds-3747	12	10	profiles	profile	NOUN
ijpds-3747	12	11	of	of	ADP
ijpds-3747	12	12	two	two	NUM
ijpds-3747	12	13	widely	widely	ADV
ijpds-3747	12	14	used	use	VERB
ijpds-3747	12	15	drugs	drug	NOUN
ijpds-3747	12	16	for	for	ADP
ijpds-3747	12	17	sle	sle	PROPN
ijpds-3747	12	18	ie	ie	X
ijpds-3747	12	19	hcq	hcq	NOUN
ijpds-3747	12	20	and	and	CCONJ
ijpds-3747	12	21	belimumab	belimumab	NOUN
ijpds-3747	12	22	.	.	PUNCT
ijpds-3747	13	1	we	we	PRON
ijpds-3747	13	2	have	have	AUX
ijpds-3747	13	3	conducted	conduct	VERB
ijpds-3747	13	4	this	this	DET
ijpds-3747	13	5	review	review	NOUN
ijpds-3747	13	6	,	,	PUNCT
ijpds-3747	13	7	critical	critical	ADJ
ijpds-3747	13	8	analysis	analysis	NOUN
ijpds-3747	13	9	was	be	AUX
ijpds-3747	13	10	done	do	VERB
ijpds-3747	13	11	to	to	PART
ijpds-3747	13	12	critically	critically	ADV
ijpds-3747	13	13	a	a	DET
ijpds-3747	13	14	nalyze	nalyze	NOUN
ijpds-3747	13	15	the	the	DET
ijpds-3747	13	16	clinical	clinical	ADJ
ijpds-3747	13	17	trials	trial	NOUN
ijpds-3747	13	18	,	,	PUNCT
ijpds-3747	13	19	and	and	CCONJ
ijpds-3747	13	20	to	to	PART
ijpds-3747	13	21	gather	gather	VERB
ijpds-3747	13	22	the	the	DET
ijpds-3747	13	23	information	information	NOUN
ijpds-3747	13	24	of	of	ADP
ijpds-3747	13	25	interest	interest	NOUN
ijpds-3747	13	26	from	from	ADP
ijpds-3747	13	27	these	these	DET
ijpds-3747	13	28	trials	trial	NOUN
ijpds-3747	13	29	.	.	PUNCT
ijpds-3747	14	1	both	both	DET
ijpds-3747	14	2	anti	anti	ADJ
ijpds-3747	14	3	-	-	ADJ
ijpds-3747	14	4	sle	sle	ADJ
ijpds-3747	14	5	drugs	drug	NOUN
ijpds-3747	14	6	;	;	PUNCT
ijpds-3747	14	7	hcq	hcq	NOUN
ijpds-3747	14	8	and	and	CCONJ
ijpds-3747	14	9	belimumab	belimumab	NOUN
ijpds-3747	14	10	were	be	AUX
ijpds-3747	14	11	found	find	VERB
ijpds-3747	14	12	to	to	PART
ijpds-3747	14	13	be	be	AUX
ijpds-3747	14	14	safe	safe	ADJ
ijpds-3747	14	15	for	for	ADP
ijpds-3747	14	16	use	use	NOUN
ijpds-3747	14	17	against	against	ADP
ijpds-3747	14	18	sle	sle	PROPN
ijpds-3747	14	19	.	.	PUNCT
ijpds-3747	15	1	but	but	CCONJ
ijpds-3747	15	2	comparatively	comparatively	ADV
ijpds-3747	15	3	,	,	PUNCT
ijpds-3747	15	4	hcq	hcq	PROPN
ijpds-3747	15	5	showed	show	VERB
ijpds-3747	15	6	a	a	DET
ijpds-3747	15	7	safer	safe	ADJ
ijpds-3747	15	8	profile	profile	NOUN
ijpds-3747	15	9	than	than	ADP
ijpds-3747	15	10	belimumab	belimumab	NOUN
ijpds-3747	15	11	which	which	PRON
ijpds-3747	15	12	can	can	AUX
ijpds-3747	15	13	be	be	AUX
ijpds-3747	15	14	attributed	attribute	VERB
ijpds-3747	15	15	to	to	ADP
ijpds-3747	15	16	hcq	hcq	PROPN
ijpds-3747	15	17	’s	’s	PART
ijpds-3747	15	18	longterm	longterm	ADJ
ijpds-3747	15	19	history	history	NOUN
ijpds-3747	15	20	of	of	ADP
ijpds-3747	15	21	use	use	NOUN
ijpds-3747	15	22	since	since	SCONJ
ijpds-3747	15	23	1955	1955	NUM
ijpds-3747	15	24	.	.	PUNCT
ijpds-3747	16	1	the	the	DET
ijpds-3747	16	2	observation	observation	NOUN
ijpds-3747	16	3	emphasized	emphasize	VERB
ijpds-3747	16	4	the	the	DET
ijpds-3747	16	5	researchers	researcher	NOUN
ijpds-3747	16	6	for	for	ADP
ijpds-3747	16	7	further	further	ADJ
ijpds-3747	16	8	clinical	clinical	ADJ
ijpds-3747	16	9	trials	trial	NOUN
ijpds-3747	16	10	with	with	ADP
ijpds-3747	16	11	a	a	DET
ijpds-3747	16	12	more	more	ADV
ijpds-3747	16	13	standardized	standardized	ADJ
ijpds-3747	16	14	approach	approach	NOUN
ijpds-3747	16	15	,	,	PUNCT
ijpds-3747	16	16	specifically	specifically	ADV
ijpds-3747	16	17	for	for	ADP
ijpds-3747	16	18	belimumab	belimumab	NOUN
ijpds-3747	16	19	to	to	PART
ijpds-3747	16	20	determine	determine	VERB
ijpds-3747	16	21	its	its	PRON
ijpds-3747	16	22	safety	safety	NOUN
ijpds-3747	16	23	and	and	CCONJ
ijpds-3747	16	24	tolerability	tolerability	NOUN
ijpds-3747	16	25	in	in	ADP
ijpds-3747	16	26	the	the	DET
ijpds-3747	16	27	post	post	ADJ
ijpds-3747	16	28	-	-	ADJ
ijpds-3747	16	29	marketing	marketing	ADJ
ijpds-3747	16	30	stage	stage	NOUN
ijpds-3747	16	31	.	.	PUNCT
ijpds-3747	17	1	key	key	ADJ
ijpds-3747	17	2	words	word	NOUN
ijpds-3747	17	3	:	:	PUNCT
ijpds-3747	17	4	systemic	systemic	ADJ
ijpds-3747	17	5	lupus	lupus	PROPN
ijpds-3747	17	6	erythematosus	erythematosus	NOUN
ijpds-3747	17	7	,	,	PUNCT
ijpds-3747	17	8	belimumab	belimumab	NOUN
ijpds-3747	17	9	,	,	PUNCT
ijpds-3747	17	10	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	17	11	,	,	PUNCT
ijpds-3747	17	12	safety	safety	NOUN
ijpds-3747	17	13	,	,	PUNCT
ijpds-3747	17	14	risk	risk	VERB
ijpds-3747	17	15	analysis	analysis	NOUN
ijpds-3747	17	16	ystemic	ystemic	ADJ
ijpds-3747	17	17	lupus	lupus	NOUN
ijpds-3747	17	18	erythematosus	erythematosus	NOUN
ijpds-3747	17	19	is	be	AUX
ijpds-3747	17	20	a	a	DET
ijpds-3747	17	21	systemic	systemic	ADJ
ijpds-3747	17	22	disease	disease	NOUN
ijpds-3747	17	23	,	,	PUNCT
ijpds-3747	17	24	involving	involve	VERB
ijpds-3747	17	25	a	a	DET
ijpds-3747	17	26	multiorgan	multiorgan	NOUN
ijpds-3747	17	27	system	system	NOUN
ijpds-3747	17	28	and	and	CCONJ
ijpds-3747	17	29	is	be	AUX
ijpds-3747	17	30	chronic	chronic	ADJ
ijpds-3747	17	31	.	.	PUNCT
ijpds-3747	18	1	it	it	PRON
ijpds-3747	18	2	results	result	VERB
ijpds-3747	18	3	in	in	ADP
ijpds-3747	18	4	severe	severe	ADJ
ijpds-3747	18	5	damage	damage	NOUN
ijpds-3747	18	6	to	to	ADP
ijpds-3747	18	7	the	the	DET
ijpds-3747	18	8	organ	organ	NOUN
ijpds-3747	18	9	system	system	NOUN
ijpds-3747	18	10	and	and	CCONJ
ijpds-3747	18	11	its	its	PRON
ijpds-3747	18	12	dysfunction	dysfunction	NOUN
ijpds-3747	18	13	.	.	PUNCT
ijpds-3747	19	1	sle	sle	PROPN
ijpds-3747	19	2	is	be	AUX
ijpds-3747	19	3	the	the	DET
ijpds-3747	19	4	result	result	NOUN
ijpds-3747	19	5	of	of	ADP
ijpds-3747	19	6	a	a	DET
ijpds-3747	19	7	multistep	multistep	ADJ
ijpds-3747	19	8	cascade	cascade	NOUN
ijpds-3747	19	9	of	of	ADP
ijpds-3747	19	10	immune	immune	ADJ
ijpds-3747	19	11	system	system	NOUN
ijpds-3747	19	12	abnormalities	abnormality	NOUN
ijpds-3747	19	13	starting	start	VERB
ijpds-3747	19	14	with	with	ADP
ijpds-3747	19	15	the	the	DET
ijpds-3747	19	16	inability	inability	NOUN
ijpds-3747	19	17	of	of	ADP
ijpds-3747	19	18	the	the	DET
ijpds-3747	19	19	cells	cell	NOUN
ijpds-3747	19	20	to	to	PART
ijpds-3747	19	21	clear	clear	ADJ
ijpds-3747	19	22	apoptotic	apoptotic	ADJ
ijpds-3747	19	23	bodies	body	NOUN
ijpds-3747	19	24	,	,	PUNCT
ijpds-3747	19	25	which	which	PRON
ijpds-3747	19	26	results	result	VERB
ijpds-3747	19	27	in	in	ADP
ijpds-3747	19	28	the	the	DET
ijpds-3747	19	29	activation	activation	NOUN
ijpds-3747	19	30	of	of	ADP
ijpds-3747	19	31	both	both	DET
ijpds-3747	19	32	arms	arm	NOUN
ijpds-3747	19	33	of	of	ADP
ijpds-3747	19	34	the	the	DET
ijpds-3747	19	35	immune	immune	ADJ
ijpds-3747	19	36	system	system	NOUN
ijpds-3747	19	37	(	(	PUNCT
ijpds-3747	19	38	adaptive	adaptive	ADJ
ijpds-3747	19	39	and	and	CCONJ
ijpds-3747	19	40	innate	innate	ADJ
ijpds-3747	19	41	immunity	immunity	NOUN
ijpds-3747	19	42	)	)	PUNCT
ijpds-3747	19	43	,	,	PUNCT
ijpds-3747	19	44	formation	formation	NOUN
ijpds-3747	19	45	of	of	ADP
ijpds-3747	19	46	immune	immune	ADJ
ijpds-3747	19	47	complexes	complex	NOUN
ijpds-3747	19	48	,	,	PUNCT
ijpds-3747	19	49	and	and	CCONJ
ijpds-3747	19	50	tissues	tissue	NOUN
ijpds-3747	19	51	’	'	PUNCT
ijpds-3747	19	52	inflammation	inflammation	NOUN
ijpds-3747	19	53	that	that	SCONJ
ijpds-3747	19	54	results	result	VERB
ijpds-3747	19	55	in	in	ADP
ijpds-3747	19	56	an	an	DET
ijpds-3747	19	57	autoimmune	autoimmune	ADJ
ijpds-3747	19	58	process	process	NOUN
ijpds-3747	19	59	[	[	X
ijpds-3747	19	60	1	1	NUM
ijpds-3747	19	61	]	]	PUNCT
ijpds-3747	19	62	.	.	PUNCT
ijpds-3747	20	1	apoptosis	apoptosis	NOUN
ijpds-3747	20	2	has	have	VERB
ijpds-3747	20	3	a	a	DET
ijpds-3747	20	4	crucial	crucial	ADJ
ijpds-3747	20	5	role	role	NOUN
ijpds-3747	20	6	in	in	ADP
ijpds-3747	20	7	the	the	DET
ijpds-3747	20	8	development	development	NOUN
ijpds-3747	20	9	of	of	ADP
ijpds-3747	20	10	lupus	lupus	PROPN
ijpds-3747	20	11	.	.	PUNCT
ijpds-3747	21	1	increased	increase	VERB
ijpds-3747	21	2	non	non	ADJ
ijpds-3747	21	3	-	-	ADJ
ijpds-3747	21	4	cleared	clear	VERB
ijpds-3747	21	5	apoptotic	apoptotic	ADJ
ijpds-3747	21	6	debris	debris	NOUN
ijpds-3747	21	7	is	be	AUX
ijpds-3747	21	8	linked	link	VERB
ijpds-3747	21	9	to	to	ADP
ijpds-3747	21	10	inflammation	inflammation	NOUN
ijpds-3747	21	11	and	and	CCONJ
ijpds-3747	21	12	the	the	DET
ijpds-3747	21	13	generation	generation	NOUN
ijpds-3747	21	14	of	of	ADP
ijpds-3747	21	15	autoantibodies	autoantibody	NOUN
ijpds-3747	21	16	[	[	X
ijpds-3747	21	17	2	2	NUM
ijpds-3747	21	18	]	]	PUNCT
ijpds-3747	21	19	.	.	PUNCT
ijpds-3747	22	1	autoantigens	autoantigen	NOUN
ijpds-3747	22	2	are	be	AUX
ijpds-3747	22	3	released	release	VERB
ijpds-3747	22	4	by	by	ADP
ijpds-3747	22	5	apoptotic	apoptotic	ADJ
ijpds-3747	22	6	cells	cell	NOUN
ijpds-3747	22	7	[	[	X
ijpds-3747	22	8	3	3	NUM
ijpds-3747	22	9	]	]	PUNCT
ijpds-3747	22	10	.	.	PUNCT
ijpds-3747	23	1	these	these	PRON
ijpds-3747	23	2	can	can	AUX
ijpds-3747	23	3	produce	produce	VERB
ijpds-3747	23	4	noticeable	noticeable	ADJ
ijpds-3747	23	5	levels	level	NOUN
ijpds-3747	23	6	of	of	ADP
ijpds-3747	23	7	type	type	NOUN
ijpds-3747	23	8	1	1	NUM
ijpds-3747	23	9	interferon	interferon	NOUN
ijpds-3747	23	10	by	by	ADP
ijpds-3747	23	11	activating	activate	VERB
ijpds-3747	23	12	tlr7	tlr7	NOUN
ijpds-3747	23	13	and	and	CCONJ
ijpds-3747	23	14	tlr9	tlr9	NOUN
ijpds-3747	23	15	in	in	ADP
ijpds-3747	23	16	dendritic	dendritic	ADJ
ijpds-3747	23	17	cells	cell	NOUN
ijpds-3747	23	18	[	[	X
ijpds-3747	23	19	4	4	NUM
ijpds-3747	23	20	,	,	PUNCT
ijpds-3747	23	21	5	5	NUM
ijpds-3747	23	22	]	]	PUNCT
ijpds-3747	23	23	.	.	PUNCT
ijpds-3747	24	1	the	the	DET
ijpds-3747	24	2	aetiology	aetiology	NOUN
ijpds-3747	24	3	of	of	ADP
ijpds-3747	24	4	sle	sle	PROPN
ijpds-3747	24	5	includes	include	VERB
ijpds-3747	24	6	aberrant	aberrant	ADJ
ijpds-3747	24	7	clearance	clearance	NOUN
ijpds-3747	24	8	of	of	ADP
ijpds-3747	24	9	immunological	immunological	ADJ
ijpds-3747	24	10	complexes	complex	NOUN
ijpds-3747	24	11	(	(	PUNCT
ijpds-3747	24	12	ics	ics	NOUN
ijpds-3747	24	13	)	)	PUNCT
ijpds-3747	24	14	and	and	CCONJ
ijpds-3747	24	15	apoptotic	apoptotic	ADJ
ijpds-3747	24	16	cells	cell	NOUN
ijpds-3747	24	17	and	and	CCONJ
ijpds-3747	24	18	low	low	ADJ
ijpds-3747	24	19	thresholds	threshold	NOUN
ijpds-3747	24	20	of	of	ADP
ijpds-3747	24	21	b	b	PROPN
ijpds-3747	24	22	and	and	CCONJ
ijpds-3747	24	23	t	t	PROPN
ijpds-3747	24	24	lymphocyte	lymphocyte	ADJ
ijpds-3747	24	25	activation	activation	NOUN
ijpds-3747	24	26	that	that	PRON
ijpds-3747	24	27	result	result	VERB
ijpds-3747	24	28	in	in	ADP
ijpds-3747	24	29	loss	loss	NOUN
ijpds-3747	24	30	of	of	ADP
ijpds-3747	24	31	self	self	NOUN
ijpds-3747	24	32	-	-	PUNCT
ijpds-3747	24	33	tolerance	tolerance	NOUN
ijpds-3747	24	34	and	and	CCONJ
ijpds-3747	24	35	autoantibody	autoantibody	ADJ
ijpds-3747	24	36	synthesis	synthesis	NOUN
ijpds-3747	24	37	.	.	PUNCT
ijpds-3747	25	1	interaction	interaction	NOUN
ijpds-3747	25	2	of	of	ADP
ijpds-3747	25	3	genetic	genetic	ADJ
ijpds-3747	25	4	predisposition	predisposition	NOUN
ijpds-3747	25	5	,	,	PUNCT
ijpds-3747	25	6	immunological	immunological	ADJ
ijpds-3747	25	7	,	,	PUNCT
ijpds-3747	25	8	and	and	CCONJ
ijpds-3747	25	9	hormonal	hormonal	ADJ
ijpds-3747	25	10	variables	variable	NOUN
ijpds-3747	25	11	,	,	PUNCT
ijpds-3747	25	12	and	and	CCONJ
ijpds-3747	25	13	environmental	environmental	ADJ
ijpds-3747	25	14	triggers	trigger	NOUN
ijpds-3747	25	15	is	be	AUX
ijpds-3747	25	16	necessary	necessary	ADJ
ijpds-3747	25	17	for	for	ADP
ijpds-3747	25	18	the	the	DET
ijpds-3747	25	19	clinical	clinical	ADJ
ijpds-3747	25	20	commencement	commencement	NOUN
ijpds-3747	25	21	of	of	ADP
ijpds-3747	25	22	sle	sle	PROPN
ijpds-3747	25	23	.	.	PUNCT
ijpds-3747	26	1	sle	sle	PROPN
ijpds-3747	26	2	shows	show	VERB
ijpds-3747	26	3	itself	itself	PRON
ijpds-3747	26	4	in	in	ADP
ijpds-3747	26	5	a	a	DET
ijpds-3747	26	6	range	range	NOUN
ijpds-3747	26	7	of	of	ADP
ijpds-3747	26	8	clinical	clinical	ADJ
ijpds-3747	26	9	manifestations	manifestation	NOUN
ijpds-3747	26	10	.	.	PUNCT
ijpds-3747	27	1	the	the	DET
ijpds-3747	27	2	symptoms	symptom	NOUN
ijpds-3747	27	3	can	can	AUX
ijpds-3747	27	4	range	range	VERB
ijpds-3747	27	5	from	from	ADP
ijpds-3747	27	6	hair	hair	NOUN
ijpds-3747	27	7	loss	loss	NOUN
ijpds-3747	27	8	(	(	PUNCT
ijpds-3747	27	9	that	that	PRON
ijpds-3747	27	10	can	can	AUX
ijpds-3747	27	11	be	be	AUX
ijpds-3747	27	12	thought	think	VERB
ijpds-3747	27	13	of	of	ADP
ijpds-3747	27	14	as	as	ADP
ijpds-3747	27	15	mineral	mineral	NOUN
ijpds-3747	27	16	deficiency	deficiency	NOUN
ijpds-3747	27	17	)	)	PUNCT
ijpds-3747	27	18	and	and	CCONJ
ijpds-3747	27	19	light	light	ADJ
ijpds-3747	27	20	sensitivity	sensitivity	NOUN
ijpds-3747	27	21	to	to	ADP
ijpds-3747	27	22	lethal	lethal	ADJ
ijpds-3747	27	23	conditions	condition	NOUN
ijpds-3747	27	24	like	like	ADP
ijpds-3747	27	25	inflammation	inflammation	NOUN
ijpds-3747	27	26	of	of	ADP
ijpds-3747	27	27	the	the	DET
ijpds-3747	27	28	myocardium	myocardium	NOUN
ijpds-3747	27	29	,	,	PUNCT
ijpds-3747	27	30	brain	brain	NOUN
ijpds-3747	27	31	,	,	PUNCT
ijpds-3747	27	32	and	and	CCONJ
ijpds-3747	27	33	nephrons	nephron	NOUN
ijpds-3747	27	34	.	.	PUNCT
ijpds-3747	28	1	thus	thus	ADV
ijpds-3747	28	2	,	,	PUNCT
ijpds-3747	28	3	symptoms	symptom	NOUN
ijpds-3747	28	4	of	of	ADP
ijpds-3747	28	5	sle	sle	PROPN
ijpds-3747	28	6	are	be	AUX
ijpds-3747	28	7	heterogeneous	heterogeneous	ADJ
ijpds-3747	28	8	and	and	CCONJ
ijpds-3747	28	9	may	may	AUX
ijpds-3747	28	10	differ	differ	VERB
ijpds-3747	28	11	in	in	ADP
ijpds-3747	28	12	different	different	ADJ
ijpds-3747	28	13	individuals	individual	NOUN
ijpds-3747	28	14	or	or	CCONJ
ijpds-3747	28	15	among	among	ADP
ijpds-3747	28	16	the	the	DET
ijpds-3747	28	17	same	same	ADJ
ijpds-3747	28	18	individual	individual	NOUN
ijpds-3747	28	19	for	for	ADP
ijpds-3747	28	20	different	different	ADJ
ijpds-3747	28	21	periods	period	NOUN
ijpds-3747	28	22	[	[	X
ijpds-3747	28	23	1	1	NUM
ijpds-3747	28	24	]	]	PUNCT
ijpds-3747	28	25	.	.	PUNCT
ijpds-3747	29	1	the	the	DET
ijpds-3747	29	2	complex	complex	ADJ
ijpds-3747	29	3	nature	nature	NOUN
ijpds-3747	29	4	of	of	ADP
ijpds-3747	29	5	sle	sle	PROPN
ijpds-3747	29	6	makes	make	VERB
ijpds-3747	29	7	it	it	PRON
ijpds-3747	29	8	more	more	ADV
ijpds-3747	29	9	difficult	difficult	ADJ
ijpds-3747	29	10	to	to	PART
ijpds-3747	29	11	treat	treat	VERB
ijpds-3747	29	12	because	because	SCONJ
ijpds-3747	29	13	of	of	ADP
ijpds-3747	29	14	its	its	PRON
ijpds-3747	29	15	unpredictable	unpredictable	ADJ
ijpds-3747	29	16	symptoms	symptom	NOUN
ijpds-3747	29	17	[	[	X
ijpds-3747	29	18	6	6	NUM
ijpds-3747	29	19	]	]	PUNCT
ijpds-3747	29	20	.	.	PUNCT
ijpds-3747	30	1	sle	sle	PROPN
ijpds-3747	30	2	can	can	AUX
ijpds-3747	30	3	affect	affect	VERB
ijpds-3747	30	4	both	both	DET
ijpds-3747	30	5	genders	gender	NOUN
ijpds-3747	30	6	,	,	PUNCT
ijpds-3747	30	7	but	but	CCONJ
ijpds-3747	30	8	it	it	PRON
ijpds-3747	30	9	affects	affect	VERB
ijpds-3747	30	10	women	woman	NOUN
ijpds-3747	30	11	more	more	ADJ
ijpds-3747	30	12	than	than	ADP
ijpds-3747	30	13	men	man	NOUN
ijpds-3747	30	14	.	.	PUNCT
ijpds-3747	31	1	the	the	DET
ijpds-3747	31	2	ratio	ratio	NOUN
ijpds-3747	31	3	of	of	ADP
ijpds-3747	31	4	sle	sle	PROPN
ijpds-3747	31	5	in	in	ADP
ijpds-3747	31	6	males	male	NOUN
ijpds-3747	31	7	to	to	ADP
ijpds-3747	31	8	females	female	NOUN
ijpds-3747	31	9	is	be	AUX
ijpds-3747	31	10	1	1	NUM
ijpds-3747	31	11	man	man	NOUN
ijpds-3747	31	12	against	against	ADP
ijpds-3747	31	13	13	13	NUM
ijpds-3747	31	14	women	woman	NOUN
ijpds-3747	31	15	making	make	VERB
ijpds-3747	31	16	it	it	PRON
ijpds-3747	31	17	a	a	DET
ijpds-3747	31	18	feminine	feminine	ADJ
ijpds-3747	31	19	disease	disease	NOUN
ijpds-3747	31	20	[	[	X
ijpds-3747	31	21	7	7	NUM
ijpds-3747	31	22	]	]	PUNCT
ijpds-3747	31	23	.	.	PUNCT
ijpds-3747	32	1	the	the	DET
ijpds-3747	32	2	disease	disease	NOUN
ijpds-3747	32	3	is	be	AUX
ijpds-3747	32	4	common	common	ADJ
ijpds-3747	32	5	in	in	ADP
ijpds-3747	32	6	african	african	ADJ
ijpds-3747	32	7	lineage	lineage	NOUN
ijpds-3747	32	8	and	and	CCONJ
ijpds-3747	32	9	african	african	ADJ
ijpds-3747	32	10	americans	americans	PROPN
ijpds-3747	32	11	inhabiting	inhabit	VERB
ijpds-3747	32	12	european	european	ADJ
ijpds-3747	32	13	countries	country	NOUN
ijpds-3747	32	14	and	and	CCONJ
ijpds-3747	32	15	the	the	DET
ijpds-3747	32	16	united	united	PROPN
ijpds-3747	32	17	states	states	PROPN
ijpds-3747	32	18	.	.	PUNCT
ijpds-3747	33	1	interestingly	interestingly	ADV
ijpds-3747	33	2	and	and	CCONJ
ijpds-3747	33	3	controversially	controversially	ADV
ijpds-3747	33	4	,	,	PUNCT
ijpds-3747	33	5	the	the	DET
ijpds-3747	33	6	disease	disease	NOUN
ijpds-3747	33	7	is	be	AUX
ijpds-3747	33	8	rare	rare	ADJ
ijpds-3747	33	9	in	in	ADP
ijpds-3747	33	10	africa	africa	PROPN
ijpds-3747	33	11	itself	itself	PRON
ijpds-3747	34	1	[	[	X
ijpds-3747	34	2	8	8	NUM
ijpds-3747	34	3	]	]	PUNCT
ijpds-3747	34	4	.	.	PUNCT
ijpds-3747	35	1	according	accord	VERB
ijpds-3747	35	2	to	to	ADP
ijpds-3747	35	3	the	the	DET
ijpds-3747	35	4	centre	centre	NOUN
ijpds-3747	35	5	for	for	ADP
ijpds-3747	35	6	disease	disease	NOUN
ijpds-3747	35	7	control	control	NOUN
ijpds-3747	35	8	and	and	CCONJ
ijpds-3747	35	9	prevention	prevention	NOUN
ijpds-3747	35	10	,	,	PUNCT
ijpds-3747	35	11	there	there	PRON
ijpds-3747	35	12	are	be	VERB
ijpds-3747	35	13	around	around	ADV
ijpds-3747	35	14	322,000	322,000	NUM
ijpds-3747	35	15	probable	probable	ADJ
ijpds-3747	35	16	or	or	CCONJ
ijpds-3747	35	17	confirmed	confirm	VERB
ijpds-3747	35	18	cases	case	NOUN
ijpds-3747	35	19	of	of	ADP
ijpds-3747	35	20	sle	sle	PROPN
ijpds-3747	35	21	,	,	PUNCT
ijpds-3747	35	22	with	with	ADP
ijpds-3747	35	23	the	the	DET
ijpds-3747	35	24	prevalence	prevalence	NOUN
ijpds-3747	35	25	being	be	AUX
ijpds-3747	35	26	higher	high	ADJ
ijpds-3747	35	27	in	in	ADP
ijpds-3747	35	28	african	african	ADJ
ijpds-3747	35	29	americans	americans	PROPN
ijpds-3747	35	30	,	,	PUNCT
ijpds-3747	35	31	american	american	ADJ
ijpds-3747	35	32	indians	indians	PROPN
ijpds-3747	35	33	,	,	PUNCT
ijpds-3747	35	34	and	and	CCONJ
ijpds-3747	35	35	alaska	alaska	PROPN
ijpds-3747	35	36	natives	native	NOUN
ijpds-3747	35	37	[	[	X
ijpds-3747	35	38	9	9	NUM
ijpds-3747	35	39	,	,	PUNCT
ijpds-3747	35	40	10	10	NUM
ijpds-3747	35	41	]	]	PUNCT
ijpds-3747	35	42	.	.	PUNCT
ijpds-3747	36	1	for	for	ADP
ijpds-3747	36	2	sle	sle	PROPN
ijpds-3747	36	3	s	s	PART
ijpds-3747	36	4	mailto:zahra.maryam489@gmail.com	mailto:zahra.maryam489@gmail.com	PROPN
ijpds-3747	36	5	maryam	maryam	PROPN
ijpds-3747	36	6	and	and	CCONJ
ijpds-3747	36	7	ahmad	ahmad	PROPN
ijpds-3747	36	8	safety	safety	PROPN
ijpds-3747	36	9	comparison	comparison	NOUN
ijpds-3747	36	10	of	of	ADP
ijpds-3747	36	11	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	36	12	and	and	CCONJ
ijpds-3747	36	13	belimumab	belimumab	NOUN
ijpds-3747	36	14	vol	vol	NOUN
ijpds-3747	36	15	2	2	NUM
ijpds-3747	36	16	|	|	NOUN
ijpds-3747	36	17	issue	issue	NOUN
ijpds-3747	36	18	1	1	NUM
ijpds-3747	36	19	|	|	ADV
ijpds-3747	36	20	jan	jan	PROPN
ijpds-3747	36	21	–	–	PUNCT
ijpds-3747	36	22	mar	mar	PROPN
ijpds-3747	36	23	2023	2023	NUM
ijpds-3747	36	24	indian	indian	PROPN
ijpds-3747	36	25	j	j	PROPN
ijpds-3747	36	26	pharm	pharm	PROPN
ijpds-3747	36	27	drug	drug	PROPN
ijpds-3747	36	28	studies	study	NOUN
ijpds-3747	36	29	|	|	ADV
ijpds-3747	36	30	6	6	NUM
ijpds-3747	36	31	“	"	PUNCT
ijpds-3747	36	32	standard	standard	NOUN
ijpds-3747	36	33	of	of	ADP
ijpds-3747	36	34	care	care	NOUN
ijpds-3747	36	35	”	"	PUNCT
ijpds-3747	36	36	therapy	therapy	NOUN
ijpds-3747	36	37	consists	consist	VERB
ijpds-3747	36	38	of	of	ADP
ijpds-3747	36	39	immunomodulators	immunomodulator	NOUN
ijpds-3747	36	40	,	,	PUNCT
ijpds-3747	36	41	antimalarials	antimalarial	NOUN
ijpds-3747	36	42	,	,	PUNCT
ijpds-3747	36	43	corticosteroids	corticosteroid	NOUN
ijpds-3747	36	44	,	,	PUNCT
ijpds-3747	36	45	immunosuppressive	immunosuppressive	ADJ
ijpds-3747	36	46	,	,	PUNCT
ijpds-3747	36	47	and	and	CCONJ
ijpds-3747	36	48	cytotoxic	cytotoxic	ADJ
ijpds-3747	36	49	agents	agent	NOUN
ijpds-3747	36	50	.	.	PUNCT
ijpds-3747	37	1	the	the	DET
ijpds-3747	37	2	purpose	purpose	NOUN
ijpds-3747	37	3	of	of	ADP
ijpds-3747	37	4	this	this	DET
ijpds-3747	37	5	treatment	treatment	NOUN
ijpds-3747	37	6	includes	include	VERB
ijpds-3747	37	7	1	1	NUM
ijpds-3747	37	8	)	)	PUNCT
ijpds-3747	37	9	minimizing	minimize	VERB
ijpds-3747	37	10	the	the	DET
ijpds-3747	37	11	activity	activity	NOUN
ijpds-3747	37	12	level	level	NOUN
ijpds-3747	37	13	of	of	ADP
ijpds-3747	37	14	the	the	DET
ijpds-3747	37	15	immune	immune	ADJ
ijpds-3747	37	16	activation	activation	NOUN
ijpds-3747	37	17	by	by	ADP
ijpds-3747	37	18	using	use	VERB
ijpds-3747	37	19	immunosuppressants	immunosuppressant	NOUN
ijpds-3747	37	20	and	and	CCONJ
ijpds-3747	37	21	by	by	ADP
ijpds-3747	37	22	avoiding	avoid	VERB
ijpds-3747	37	23	the	the	DET
ijpds-3747	37	24	triggers	trigger	NOUN
ijpds-3747	37	25	2	2	NUM
ijpds-3747	37	26	)	)	PUNCT
ijpds-3747	37	27	protecting	protect	VERB
ijpds-3747	37	28	the	the	DET
ijpds-3747	37	29	organs	organ	NOUN
ijpds-3747	37	30	from	from	ADP
ijpds-3747	37	31	damage	damage	NOUN
ijpds-3747	37	32	3	3	NUM
ijpds-3747	37	33	)	)	PUNCT
ijpds-3747	37	34	minimizing	minimize	VERB
ijpds-3747	37	35	the	the	DET
ijpds-3747	37	36	risk	risk	NOUN
ijpds-3747	37	37	of	of	ADP
ijpds-3747	37	38	comorbid	comorbid	NOUN
ijpds-3747	37	39	conditions	condition	NOUN
ijpds-3747	37	40	associated	associate	VERB
ijpds-3747	37	41	with	with	ADP
ijpds-3747	37	42	lupus	lupus	ADJ
ijpds-3747	37	43	4	4	NUM
ijpds-3747	37	44	)	)	PUNCT
ijpds-3747	37	45	reduction	reduction	NOUN
ijpds-3747	37	46	of	of	ADP
ijpds-3747	37	47	pain	pain	NOUN
ijpds-3747	37	48	and	and	CCONJ
ijpds-3747	37	49	lethargy	lethargy	NOUN
ijpds-3747	37	50	.	.	PUNCT
ijpds-3747	38	1	the	the	DET
ijpds-3747	38	2	treatment	treatment	NOUN
ijpds-3747	38	3	is	be	AUX
ijpds-3747	38	4	necessary	necessary	ADJ
ijpds-3747	38	5	for	for	SCONJ
ijpds-3747	38	6	the	the	DET
ijpds-3747	38	7	early	early	ADJ
ijpds-3747	38	8	stages	stage	NOUN
ijpds-3747	38	9	of	of	ADP
ijpds-3747	38	10	sle	sle	PROPN
ijpds-3747	38	11	to	to	PART
ijpds-3747	38	12	avoid	avoid	VERB
ijpds-3747	38	13	known	know	VERB
ijpds-3747	38	14	triggers	trigger	NOUN
ijpds-3747	38	15	and	and	CCONJ
ijpds-3747	38	16	to	to	PART
ijpds-3747	38	17	maximize	maximize	VERB
ijpds-3747	38	18	the	the	DET
ijpds-3747	38	19	effects	effect	NOUN
ijpds-3747	38	20	of	of	ADP
ijpds-3747	38	21	immunomodulators	immunomodulator	NOUN
ijpds-3747	38	22	.	.	PUNCT
ijpds-3747	39	1	this	this	DET
ijpds-3747	39	2	critical	critical	ADJ
ijpds-3747	39	3	review	review	NOUN
ijpds-3747	39	4	aims	aim	VERB
ijpds-3747	39	5	to	to	PART
ijpds-3747	39	6	analyse	analyse	VERB
ijpds-3747	39	7	the	the	DET
ijpds-3747	39	8	safety	safety	NOUN
ijpds-3747	39	9	profiles	profile	NOUN
ijpds-3747	39	10	of	of	ADP
ijpds-3747	39	11	the	the	DET
ijpds-3747	39	12	two	two	NUM
ijpds-3747	39	13	drugs	drug	NOUN
ijpds-3747	39	14	used	use	VERB
ijpds-3747	39	15	for	for	ADP
ijpds-3747	39	16	the	the	DET
ijpds-3747	39	17	treatment	treatment	NOUN
ijpds-3747	39	18	of	of	ADP
ijpds-3747	39	19	sle	sle	PROPN
ijpds-3747	39	20	i	i	PROPN
ijpds-3747	39	21	-	-	PUNCT
ijpds-3747	39	22	e	e	VERB
ijpds-3747	39	23	hcq	hcq	NOUN
ijpds-3747	39	24	and	and	CCONJ
ijpds-3747	39	25	belimumab	belimumab	NOUN
ijpds-3747	39	26	.	.	PUNCT
ijpds-3747	40	1	sle	sle	PROPN
ijpds-3747	40	2	is	be	AUX
ijpds-3747	40	3	a	a	DET
ijpds-3747	40	4	challenging	challenging	ADJ
ijpds-3747	40	5	disease	disease	NOUN
ijpds-3747	40	6	with	with	ADP
ijpds-3747	40	7	current	current	ADJ
ijpds-3747	40	8	therapy	therapy	NOUN
ijpds-3747	40	9	aimed	aim	VERB
ijpds-3747	40	10	to	to	PART
ijpds-3747	40	11	restore	restore	VERB
ijpds-3747	40	12	the	the	DET
ijpds-3747	40	13	imbalance	imbalance	NOUN
ijpds-3747	40	14	of	of	ADP
ijpds-3747	40	15	the	the	DET
ijpds-3747	40	16	dysregulated	dysregulated	ADJ
ijpds-3747	40	17	immune	immune	ADJ
ijpds-3747	40	18	system	system	NOUN
ijpds-3747	40	19	.	.	PUNCT
ijpds-3747	41	1	b	b	NOUN
ijpds-3747	41	2	cells	cell	NOUN
ijpds-3747	41	3	are	be	AUX
ijpds-3747	41	4	important	important	ADJ
ijpds-3747	41	5	in	in	ADP
ijpds-3747	41	6	the	the	DET
ijpds-3747	41	7	development	development	NOUN
ijpds-3747	41	8	of	of	ADP
ijpds-3747	41	9	sle	sle	PROPN
ijpds-3747	41	10	's	's	PART
ijpds-3747	41	11	pathophysiology	pathophysiology	NOUN
ijpds-3747	41	12	.	.	PUNCT
ijpds-3747	42	1	therefore	therefore	ADV
ijpds-3747	42	2	,	,	PUNCT
ijpds-3747	42	3	attempts	attempt	VERB
ijpds-3747	42	4	to	to	PART
ijpds-3747	42	5	interfere	interfere	VERB
ijpds-3747	42	6	with	with	ADP
ijpds-3747	42	7	disease	disease	NOUN
ijpds-3747	42	8	activity	activity	NOUN
ijpds-3747	42	9	by	by	ADP
ijpds-3747	42	10	targeting	target	VERB
ijpds-3747	42	11	b	b	NOUN
ijpds-3747	42	12	lymphocytes	lymphocyte	NOUN
ijpds-3747	42	13	for	for	ADP
ijpds-3747	42	14	selective	selective	ADJ
ijpds-3747	42	15	depletion	depletion	NOUN
ijpds-3747	42	16	using	use	VERB
ijpds-3747	42	17	monoclonal	monoclonal	NOUN
ijpds-3747	42	18	antibodies	antibody	NOUN
ijpds-3747	42	19	is	be	AUX
ijpds-3747	42	20	a	a	DET
ijpds-3747	42	21	promising	promising	ADJ
ijpds-3747	42	22	strategy	strategy	NOUN
ijpds-3747	42	23	to	to	PART
ijpds-3747	42	24	increase	increase	VERB
ijpds-3747	42	25	therapeutic	therapeutic	ADJ
ijpds-3747	42	26	effectiveness	effectiveness	NOUN
ijpds-3747	42	27	.	.	PUNCT
ijpds-3747	43	1	thus	thus	ADV
ijpds-3747	43	2	,	,	PUNCT
ijpds-3747	43	3	recent	recent	ADJ
ijpds-3747	43	4	therapies	therapy	NOUN
ijpds-3747	43	5	focus	focus	VERB
ijpds-3747	43	6	on	on	ADP
ijpds-3747	43	7	the	the	DET
ijpds-3747	43	8	development	development	NOUN
ijpds-3747	43	9	of	of	ADP
ijpds-3747	43	10	monoclonal	monoclonal	NOUN
ijpds-3747	43	11	antibodies	antibody	NOUN
ijpds-3747	43	12	.	.	PUNCT
ijpds-3747	44	1	belimumab	belimumab	NOUN
ijpds-3747	44	2	is	be	AUX
ijpds-3747	44	3	an	an	DET
ijpds-3747	44	4	immunoglobulin	immunoglobulin	NOUN
ijpds-3747	44	5	monoclonal	monoclonal	NOUN
ijpds-3747	44	6	antibody	antibody	NOUN
ijpds-3747	44	7	that	that	PRON
ijpds-3747	44	8	was	be	AUX
ijpds-3747	44	9	approved	approve	VERB
ijpds-3747	44	10	by	by	ADP
ijpds-3747	44	11	food	food	NOUN
ijpds-3747	44	12	and	and	CCONJ
ijpds-3747	44	13	drug	drug	NOUN
ijpds-3747	44	14	administration	administration	NOUN
ijpds-3747	44	15	in	in	ADP
ijpds-3747	44	16	2011	2011	NUM
ijpds-3747	44	17	for	for	ADP
ijpds-3747	44	18	treating	treat	VERB
ijpds-3747	44	19	adults	adult	NOUN
ijpds-3747	44	20	with	with	ADP
ijpds-3747	44	21	sle	sle	PROPN
ijpds-3747	44	22	[	[	X
ijpds-3747	44	23	11	11	NUM
ijpds-3747	44	24	]	]	PUNCT
ijpds-3747	44	25	.	.	PUNCT
ijpds-3747	45	1	it	it	PRON
ijpds-3747	45	2	is	be	AUX
ijpds-3747	45	3	a	a	DET
ijpds-3747	45	4	fully	fully	ADV
ijpds-3747	45	5	human	human	ADJ
ijpds-3747	45	6	antibody	antibody	NOUN
ijpds-3747	45	7	that	that	PRON
ijpds-3747	45	8	inhibits	inhibit	VERB
ijpds-3747	45	9	soluble	soluble	ADJ
ijpds-3747	45	10	b	b	PROPN
ijpds-3747	45	11	lymphocyte	lymphocyte	ADJ
ijpds-3747	45	12	stimulator	stimulator	NOUN
ijpds-3747	45	13	(	(	PUNCT
ijpds-3747	45	14	blys	blys	PROPN
ijpds-3747	45	15	)	)	PUNCT
ijpds-3747	45	16	,	,	PUNCT
ijpds-3747	45	17	which	which	PRON
ijpds-3747	45	18	in	in	ADP
ijpds-3747	45	19	turn	turn	NOUN
ijpds-3747	45	20	inhibits	inhibit	VERB
ijpds-3747	45	21	the	the	DET
ijpds-3747	45	22	production	production	NOUN
ijpds-3747	45	23	of	of	ADP
ijpds-3747	45	24	a	a	DET
ijpds-3747	45	25	crucial	crucial	ADJ
ijpds-3747	45	26	cytokine	cytokine	NOUN
ijpds-3747	45	27	that	that	PRON
ijpds-3747	45	28	is	be	AUX
ijpds-3747	45	29	essential	essential	ADJ
ijpds-3747	45	30	for	for	ADP
ijpds-3747	45	31	b	b	PROPN
ijpds-3747	45	32	cell	cell	NOUN
ijpds-3747	45	33	survival	survival	NOUN
ijpds-3747	45	34	,	,	PUNCT
ijpds-3747	45	35	proliferation	proliferation	NOUN
ijpds-3747	45	36	,	,	PUNCT
ijpds-3747	45	37	and	and	CCONJ
ijpds-3747	45	38	differentiation	differentiation	NOUN
ijpds-3747	45	39	[	[	X
ijpds-3747	45	40	12	12	NUM
ijpds-3747	45	41	–	–	SYM
ijpds-3747	45	42	14	14	NUM
ijpds-3747	45	43	]	]	PUNCT
ijpds-3747	45	44	.	.	PUNCT
ijpds-3747	46	1	therapy	therapy	NOUN
ijpds-3747	46	2	with	with	ADP
ijpds-3747	46	3	belimumab	belimumab	NOUN
ijpds-3747	46	4	is	be	AUX
ijpds-3747	46	5	a	a	DET
ijpds-3747	46	6	helpful	helpful	ADJ
ijpds-3747	46	7	treatment	treatment	NOUN
ijpds-3747	46	8	option	option	NOUN
ijpds-3747	46	9	for	for	ADP
ijpds-3747	46	10	patients	patient	NOUN
ijpds-3747	46	11	with	with	ADP
ijpds-3747	46	12	active	active	ADJ
ijpds-3747	46	13	sle	sle	NOUN
ijpds-3747	46	14	despite	despite	SCONJ
ijpds-3747	46	15	conventional	conventional	ADJ
ijpds-3747	46	16	therapy	therapy	NOUN
ijpds-3747	46	17	due	due	ADP
ijpds-3747	46	18	to	to	ADP
ijpds-3747	46	19	the	the	DET
ijpds-3747	46	20	adaptability	adaptability	NOUN
ijpds-3747	46	21	of	of	ADP
ijpds-3747	46	22	the	the	DET
ijpds-3747	46	23	route	route	NOUN
ijpds-3747	46	24	of	of	ADP
ijpds-3747	46	25	administration	administration	NOUN
ijpds-3747	46	26	and	and	CCONJ
ijpds-3747	46	27	the	the	DET
ijpds-3747	46	28	ease	ease	NOUN
ijpds-3747	46	29	of	of	ADP
ijpds-3747	46	30	the	the	DET
ijpds-3747	46	31	once	once	ADV
ijpds-3747	46	32	-	-	PUNCT
ijpds-3747	46	33	weekly	weekly	ADJ
ijpds-3747	46	34	regimen	regiman	NOUN
ijpds-3747	46	35	.	.	PUNCT
ijpds-3747	47	1	the	the	DET
ijpds-3747	47	2	belimumab	belimumab	NOUN
ijpds-3747	47	3	is	be	AUX
ijpds-3747	47	4	metabolized	metabolize	VERB
ijpds-3747	47	5	by	by	ADP
ijpds-3747	47	6	proteolytic	proteolytic	ADJ
ijpds-3747	47	7	enzymes	enzyme	NOUN
ijpds-3747	47	8	and	and	CCONJ
ijpds-3747	47	9	the	the	DET
ijpds-3747	47	10	proteolytic	proteolytic	ADJ
ijpds-3747	47	11	enzymes	enzyme	NOUN
ijpds-3747	47	12	are	be	AUX
ijpds-3747	47	13	not	not	PART
ijpds-3747	47	14	only	only	ADV
ijpds-3747	47	15	restricted	restrict	VERB
ijpds-3747	47	16	to	to	ADP
ijpds-3747	47	17	hepatic	hepatic	ADJ
ijpds-3747	47	18	tissue	tissue	NOUN
ijpds-3747	47	19	.	.	PUNCT
ijpds-3747	48	1	moreover	moreover	ADV
ijpds-3747	48	2	,	,	PUNCT
ijpds-3747	48	3	the	the	DET
ijpds-3747	48	4	level	level	NOUN
ijpds-3747	48	5	of	of	ADP
ijpds-3747	48	6	hepatic	hepatic	ADJ
ijpds-3747	48	7	enzymes	enzyme	NOUN
ijpds-3747	48	8	e.g.	e.g.	ADV
ijpds-3747	48	9	,	,	PUNCT
ijpds-3747	48	10	aspartate	aspartate	NOUN
ijpds-3747	48	11	aminotransferase	aminotransferase	NOUN
ijpds-3747	48	12	(	(	PUNCT
ijpds-3747	48	13	ast	ast	NOUN
ijpds-3747	48	14	)	)	PUNCT
ijpds-3747	48	15	and	and	CCONJ
ijpds-3747	48	16	alanine	alanine	NOUN
ijpds-3747	48	17	aminotransferase	aminotransferase	PROPN
ijpds-3747	48	18	(	(	PUNCT
ijpds-3747	48	19	alt	alt	PROPN
ijpds-3747	48	20	)	)	PUNCT
ijpds-3747	48	21	had	have	VERB
ijpds-3747	48	22	no	no	DET
ijpds-3747	48	23	discernible	discernible	ADJ
ijpds-3747	48	24	effect	effect	NOUN
ijpds-3747	48	25	on	on	ADP
ijpds-3747	48	26	the	the	DET
ijpds-3747	48	27	pharmacokinetics	pharmacokinetic	NOUN
ijpds-3747	48	28	of	of	ADP
ijpds-3747	48	29	belimumab	belimumab	NOUN
ijpds-3747	48	30	in	in	ADP
ijpds-3747	48	31	trials	trial	NOUN
ijpds-3747	48	32	.	.	PUNCT
ijpds-3747	49	1	thus	thus	ADV
ijpds-3747	49	2	,	,	PUNCT
ijpds-3747	49	3	no	no	DET
ijpds-3747	49	4	dose	dose	NOUN
ijpds-3747	49	5	adjustment	adjustment	NOUN
ijpds-3747	49	6	of	of	ADP
ijpds-3747	49	7	belimumab	belimumab	NOUN
ijpds-3747	49	8	is	be	AUX
ijpds-3747	49	9	necessary	necessary	ADJ
ijpds-3747	49	10	for	for	ADP
ijpds-3747	49	11	patients	patient	NOUN
ijpds-3747	49	12	with	with	ADP
ijpds-3747	49	13	hepatic	hepatic	ADJ
ijpds-3747	49	14	impairment	impairment	NOUN
ijpds-3747	49	15	.	.	PUNCT
ijpds-3747	50	1	the	the	DET
ijpds-3747	50	2	previous	previous	ADJ
ijpds-3747	50	3	studies	study	NOUN
ijpds-3747	50	4	reported	report	VERB
ijpds-3747	50	5	belimumab	belimumab	NOUN
ijpds-3747	50	6	to	to	PART
ijpds-3747	50	7	cause	cause	VERB
ijpds-3747	50	8	bronchitis	bronchitis	NOUN
ijpds-3747	50	9	,	,	PUNCT
ijpds-3747	50	10	diarrhoea	diarrhoea	NOUN
ijpds-3747	50	11	,	,	PUNCT
ijpds-3747	50	12	viral	viral	ADJ
ijpds-3747	50	13	upper	upper	ADJ
ijpds-3747	50	14	respiratory	respiratory	ADJ
ijpds-3747	50	15	tract	tract	NOUN
ijpds-3747	50	16	infections	infection	NOUN
ijpds-3747	50	17	(	(	PUNCT
ijpds-3747	50	18	urti	urti	ADJ
ijpds-3747	50	19	)	)	PUNCT
ijpds-3747	50	20	,	,	PUNCT
ijpds-3747	50	21	multifocal	multifocal	ADJ
ijpds-3747	50	22	leukoencephalopathy	leukoencephalopathy	NOUN
ijpds-3747	50	23	,	,	PUNCT
ijpds-3747	50	24	fatal	fatal	ADJ
ijpds-3747	50	25	hypersensitivity	hypersensitivity	NOUN
ijpds-3747	50	26	,	,	PUNCT
ijpds-3747	50	27	and	and	CCONJ
ijpds-3747	50	28	infusion	infusion	NOUN
ijpds-3747	50	29	reactions	reaction	NOUN
ijpds-3747	50	30	[	[	X
ijpds-3747	50	31	15	15	NUM
ijpds-3747	50	32	,	,	PUNCT
ijpds-3747	50	33	16	16	NUM
ijpds-3747	50	34	]	]	PUNCT
ijpds-3747	50	35	.	.	PUNCT
ijpds-3747	51	1	hcq	hcq	PROPN
ijpds-3747	51	2	is	be	AUX
ijpds-3747	51	3	an	an	DET
ijpds-3747	51	4	alkalinizing	alkalinize	VERB
ijpds-3747	51	5	substance	substance	NOUN
ijpds-3747	51	6	.	.	PUNCT
ijpds-3747	52	1	it	it	PRON
ijpds-3747	52	2	is	be	AUX
ijpds-3747	52	3	a	a	DET
ijpds-3747	52	4	lysosomotropic	lysosomotropic	ADJ
ijpds-3747	52	5	medication	medication	NOUN
ijpds-3747	52	6	having	have	VERB
ijpds-3747	52	7	high	high	ADJ
ijpds-3747	52	8	cell	cell	NOUN
ijpds-3747	52	9	permeability	permeability	NOUN
ijpds-3747	52	10	that	that	PRON
ijpds-3747	52	11	is	be	AUX
ijpds-3747	52	12	accumulated	accumulate	VERB
ijpds-3747	52	13	in	in	ADP
ijpds-3747	52	14	lysosomes	lysosome	NOUN
ijpds-3747	52	15	where	where	SCONJ
ijpds-3747	52	16	it	it	PRON
ijpds-3747	52	17	raises	raise	VERB
ijpds-3747	52	18	the	the	DET
ijpds-3747	52	19	ph	ph	NOUN
ijpds-3747	53	1	[	[	X
ijpds-3747	53	2	17	17	NUM
ijpds-3747	53	3	]	]	PUNCT
ijpds-3747	53	4	.	.	PUNCT
ijpds-3747	54	1	figure	figure	NOUN
ijpds-3747	54	2	1	1	NUM
ijpds-3747	54	3	–	–	PUNCT
ijpds-3747	54	4	chemical	chemical	NOUN
ijpds-3747	54	5	structure	structure	NOUN
ijpds-3747	54	6	of	of	ADP
ijpds-3747	54	7	hcq	hcq	PROPN
ijpds-3747	54	8	hcq	hcq	NOUN
ijpds-3747	54	9	was	be	AUX
ijpds-3747	54	10	originally	originally	ADV
ijpds-3747	54	11	used	use	VERB
ijpds-3747	54	12	as	as	ADP
ijpds-3747	54	13	an	an	DET
ijpds-3747	54	14	antimalarial	antimalarial	ADJ
ijpds-3747	54	15	drug	drug	NOUN
ijpds-3747	54	16	,	,	PUNCT
ijpds-3747	54	17	but	but	CCONJ
ijpds-3747	54	18	also	also	ADV
ijpds-3747	54	19	found	find	VERB
ijpds-3747	54	20	beneficial	beneficial	ADJ
ijpds-3747	54	21	for	for	ADP
ijpds-3747	54	22	treating	treat	VERB
ijpds-3747	54	23	autoimmune	autoimmune	ADJ
ijpds-3747	54	24	conditions	condition	NOUN
ijpds-3747	54	25	like	like	ADP
ijpds-3747	54	26	rheumatoid	rheumatoid	VERB
ijpds-3747	54	27	arthritis	arthritis	NOUN
ijpds-3747	54	28	and	and	CCONJ
ijpds-3747	54	29	sle	sle	PROPN
ijpds-3747	54	30	.	.	PUNCT
ijpds-3747	55	1	it	it	PRON
ijpds-3747	55	2	has	have	AUX
ijpds-3747	55	3	been	be	AUX
ijpds-3747	55	4	demonstrated	demonstrate	VERB
ijpds-3747	55	5	to	to	PART
ijpds-3747	55	6	slow	slow	VERB
ijpds-3747	55	7	the	the	DET
ijpds-3747	55	8	onset	onset	NOUN
ijpds-3747	55	9	of	of	ADP
ijpds-3747	55	10	disease	disease	NOUN
ijpds-3747	55	11	,	,	PUNCT
ijpds-3747	55	12	maintain	maintain	VERB
ijpds-3747	55	13	remission	remission	NOUN
ijpds-3747	55	14	,	,	PUNCT
ijpds-3747	55	15	lessen	lessen	VERB
ijpds-3747	55	16	the	the	DET
ijpds-3747	55	17	likelihood	likelihood	NOUN
ijpds-3747	55	18	of	of	ADP
ijpds-3747	55	19	complications	complication	NOUN
ijpds-3747	55	20	,	,	PUNCT
ijpds-3747	55	21	and	and	CCONJ
ijpds-3747	55	22	decrease	decrease	VERB
ijpds-3747	55	23	the	the	DET
ijpds-3747	55	24	frequency	frequency	NOUN
ijpds-3747	55	25	of	of	ADP
ijpds-3747	55	26	disease	disease	NOUN
ijpds-3747	55	27	flare	flare	NOUN
ijpds-3747	55	28	-	-	PUNCT
ijpds-3747	55	29	ups	up	NOUN
ijpds-3747	55	30	[	[	X
ijpds-3747	55	31	18,19	18,19	NUM
ijpds-3747	55	32	]	]	PUNCT
ijpds-3747	55	33	.	.	PUNCT
ijpds-3747	56	1	hcq	hcq	PROPN
ijpds-3747	56	2	has	have	VERB
ijpds-3747	56	3	a	a	DET
ijpds-3747	56	4	broad	broad	ADJ
ijpds-3747	56	5	spectrum	spectrum	NOUN
ijpds-3747	56	6	of	of	ADP
ijpds-3747	56	7	activity	activity	NOUN
ijpds-3747	56	8	and	and	CCONJ
ijpds-3747	56	9	safety	safety	NOUN
ijpds-3747	56	10	profiles	profile	NOUN
ijpds-3747	56	11	;	;	PUNCT
ijpds-3747	56	12	thus	thus	ADV
ijpds-3747	56	13	,	,	PUNCT
ijpds-3747	56	14	it	it	PRON
ijpds-3747	56	15	can	can	AUX
ijpds-3747	56	16	be	be	AUX
ijpds-3747	56	17	given	give	VERB
ijpds-3747	56	18	to	to	ADP
ijpds-3747	56	19	the	the	DET
ijpds-3747	56	20	majority	majority	NOUN
ijpds-3747	56	21	of	of	ADP
ijpds-3747	56	22	sle	sle	PROPN
ijpds-3747	56	23	patients	patient	NOUN
ijpds-3747	56	24	and	and	CCONJ
ijpds-3747	56	25	can	can	AUX
ijpds-3747	56	26	be	be	AUX
ijpds-3747	56	27	continued	continue	VERB
ijpds-3747	56	28	throughout	throughout	ADP
ijpds-3747	56	29	pregnancy	pregnancy	NOUN
ijpds-3747	56	30	.	.	PUNCT
ijpds-3747	57	1	hcq	hcq	NOUN
ijpds-3747	57	2	-	-	PUNCT
ijpds-3747	57	3	associated	associate	VERB
ijpds-3747	57	4	toxicity	toxicity	NOUN
ijpds-3747	57	5	is	be	AUX
ijpds-3747	57	6	uncommon	uncommon	ADJ
ijpds-3747	57	7	,	,	PUNCT
ijpds-3747	57	8	minor	minor	ADJ
ijpds-3747	57	9	,	,	PUNCT
ijpds-3747	57	10	and	and	CCONJ
ijpds-3747	57	11	typically	typically	ADV
ijpds-3747	57	12	reversible	reversible	ADJ
ijpds-3747	57	13	and	and	CCONJ
ijpds-3747	57	14	it	it	PRON
ijpds-3747	57	15	can	can	AUX
ijpds-3747	57	16	reduce	reduce	VERB
ijpds-3747	57	17	lupus	lupus	ADJ
ijpds-3747	57	18	activity	activity	NOUN
ijpds-3747	57	19	in	in	ADP
ijpds-3747	57	20	pregnant	pregnant	ADJ
ijpds-3747	57	21	women	woman	NOUN
ijpds-3747	57	22	without	without	ADP
ijpds-3747	57	23	endangering	endanger	VERB
ijpds-3747	57	24	the	the	DET
ijpds-3747	57	25	unborn	unborn	ADJ
ijpds-3747	57	26	child	child	NOUN
ijpds-3747	57	27	[	[	X
ijpds-3747	57	28	20	20	NUM
ijpds-3747	57	29	]	]	PUNCT
ijpds-3747	57	30	.	.	PUNCT
ijpds-3747	58	1	the	the	DET
ijpds-3747	58	2	adverse	adverse	ADJ
ijpds-3747	58	3	drug	drug	NOUN
ijpds-3747	58	4	reactions	reaction	NOUN
ijpds-3747	58	5	(	(	PUNCT
ijpds-3747	58	6	adr	adr	PROPN
ijpds-3747	58	7	)	)	PUNCT
ijpds-3747	58	8	requiring	require	VERB
ijpds-3747	58	9	clinical	clinical	ADJ
ijpds-3747	58	10	aid	aid	NOUN
ijpds-3747	58	11	include	include	VERB
ijpds-3747	58	12	ocular	ocular	ADJ
ijpds-3747	58	13	adrs	adr	NOUN
ijpds-3747	58	14	and	and	CCONJ
ijpds-3747	58	15	effects	effect	NOUN
ijpds-3747	58	16	on	on	ADP
ijpds-3747	58	17	the	the	DET
ijpds-3747	58	18	heart	heart	NOUN
ijpds-3747	58	19	[	[	X
ijpds-3747	58	20	21	21	NUM
ijpds-3747	58	21	]	]	PUNCT
ijpds-3747	58	22	.	.	PUNCT
ijpds-3747	59	1	the	the	DET
ijpds-3747	59	2	present	present	ADJ
ijpds-3747	59	3	review	review	NOUN
ijpds-3747	59	4	is	be	AUX
ijpds-3747	59	5	aimed	aim	VERB
ijpds-3747	59	6	at	at	ADP
ijpds-3747	59	7	analyzing	analyze	VERB
ijpds-3747	59	8	the	the	DET
ijpds-3747	59	9	safety	safety	NOUN
ijpds-3747	59	10	profiles	profile	NOUN
ijpds-3747	59	11	of	of	ADP
ijpds-3747	59	12	hcq	hcq	NOUN
ijpds-3747	59	13	and	and	CCONJ
ijpds-3747	59	14	belimumab	belimumab	NOUN
ijpds-3747	59	15	by	by	ADP
ijpds-3747	59	16	the	the	DET
ijpds-3747	59	17	critical	critical	ADJ
ijpds-3747	59	18	review	review	NOUN
ijpds-3747	59	19	as	as	SCONJ
ijpds-3747	59	20	hcq	hcq	NOUN
ijpds-3747	59	21	was	be	AUX
ijpds-3747	59	22	recently	recently	ADV
ijpds-3747	59	23	used	use	VERB
ijpds-3747	59	24	in	in	ADP
ijpds-3747	59	25	the	the	DET
ijpds-3747	59	26	global	global	ADJ
ijpds-3747	59	27	pandemic	pandemic	NOUN
ijpds-3747	59	28	of	of	ADP
ijpds-3747	59	29	covid-19	covid-19	PROPN
ijpds-3747	59	30	and	and	CCONJ
ijpds-3747	59	31	recent	recent	ADJ
ijpds-3747	59	32	data	datum	NOUN
ijpds-3747	59	33	is	be	AUX
ijpds-3747	59	34	available	available	ADJ
ijpds-3747	59	35	on	on	ADP
ijpds-3747	59	36	hcq	hcq	NOUN
ijpds-3747	59	37	safety	safety	NOUN
ijpds-3747	59	38	profiling	profiling	NOUN
ijpds-3747	59	39	.	.	PUNCT
ijpds-3747	60	1	the	the	DET
ijpds-3747	60	2	review	review	NOUN
ijpds-3747	60	3	will	will	AUX
ijpds-3747	60	4	focus	focus	VERB
ijpds-3747	60	5	on	on	ADP
ijpds-3747	60	6	statistically	statistically	ADV
ijpds-3747	60	7	analyzing	analyze	VERB
ijpds-3747	60	8	the	the	DET
ijpds-3747	60	9	adverse	adverse	ADJ
ijpds-3747	60	10	drug	drug	NOUN
ijpds-3747	60	11	effects	effect	NOUN
ijpds-3747	60	12	of	of	ADP
ijpds-3747	60	13	the	the	DET
ijpds-3747	60	14	two	two	NUM
ijpds-3747	60	15	drugs	drug	NOUN
ijpds-3747	60	16	:	:	PUNCT
ijpds-3747	60	17	hcq	hcq	NOUN
ijpds-3747	60	18	and	and	CCONJ
ijpds-3747	60	19	belimumab	belimumab	NOUN
ijpds-3747	60	20	and	and	CCONJ
ijpds-3747	60	21	theoretically	theoretically	ADV
ijpds-3747	60	22	choosing	choose	VERB
ijpds-3747	60	23	the	the	DET
ijpds-3747	60	24	best	good	ADJ
ijpds-3747	60	25	drug	drug	NOUN
ijpds-3747	60	26	choice	choice	NOUN
ijpds-3747	60	27	for	for	ADP
ijpds-3747	60	28	sle	sle	PROPN
ijpds-3747	60	29	.	.	PUNCT
ijpds-3747	61	1	this	this	PRON
ijpds-3747	61	2	can	can	AUX
ijpds-3747	61	3	be	be	AUX
ijpds-3747	61	4	done	do	VERB
ijpds-3747	61	5	by	by	ADP
ijpds-3747	61	6	signal	signal	ADJ
ijpds-3747	61	7	detection	detection	NOUN
ijpds-3747	61	8	from	from	ADP
ijpds-3747	61	9	scientific	scientific	ADJ
ijpds-3747	61	10	databases	database	NOUN
ijpds-3747	61	11	;	;	PUNCT
ijpds-3747	61	12	clinicaltrial.gov	clinicaltrial.gov	X
ijpds-3747	61	13	,	,	PUNCT
ijpds-3747	61	14	pubmed	pubmed	PROPN
ijpds-3747	61	15	,	,	PUNCT
ijpds-3747	61	16	and	and	CCONJ
ijpds-3747	61	17	other	other	ADJ
ijpds-3747	61	18	research	research	NOUN
ijpds-3747	61	19	articles	article	NOUN
ijpds-3747	61	20	.	.	PUNCT
ijpds-3747	62	1	methodology	methodology	NOUN
ijpds-3747	62	2	this	this	DET
ijpds-3747	62	3	critical	critical	ADJ
ijpds-3747	62	4	review	review	NOUN
ijpds-3747	62	5	is	be	AUX
ijpds-3747	62	6	aimed	aim	VERB
ijpds-3747	62	7	at	at	ADP
ijpds-3747	62	8	analyzing	analyze	VERB
ijpds-3747	62	9	the	the	DET
ijpds-3747	62	10	pharmacovigilance	pharmacovigilance	NOUN
ijpds-3747	62	11	studies	study	NOUN
ijpds-3747	62	12	and	and	CCONJ
ijpds-3747	62	13	comparing	compare	VERB
ijpds-3747	62	14	the	the	DET
ijpds-3747	62	15	adverse	adverse	ADJ
ijpds-3747	62	16	effects	effect	NOUN
ijpds-3747	62	17	of	of	ADP
ijpds-3747	62	18	the	the	DET
ijpds-3747	62	19	two	two	NUM
ijpds-3747	62	20	drugs	drug	NOUN
ijpds-3747	62	21	used	use	VERB
ijpds-3747	62	22	for	for	ADP
ijpds-3747	62	23	treating	treat	VERB
ijpds-3747	62	24	sle	sle	PROPN
ijpds-3747	62	25	.	.	PUNCT
ijpds-3747	63	1	database	database	NOUN
ijpds-3747	63	2	selection	selection	NOUN
ijpds-3747	63	3	:	:	PUNCT
ijpds-3747	63	4	we	we	PRON
ijpds-3747	63	5	searched	search	VERB
ijpds-3747	63	6	authentic	authentic	ADJ
ijpds-3747	63	7	electronic	electronic	ADJ
ijpds-3747	63	8	databases	database	NOUN
ijpds-3747	63	9	pubmed	pubmed	VERB
ijpds-3747	63	10	,	,	PUNCT
ijpds-3747	63	11	google	google	PROPN
ijpds-3747	63	12	scholar	scholar	NOUN
ijpds-3747	63	13	,	,	PUNCT
ijpds-3747	63	14	ncbi	ncbi	PROPN
ijpds-3747	63	15	(	(	PUNCT
ijpds-3747	63	16	national	national	ADJ
ijpds-3747	63	17	center	center	NOUN
ijpds-3747	63	18	for	for	ADP
ijpds-3747	63	19	biotechnology	biotechnology	NOUN
ijpds-3747	63	20	information	information	NOUN
ijpds-3747	63	21	)	)	PUNCT
ijpds-3747	63	22	,	,	PUNCT
ijpds-3747	63	23	and	and	CCONJ
ijpds-3747	63	24	sciencedirect	sciencedirect	VERB
ijpds-3747	63	25	to	to	PART
ijpds-3747	63	26	collect	collect	VERB
ijpds-3747	63	27	data	datum	NOUN
ijpds-3747	63	28	.	.	PUNCT
ijpds-3747	64	1	these	these	DET
ijpds-3747	64	2	scientific	scientific	ADJ
ijpds-3747	64	3	databases	database	NOUN
ijpds-3747	64	4	help	help	VERB
ijpds-3747	64	5	find	find	VERB
ijpds-3747	64	6	citations	citation	NOUN
ijpds-3747	64	7	for	for	ADP
ijpds-3747	64	8	sources	source	NOUN
ijpds-3747	64	9	,	,	PUNCT
ijpds-3747	64	10	which	which	PRON
ijpds-3747	64	11	can	can	AUX
ijpds-3747	64	12	broaden	broaden	VERB
ijpds-3747	64	13	the	the	DET
ijpds-3747	64	14	scope	scope	NOUN
ijpds-3747	64	15	of	of	ADP
ijpds-3747	64	16	the	the	DET
ijpds-3747	64	17	articles	article	NOUN
ijpds-3747	64	18	retrieved	retrieve	VERB
ijpds-3747	64	19	.	.	PUNCT
ijpds-3747	65	1	for	for	ADP
ijpds-3747	65	2	unpublished	unpublished	ADJ
ijpds-3747	65	3	data	datum	NOUN
ijpds-3747	65	4	extraction	extraction	NOUN
ijpds-3747	65	5	and	and	CCONJ
ijpds-3747	65	6	collection	collection	NOUN
ijpds-3747	65	7	of	of	ADP
ijpds-3747	65	8	data	datum	NOUN
ijpds-3747	65	9	directly	directly	ADV
ijpds-3747	65	10	from	from	ADP
ijpds-3747	65	11	clinical	clinical	ADJ
ijpds-3747	65	12	trials	trial	NOUN
ijpds-3747	65	13	,	,	PUNCT
ijpds-3747	65	14	the	the	DET
ijpds-3747	65	15	website	website	NOUN
ijpds-3747	65	16	clinicaltrials.gov	clinicaltrials.gov	PROPN
ijpds-3747	65	17	was	be	AUX
ijpds-3747	65	18	used	use	VERB
ijpds-3747	65	19	.	.	PUNCT
ijpds-3747	66	1	for	for	ADP
ijpds-3747	66	2	the	the	DET
ijpds-3747	66	3	clinical	clinical	ADJ
ijpds-3747	66	4	trials	trial	NOUN
ijpds-3747	66	5	search	search	VERB
ijpds-3747	66	6	,	,	PUNCT
ijpds-3747	66	7	the	the	DET
ijpds-3747	66	8	keywords	keyword	NOUN
ijpds-3747	66	9	hcq	hcq	NOUN
ijpds-3747	66	10	,	,	PUNCT
ijpds-3747	66	11	belimumab	belimumab	NOUN
ijpds-3747	66	12	,	,	PUNCT
ijpds-3747	66	13	and	and	CCONJ
ijpds-3747	66	14	sle	sle	PROPN
ijpds-3747	66	15	were	be	AUX
ijpds-3747	66	16	employed	employ	VERB
ijpds-3747	66	17	.	.	PUNCT
ijpds-3747	67	1	all	all	DET
ijpds-3747	67	2	clinical	clinical	ADJ
ijpds-3747	67	3	trials	trial	NOUN
ijpds-3747	67	4	that	that	PRON
ijpds-3747	67	5	focussed	focusse	VERB
ijpds-3747	67	6	on	on	ADP
ijpds-3747	67	7	the	the	DET
ijpds-3747	67	8	safety	safety	NOUN
ijpds-3747	67	9	and	and	CCONJ
ijpds-3747	67	10	efficacy	efficacy	NOUN
ijpds-3747	67	11	of	of	ADP
ijpds-3747	67	12	hcq	hcq	NOUN
ijpds-3747	67	13	and	and	CCONJ
ijpds-3747	67	14	belimumab	belimumab	NOUN
ijpds-3747	67	15	were	be	AUX
ijpds-3747	67	16	considered	consider	VERB
ijpds-3747	67	17	acceptable	acceptable	ADJ
ijpds-3747	67	18	for	for	ADP
ijpds-3747	67	19	the	the	DET
ijpds-3747	67	20	study	study	NOUN
ijpds-3747	67	21	.	.	PUNCT
ijpds-3747	68	1	because	because	SCONJ
ijpds-3747	68	2	the	the	DET
ijpds-3747	68	3	number	number	NOUN
ijpds-3747	68	4	of	of	ADP
ijpds-3747	68	5	clinical	clinical	ADJ
ijpds-3747	68	6	trials	trial	NOUN
ijpds-3747	68	7	was	be	AUX
ijpds-3747	68	8	small	small	ADJ
ijpds-3747	68	9	,	,	PUNCT
ijpds-3747	68	10	thus	thus	ADV
ijpds-3747	68	11	,	,	PUNCT
ijpds-3747	68	12	the	the	DET
ijpds-3747	68	13	area	area	NOUN
ijpds-3747	68	14	of	of	ADP
ijpds-3747	68	15	research	research	NOUN
ijpds-3747	68	16	was	be	AUX
ijpds-3747	68	17	broadened	broaden	VERB
ijpds-3747	68	18	to	to	ADP
ijpds-3747	68	19	the	the	DET
ijpds-3747	68	20	published	publish	VERB
ijpds-3747	68	21	articles	article	NOUN
ijpds-3747	68	22	as	as	ADV
ijpds-3747	68	23	well	well	ADV
ijpds-3747	68	24	.	.	PUNCT
ijpds-3747	69	1	the	the	DET
ijpds-3747	69	2	trials	trial	NOUN
ijpds-3747	69	3	were	be	AUX
ijpds-3747	69	4	then	then	ADV
ijpds-3747	69	5	scrutinized	scrutinize	VERB
ijpds-3747	69	6	for	for	ADP
ijpds-3747	69	7	inclusion	inclusion	NOUN
ijpds-3747	69	8	and	and	CCONJ
ijpds-3747	69	9	exclusion	exclusion	NOUN
ijpds-3747	69	10	criteria	criterion	NOUN
ijpds-3747	69	11	.	.	PUNCT
ijpds-3747	70	1	inclusion	inclusion	NOUN
ijpds-3747	70	2	and	and	CCONJ
ijpds-3747	70	3	exclusion	exclusion	NOUN
ijpds-3747	70	4	criteria	criterion	NOUN
ijpds-3747	70	5	:	:	PUNCT
ijpds-3747	70	6	a	a	DET
ijpds-3747	70	7	pico	pico	NOUN
ijpds-3747	70	8	(	(	PUNCT
ijpds-3747	70	9	patient	patient	ADJ
ijpds-3747	70	10	,	,	PUNCT
ijpds-3747	70	11	intervention	intervention	NOUN
ijpds-3747	70	12	,	,	PUNCT
ijpds-3747	70	13	comparison	comparison	NOUN
ijpds-3747	70	14	,	,	PUNCT
ijpds-3747	70	15	and	and	CCONJ
ijpds-3747	70	16	outcomes	outcome	NOUN
ijpds-3747	70	17	)	)	PUNCT
ijpds-3747	70	18	approach	approach	NOUN
ijpds-3747	70	19	was	be	AUX
ijpds-3747	70	20	applied	apply	VERB
ijpds-3747	70	21	to	to	PART
ijpds-3747	70	22	include	include	VERB
ijpds-3747	70	23	the	the	DET
ijpds-3747	70	24	studies	study	NOUN
ijpds-3747	70	25	in	in	ADP
ijpds-3747	70	26	this	this	DET
ijpds-3747	70	27	comprehensive	comprehensive	ADJ
ijpds-3747	70	28	review	review	NOUN
ijpds-3747	70	29	.	.	PUNCT
ijpds-3747	71	1	all	all	DET
ijpds-3747	71	2	the	the	DET
ijpds-3747	71	3	participants	participant	NOUN
ijpds-3747	71	4	in	in	ADP
ijpds-3747	71	5	the	the	DET
ijpds-3747	71	6	clinical	clinical	ADJ
ijpds-3747	71	7	trials	trial	NOUN
ijpds-3747	71	8	were	be	AUX
ijpds-3747	71	9	included	include	VERB
ijpds-3747	71	10	in	in	ADP
ijpds-3747	71	11	this	this	DET
ijpds-3747	71	12	study	study	NOUN
ijpds-3747	71	13	.	.	PUNCT
ijpds-3747	72	1	patients	patient	NOUN
ijpds-3747	72	2	of	of	ADP
ijpds-3747	72	3	both	both	DET
ijpds-3747	72	4	sexes	sex	NOUN
ijpds-3747	72	5	(	(	PUNCT
ijpds-3747	72	6	males	male	NOUN
ijpds-3747	72	7	and	and	CCONJ
ijpds-3747	72	8	females	female	NOUN
ijpds-3747	72	9	)	)	PUNCT
ijpds-3747	72	10	of	of	ADP
ijpds-3747	72	11	age	age	NOUN
ijpds-3747	72	12	more	more	ADJ
ijpds-3747	72	13	than	than	ADP
ijpds-3747	72	14	18	18	NUM
ijpds-3747	72	15	were	be	AUX
ijpds-3747	72	16	enrolled	enrol	VERB
ijpds-3747	72	17	.	.	PUNCT
ijpds-3747	73	1	the	the	DET
ijpds-3747	73	2	outcomes	outcome	NOUN
ijpds-3747	73	3	considered	consider	VERB
ijpds-3747	73	4	for	for	ADP
ijpds-3747	73	5	this	this	DET
ijpds-3747	73	6	critical	critical	ADJ
ijpds-3747	73	7	analysis	analysis	NOUN
ijpds-3747	73	8	were	be	AUX
ijpds-3747	73	9	serious	serious	ADJ
ijpds-3747	73	10	adverse	adverse	ADJ
ijpds-3747	73	11	effects	effect	NOUN
ijpds-3747	73	12	,	,	PUNCT
ijpds-3747	73	13	all	all	DET
ijpds-3747	73	14	-	-	PUNCT
ijpds-3747	73	15	cause	cause	NOUN
ijpds-3747	73	16	mortality	mortality	NOUN
ijpds-3747	73	17	,	,	PUNCT
ijpds-3747	73	18	serious	serious	ADJ
ijpds-3747	73	19	adverse	adverse	ADJ
ijpds-3747	73	20	events	event	NOUN
ijpds-3747	73	21	,	,	PUNCT
ijpds-3747	73	22	and	and	CCONJ
ijpds-3747	73	23	non	non	ADJ
ijpds-3747	73	24	-	-	ADJ
ijpds-3747	73	25	serious	serious	ADJ
ijpds-3747	73	26	adverse	adverse	ADJ
ijpds-3747	73	27	events	event	NOUN
ijpds-3747	73	28	.	.	PUNCT
ijpds-3747	74	1	the	the	DET
ijpds-3747	74	2	adverse	adverse	ADJ
ijpds-3747	74	3	effects	effect	NOUN
ijpds-3747	74	4	of	of	ADP
ijpds-3747	74	5	the	the	DET
ijpds-3747	74	6	drugs	drug	NOUN
ijpds-3747	74	7	after	after	ADP
ijpds-3747	74	8	treating	treat	VERB
ijpds-3747	74	9	the	the	DET
ijpds-3747	74	10	patients	patient	NOUN
ijpds-3747	74	11	with	with	ADP
ijpds-3747	74	12	hcq	hcq	NOUN
ijpds-3747	74	13	and	and	CCONJ
ijpds-3747	74	14	belimumab	belimumab	NOUN
ijpds-3747	74	15	were	be	AUX
ijpds-3747	74	16	compared	compare	VERB
ijpds-3747	74	17	with	with	ADP
ijpds-3747	74	18	the	the	DET
ijpds-3747	74	19	adverse	adverse	ADJ
ijpds-3747	74	20	effects	effect	NOUN
ijpds-3747	74	21	observed	observe	VERB
ijpds-3747	74	22	in	in	ADP
ijpds-3747	74	23	the	the	DET
ijpds-3747	74	24	placebo	placebo	NOUN
ijpds-3747	74	25	maryam	maryam	PROPN
ijpds-3747	74	26	and	and	CCONJ
ijpds-3747	74	27	ahmad	ahmad	PROPN
ijpds-3747	74	28	safety	safety	PROPN
ijpds-3747	74	29	comparison	comparison	NOUN
ijpds-3747	74	30	of	of	ADP
ijpds-3747	74	31	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	74	32	and	and	CCONJ
ijpds-3747	74	33	belimumab	belimumab	NOUN
ijpds-3747	74	34	vol	vol	NOUN
ijpds-3747	74	35	2	2	NUM
ijpds-3747	74	36	|	|	NOUN
ijpds-3747	74	37	issue	issue	NOUN
ijpds-3747	74	38	1	1	NUM
ijpds-3747	74	39	|	|	ADV
ijpds-3747	74	40	jan	jan	PROPN
ijpds-3747	74	41	–	–	PUNCT
ijpds-3747	74	42	mar	mar	PROPN
ijpds-3747	74	43	2023	2023	NUM
ijpds-3747	74	44	indian	indian	PROPN
ijpds-3747	74	45	j	j	PROPN
ijpds-3747	74	46	pharm	pharm	PROPN
ijpds-3747	74	47	drug	drug	PROPN
ijpds-3747	74	48	studies	study	NOUN
ijpds-3747	74	49	|	|	ADV
ijpds-3747	74	50	7	7	NUM
ijpds-3747	74	51	group	group	NOUN
ijpds-3747	74	52	.	.	PUNCT
ijpds-3747	75	1	the	the	DET
ijpds-3747	75	2	data	datum	NOUN
ijpds-3747	75	3	relating	relate	VERB
ijpds-3747	75	4	to	to	ADP
ijpds-3747	75	5	adverse	adverse	ADJ
ijpds-3747	75	6	events	event	NOUN
ijpds-3747	75	7	were	be	AUX
ijpds-3747	75	8	considered	consider	VERB
ijpds-3747	75	9	for	for	ADP
ijpds-3747	75	10	extraction	extraction	NOUN
ijpds-3747	75	11	.	.	PUNCT
ijpds-3747	76	1	the	the	DET
ijpds-3747	76	2	data	datum	NOUN
ijpds-3747	76	3	was	be	AUX
ijpds-3747	76	4	extracted	extract	VERB
ijpds-3747	76	5	in	in	ADP
ijpds-3747	76	6	the	the	DET
ijpds-3747	76	7	form	form	NOUN
ijpds-3747	76	8	of	of	ADP
ijpds-3747	76	9	the	the	DET
ijpds-3747	76	10	number	number	NOUN
ijpds-3747	76	11	of	of	ADP
ijpds-3747	76	12	persons	person	NOUN
ijpds-3747	76	13	having	have	VERB
ijpds-3747	76	14	adverse	adverse	ADJ
ijpds-3747	76	15	events	event	NOUN
ijpds-3747	76	16	.	.	PUNCT
ijpds-3747	77	1	figure	figure	NOUN
ijpds-3747	77	2	2	2	NUM
ijpds-3747	77	3	–	–	PUNCT
ijpds-3747	77	4	flow	flow	NOUN
ijpds-3747	77	5	diagram	diagram	NOUN
ijpds-3747	77	6	of	of	ADP
ijpds-3747	77	7	search	search	NOUN
ijpds-3747	77	8	strategy	strategy	NOUN
ijpds-3747	77	9	statistical	statistical	ADJ
ijpds-3747	77	10	analysis	analysis	NOUN
ijpds-3747	77	11	:	:	PUNCT
ijpds-3747	77	12	all	all	DET
ijpds-3747	77	13	the	the	DET
ijpds-3747	77	14	statistical	statistical	ADJ
ijpds-3747	77	15	analyses	analysis	NOUN
ijpds-3747	77	16	were	be	AUX
ijpds-3747	77	17	performed	perform	VERB
ijpds-3747	77	18	using	use	VERB
ijpds-3747	77	19	microsoft	microsoft	PROPN
ijpds-3747	77	20	excel	excel	PROPN
ijpds-3747	77	21	software	software	NOUN
ijpds-3747	77	22	.	.	PUNCT
ijpds-3747	78	1	we	we	PRON
ijpds-3747	78	2	extracted	extract	VERB
ijpds-3747	78	3	the	the	DET
ijpds-3747	78	4	number	number	NOUN
ijpds-3747	78	5	of	of	ADP
ijpds-3747	78	6	persons	person	NOUN
ijpds-3747	78	7	from	from	ADP
ijpds-3747	78	8	trials	trial	NOUN
ijpds-3747	78	9	and	and	CCONJ
ijpds-3747	78	10	then	then	ADV
ijpds-3747	78	11	the	the	DET
ijpds-3747	78	12	percentage	percentage	NOUN
ijpds-3747	78	13	of	of	ADP
ijpds-3747	78	14	persons	person	NOUN
ijpds-3747	78	15	having	have	VERB
ijpds-3747	78	16	adverse	adverse	ADJ
ijpds-3747	78	17	events	event	NOUN
ijpds-3747	78	18	was	be	AUX
ijpds-3747	78	19	determined	determine	VERB
ijpds-3747	78	20	.	.	PUNCT
ijpds-3747	79	1	the	the	DET
ijpds-3747	79	2	formula	formula	NOUN
ijpds-3747	79	3	employed	employ	VERB
ijpds-3747	79	4	for	for	ADP
ijpds-3747	79	5	the	the	DET
ijpds-3747	79	6	percentage	percentage	NOUN
ijpds-3747	79	7	determination	determination	NOUN
ijpds-3747	79	8	is	be	AUX
ijpds-3747	79	9	given	give	VERB
ijpds-3747	79	10	in	in	ADP
ijpds-3747	79	11	equation	equation	NOUN
ijpds-3747	79	12	1	1	NUM
ijpds-3747	79	13	.	.	PUNCT
ijpds-3747	80	1	the	the	DET
ijpds-3747	80	2	absolute	absolute	ADJ
ijpds-3747	80	3	risk	risk	NOUN
ijpds-3747	80	4	,	,	PUNCT
ijpds-3747	80	5	relative	relative	ADJ
ijpds-3747	80	6	risk	risk	NOUN
ijpds-3747	80	7	,	,	PUNCT
ijpds-3747	80	8	risk	risk	NOUN
ijpds-3747	80	9	difference	difference	NOUN
ijpds-3747	80	10	,	,	PUNCT
ijpds-3747	80	11	and	and	CCONJ
ijpds-3747	80	12	odds	odd	NOUN
ijpds-3747	80	13	ratio	ratio	NOUN
ijpds-3747	80	14	were	be	AUX
ijpds-3747	80	15	calculated	calculate	VERB
ijpds-3747	80	16	.	.	PUNCT
ijpds-3747	81	1	the	the	DET
ijpds-3747	81	2	absolute	absolute	ADJ
ijpds-3747	81	3	risk	risk	NOUN
ijpds-3747	81	4	was	be	AUX
ijpds-3747	81	5	calculated	calculate	VERB
ijpds-3747	81	6	by	by	ADP
ijpds-3747	81	7	dividing	divide	VERB
ijpds-3747	81	8	the	the	DET
ijpds-3747	81	9	number	number	NOUN
ijpds-3747	81	10	of	of	ADP
ijpds-3747	81	11	participants	participant	NOUN
ijpds-3747	81	12	having	have	VERB
ijpds-3747	81	13	adverse	adverse	ADJ
ijpds-3747	81	14	effects	effect	NOUN
ijpds-3747	81	15	(	(	PUNCT
ijpds-3747	81	16	ae	ae	PROPN
ijpds-3747	81	17	)	)	PUNCT
ijpds-3747	81	18	by	by	ADP
ijpds-3747	81	19	the	the	DET
ijpds-3747	81	20	total	total	ADJ
ijpds-3747	81	21	number	number	NOUN
ijpds-3747	81	22	of	of	ADP
ijpds-3747	81	23	participants	participant	NOUN
ijpds-3747	81	24	for	for	ADP
ijpds-3747	81	25	both	both	DET
ijpds-3747	81	26	drugs	drug	NOUN
ijpds-3747	81	27	(	(	PUNCT
ijpds-3747	81	28	hcq	hcq	NOUN
ijpds-3747	81	29	and	and	CCONJ
ijpds-3747	81	30	belimumab	belimumab	NOUN
ijpds-3747	81	31	)	)	PUNCT
ijpds-3747	81	32	separately	separately	ADV
ijpds-3747	81	33	.	.	PUNCT
ijpds-3747	82	1	the	the	DET
ijpds-3747	82	2	formula	formula	NOUN
ijpds-3747	82	3	for	for	ADP
ijpds-3747	82	4	absolute	absolute	ADJ
ijpds-3747	82	5	risk	risk	NOUN
ijpds-3747	82	6	is	be	AUX
ijpds-3747	82	7	given	give	VERB
ijpds-3747	82	8	in	in	ADP
ijpds-3747	82	9	equation	equation	NOUN
ijpds-3747	82	10	2	2	NUM
ijpds-3747	82	11	.	.	PUNCT
ijpds-3747	83	1	the	the	DET
ijpds-3747	83	2	risk	risk	NOUN
ijpds-3747	83	3	difference	difference	NOUN
ijpds-3747	83	4	was	be	AUX
ijpds-3747	83	5	calculated	calculate	VERB
ijpds-3747	83	6	by	by	ADP
ijpds-3747	83	7	equation	equation	NOUN
ijpds-3747	83	8	3	3	NUM
ijpds-3747	83	9	.	.	PUNCT
ijpds-3747	84	1	the	the	DET
ijpds-3747	84	2	odds	odd	NOUN
ijpds-3747	84	3	ratio	ratio	NOUN
ijpds-3747	84	4	shows	show	VERB
ijpds-3747	84	5	the	the	DET
ijpds-3747	84	6	likelihood	likelihood	NOUN
ijpds-3747	84	7	that	that	SCONJ
ijpds-3747	84	8	an	an	DET
ijpds-3747	84	9	outcome	outcome	NOUN
ijpds-3747	84	10	will	will	AUX
ijpds-3747	84	11	occur	occur	VERB
ijpds-3747	84	12	given	give	VERB
ijpds-3747	84	13	a	a	DET
ijpds-3747	84	14	specific	specific	ADJ
ijpds-3747	84	15	exposure	exposure	NOUN
ijpds-3747	84	16	in	in	ADP
ijpds-3747	84	17	comparison	comparison	NOUN
ijpds-3747	84	18	to	to	ADP
ijpds-3747	84	19	the	the	DET
ijpds-3747	84	20	chances	chance	NOUN
ijpds-3747	84	21	of	of	ADP
ijpds-3747	84	22	the	the	DET
ijpds-3747	84	23	event	event	NOUN
ijpds-3747	84	24	occurring	occur	VERB
ijpds-3747	84	25	without	without	ADP
ijpds-3747	84	26	that	that	DET
ijpds-3747	84	27	exposure	exposure	NOUN
ijpds-3747	84	28	[	[	X
ijpds-3747	84	29	22	22	NUM
ijpds-3747	84	30	]	]	PUNCT
ijpds-3747	84	31	.	.	PUNCT
ijpds-3747	85	1	the	the	DET
ijpds-3747	85	2	odds	odd	NOUN
ijpds-3747	85	3	ratio	ratio	NOUN
ijpds-3747	85	4	ranges	range	VERB
ijpds-3747	85	5	from	from	ADP
ijpds-3747	85	6	0	0	NUM
ijpds-3747	85	7	to	to	ADP
ijpds-3747	85	8	1	1	NUM
ijpds-3747	85	9	and	and	CCONJ
ijpds-3747	85	10	is	be	AUX
ijpds-3747	85	11	always	always	ADV
ijpds-3747	85	12	positive	positive	ADJ
ijpds-3747	85	13	.	.	PUNCT
ijpds-3747	86	1	if	if	SCONJ
ijpds-3747	86	2	the	the	PRON
ijpds-3747	86	3	or	or	CCONJ
ijpds-3747	86	4	is	be	AUX
ijpds-3747	86	5	1	1	NUM
ijpds-3747	86	6	,	,	PUNCT
ijpds-3747	86	7	it	it	PRON
ijpds-3747	86	8	means	mean	VERB
ijpds-3747	86	9	that	that	SCONJ
ijpds-3747	86	10	there	there	PRON
ijpds-3747	86	11	is	be	VERB
ijpds-3747	86	12	no	no	DET
ijpds-3747	86	13	difference	difference	NOUN
ijpds-3747	86	14	in	in	ADP
ijpds-3747	86	15	the	the	DET
ijpds-3747	86	16	outcome	outcome	NOUN
ijpds-3747	86	17	of	of	ADP
ijpds-3747	86	18	interest	interest	NOUN
ijpds-3747	86	19	between	between	ADP
ijpds-3747	86	20	the	the	DET
ijpds-3747	86	21	treatment	treatment	NOUN
ijpds-3747	86	22	and	and	CCONJ
ijpds-3747	86	23	the	the	DET
ijpds-3747	86	24	control	control	NOUN
ijpds-3747	86	25	.	.	PUNCT
ijpds-3747	87	1	when	when	SCONJ
ijpds-3747	87	2	the	the	PRON
ijpds-3747	87	3	or	or	CCONJ
ijpds-3747	87	4	is	be	AUX
ijpds-3747	87	5	greater	great	ADJ
ijpds-3747	87	6	than	than	ADP
ijpds-3747	87	7	1	1	NUM
ijpds-3747	87	8	,	,	PUNCT
ijpds-3747	87	9	the	the	DET
ijpds-3747	87	10	treatment	treatment	NOUN
ijpds-3747	87	11	is	be	AUX
ijpds-3747	87	12	more	more	ADV
ijpds-3747	87	13	likely	likely	ADJ
ijpds-3747	87	14	than	than	ADP
ijpds-3747	87	15	the	the	DET
ijpds-3747	87	16	control	control	NOUN
ijpds-3747	87	17	to	to	PART
ijpds-3747	87	18	cause	cause	VERB
ijpds-3747	87	19	the	the	DET
ijpds-3747	87	20	desired	desire	VERB
ijpds-3747	87	21	outcome	outcome	NOUN
ijpds-3747	87	22	[	[	X
ijpds-3747	87	23	23	23	NUM
ijpds-3747	87	24	]	]	PUNCT
ijpds-3747	87	25	.	.	PUNCT
ijpds-3747	88	1	the	the	DET
ijpds-3747	88	2	odd	odd	ADJ
ijpds-3747	88	3	ratio	ratio	NOUN
ijpds-3747	88	4	was	be	AUX
ijpds-3747	88	5	calculated	calculate	VERB
ijpds-3747	88	6	using	use	VERB
ijpds-3747	88	7	the	the	DET
ijpds-3747	88	8	following	follow	VERB
ijpds-3747	88	9	formula	formula	NOUN
ijpds-3747	88	10	mentioned	mention	VERB
ijpds-3747	88	11	in	in	ADP
ijpds-3747	88	12	equation	equation	NOUN
ijpds-3747	88	13	4	4	NUM
ijpds-3747	88	14	.	.	PUNCT
ijpds-3747	88	15	relative	relative	ADJ
ijpds-3747	88	16	risk	risk	NOUN
ijpds-3747	88	17	compares	compare	VERB
ijpds-3747	88	18	the	the	DET
ijpds-3747	88	19	likelihood	likelihood	NOUN
ijpds-3747	88	20	of	of	ADP
ijpds-3747	88	21	a	a	DET
ijpds-3747	88	22	health	health	NOUN
ijpds-3747	88	23	event	event	NOUN
ijpds-3747	88	24	(	(	PUNCT
ijpds-3747	88	25	in	in	ADP
ijpds-3747	88	26	the	the	DET
ijpds-3747	88	27	present	present	ADJ
ijpds-3747	88	28	study	study	NOUN
ijpds-3747	88	29	,	,	PUNCT
ijpds-3747	88	30	the	the	DET
ijpds-3747	88	31	adverse	adverse	ADJ
ijpds-3747	88	32	event	event	NOUN
ijpds-3747	88	33	)	)	PUNCT
ijpds-3747	88	34	among	among	ADP
ijpds-3747	88	35	two	two	NUM
ijpds-3747	88	36	groups	group	NOUN
ijpds-3747	88	37	.	.	PUNCT
ijpds-3747	89	1	relative	relative	ADJ
ijpds-3747	89	2	risk	risk	NOUN
ijpds-3747	89	3	was	be	AUX
ijpds-3747	89	4	determined	determine	VERB
ijpds-3747	89	5	using	use	VERB
ijpds-3747	89	6	equation	equation	NOUN
ijpds-3747	89	7	5	5	NUM
ijpds-3747	89	8	.	.	PUNCT
ijpds-3747	90	1	results	result	NOUN
ijpds-3747	90	2	we	we	PRON
ijpds-3747	90	3	identified	identify	VERB
ijpds-3747	90	4	90	90	NUM
ijpds-3747	90	5	records	record	NOUN
ijpds-3747	90	6	for	for	ADP
ijpds-3747	90	7	belimumab	belimumab	NOUN
ijpds-3747	90	8	and	and	CCONJ
ijpds-3747	90	9	509	509	NUM
ijpds-3747	90	10	studies	study	NOUN
ijpds-3747	90	11	on	on	ADP
ijpds-3747	90	12	hcq	hcq	PROPN
ijpds-3747	90	13	.	.	PUNCT
ijpds-3747	91	1	the	the	DET
ijpds-3747	91	2	clinical	clinical	ADJ
ijpds-3747	91	3	trials	trial	NOUN
ijpds-3747	91	4	not	not	PART
ijpds-3747	91	5	focussing	focusse	VERB
ijpds-3747	91	6	on	on	ADP
ijpds-3747	91	7	safety	safety	NOUN
ijpds-3747	91	8	and	and	CCONJ
ijpds-3747	91	9	efficacy	efficacy	NOUN
ijpds-3747	91	10	were	be	AUX
ijpds-3747	91	11	excluded	exclude	VERB
ijpds-3747	91	12	.	.	PUNCT
ijpds-3747	92	1	the	the	DET
ijpds-3747	92	2	articles	article	NOUN
ijpds-3747	92	3	on	on	ADP
ijpds-3747	92	4	safety	safety	NOUN
ijpds-3747	92	5	and	and	CCONJ
ijpds-3747	92	6	efficacy	efficacy	NOUN
ijpds-3747	92	7	were	be	AUX
ijpds-3747	92	8	then	then	ADV
ijpds-3747	92	9	screened	screen	VERB
ijpds-3747	92	10	for	for	ADP
ijpds-3747	92	11	inclusion	inclusion	NOUN
ijpds-3747	92	12	in	in	ADP
ijpds-3747	92	13	studies	study	NOUN
ijpds-3747	92	14	.	.	PUNCT
ijpds-3747	93	1	among	among	ADP
ijpds-3747	93	2	the	the	DET
ijpds-3747	93	3	selected	select	VERB
ijpds-3747	93	4	trials	trial	NOUN
ijpds-3747	93	5	,	,	PUNCT
ijpds-3747	93	6	the	the	DET
ijpds-3747	93	7	trials	trial	NOUN
ijpds-3747	93	8	having	have	VERB
ijpds-3747	93	9	no	no	DET
ijpds-3747	93	10	results	result	NOUN
ijpds-3747	93	11	posted	post	VERB
ijpds-3747	93	12	were	be	AUX
ijpds-3747	93	13	also	also	ADV
ijpds-3747	93	14	excluded	exclude	VERB
ijpds-3747	93	15	and	and	CCONJ
ijpds-3747	93	16	finally	finally	ADV
ijpds-3747	93	17	,	,	PUNCT
ijpds-3747	93	18	four	four	NUM
ijpds-3747	93	19	articles	article	NOUN
ijpds-3747	93	20	were	be	AUX
ijpds-3747	93	21	included	include	VERB
ijpds-3747	93	22	in	in	ADP
ijpds-3747	93	23	this	this	DET
ijpds-3747	93	24	critical	critical	ADJ
ijpds-3747	93	25	analysis	analysis	NOUN
ijpds-3747	93	26	.	.	PUNCT
ijpds-3747	94	1	to	to	PART
ijpds-3747	94	2	compare	compare	VERB
ijpds-3747	94	3	the	the	DET
ijpds-3747	94	4	data	datum	NOUN
ijpds-3747	94	5	on	on	ADP
ijpds-3747	94	6	adverse	adverse	ADJ
ijpds-3747	94	7	effects	effect	NOUN
ijpds-3747	94	8	between	between	ADP
ijpds-3747	94	9	belimumab	belimumab	NOUN
ijpds-3747	94	10	and	and	CCONJ
ijpds-3747	94	11	hcq	hcq	NOUN
ijpds-3747	94	12	,	,	PUNCT
ijpds-3747	94	13	the	the	DET
ijpds-3747	94	14	risk	risk	NOUN
ijpds-3747	94	15	difference	difference	NOUN
ijpds-3747	94	16	and	and	CCONJ
ijpds-3747	94	17	relative	relative	ADJ
ijpds-3747	94	18	risk	risk	NOUN
ijpds-3747	94	19	between	between	ADP
ijpds-3747	94	20	the	the	DET
ijpds-3747	94	21	two	two	NUM
ijpds-3747	94	22	were	be	AUX
ijpds-3747	94	23	calculated	calculate	VERB
ijpds-3747	94	24	.	.	PUNCT
ijpds-3747	95	1	table	table	NOUN
ijpds-3747	95	2	1	1	NUM
ijpds-3747	95	3	shows	show	VERB
ijpds-3747	95	4	the	the	DET
ijpds-3747	95	5	risk	risk	NOUN
ijpds-3747	95	6	difference	difference	NOUN
ijpds-3747	95	7	and	and	CCONJ
ijpds-3747	95	8	relative	relative	ADJ
ijpds-3747	95	9	risk	risk	NOUN
ijpds-3747	95	10	between	between	ADP
ijpds-3747	95	11	the	the	DET
ijpds-3747	95	12	two	two	NUM
ijpds-3747	95	13	drugs	drug	NOUN
ijpds-3747	95	14	.	.	PUNCT
ijpds-3747	96	1	table	table	NOUN
ijpds-3747	96	2	1	1	NUM
ijpds-3747	96	3	–	–	PUNCT
ijpds-3747	96	4	risk	risk	NOUN
ijpds-3747	96	5	difference	difference	NOUN
ijpds-3747	96	6	and	and	CCONJ
ijpds-3747	96	7	relative	relative	ADJ
ijpds-3747	96	8	risk	risk	NOUN
ijpds-3747	96	9	calculation	calculation	NOUN
ijpds-3747	96	10	ar	ar	PROPN
ijpds-3747	96	11	bel	bel	PROPN
ijpds-3747	96	12	ar	ar	PROPN
ijpds-3747	96	13	hcq	hcq	PROPN
ijpds-3747	96	14	rd	rd	PROPN
ijpds-3747	96	15	p1	p1	PROPN
ijpds-3747	96	16	/	/	SYM
ijpds-3747	96	17	p2	p2	PROPN
ijpds-3747	96	18	(	(	PUNCT
ijpds-3747	96	19	rr	rr	NOUN
ijpds-3747	96	20	)	)	PUNCT
ijpds-3747	96	21	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	96	22	disorders	disorder	NOUN
ijpds-3747	96	23	31.88	31.88	NUM
ijpds-3747	96	24	15.66	15.66	NUM
ijpds-3747	96	25	16.22	16.22	NUM
ijpds-3747	96	26	2.04	2.04	NUM
ijpds-3747	96	27	general	general	ADJ
ijpds-3747	96	28	disorders	disorder	NOUN
ijpds-3747	96	29	10.43	10.43	NUM
ijpds-3747	96	30	6.56	6.56	NUM
ijpds-3747	96	31	3.87	3.87	NUM
ijpds-3747	96	32	1.59	1.59	NUM
ijpds-3747	96	33	nervous	nervous	ADJ
ijpds-3747	96	34	system	system	NOUN
ijpds-3747	96	35	disorder	disorder	NOUN
ijpds-3747	96	36	20.80	20.80	NUM
ijpds-3747	96	37	3.27	3.27	NUM
ijpds-3747	96	38	17.53	17.53	NUM
ijpds-3747	96	39	6.36	6.36	NUM
ijpds-3747	96	40	psychiatric	psychiatric	ADJ
ijpds-3747	96	41	disorders	disorder	NOUN
ijpds-3747	96	42	9.61	9.61	NUM
ijpds-3747	96	43	2.18	2.18	NUM
ijpds-3747	96	44	7.43	7.43	NUM
ijpds-3747	96	45	4.41	4.41	NUM
ijpds-3747	96	46	skin	skin	NOUN
ijpds-3747	96	47	disorders	disorder	NOUN
ijpds-3747	96	48	3.60	3.60	NUM
ijpds-3747	96	49	4.61	4.61	NUM
ijpds-3747	96	50	-1.01	-1.01	NUM
ijpds-3747	96	51	0.78	0.78	NUM
ijpds-3747	96	52	cardiac	cardiac	ADJ
ijpds-3747	96	53	disorders	disorder	NOUN
ijpds-3747	96	54	1.27	1.27	NUM
ijpds-3747	96	55	4.36	4.36	NUM
ijpds-3747	96	56	-3.09	-3.09	NUM
ijpds-3747	96	57	0.29	0.29	NUM
ijpds-3747	96	58	eye	eye	NOUN
ijpds-3747	96	59	disorders	disorder	NOUN
ijpds-3747	96	60	0.33	0.33	NUM
ijpds-3747	96	61	0.49	0.49	NUM
ijpds-3747	96	62	-0.16	-0.16	NUM
ijpds-3747	96	63	0.67	0.67	NUM
ijpds-3747	96	64	immune	immune	ADJ
ijpds-3747	96	65	disorders	disorder	NOUN
ijpds-3747	96	66	0.35	0.35	NUM
ijpds-3747	96	67	0.37	0.37	NUM
ijpds-3747	96	68	-0.02	-0.02	NUM
ijpds-3747	96	69	0.95	0.95	NUM
ijpds-3747	96	70	*	*	PUNCT
ijpds-3747	96	71	ar	ar	PROPN
ijpds-3747	96	72	–	–	PUNCT
ijpds-3747	96	73	absolute	absolute	ADJ
ijpds-3747	96	74	risk	risk	NOUN
ijpds-3747	96	75	,	,	PUNCT
ijpds-3747	96	76	rd	rd	NOUN
ijpds-3747	96	77	–	–	PUNCT
ijpds-3747	96	78	risk	risk	NOUN
ijpds-3747	96	79	difference	difference	NOUN
ijpds-3747	96	80	,	,	PUNCT
ijpds-3747	96	81	rr	rr	ADJ
ijpds-3747	96	82	–	–	PUNCT
ijpds-3747	96	83	relative	relative	ADJ
ijpds-3747	96	84	risk	risk	NOUN
ijpds-3747	96	85	,	,	PUNCT
ijpds-3747	96	86	hcq	hcq	NOUN
ijpds-3747	96	87	–	–	PUNCT
ijpds-3747	96	88	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	96	89	,	,	PUNCT
ijpds-3747	96	90	bel	bel	NOUN
ijpds-3747	96	91	–	–	PUNCT
ijpds-3747	96	92	belimumab	belimumab	NOUN
ijpds-3747	96	93	the	the	DET
ijpds-3747	96	94	results	result	NOUN
ijpds-3747	96	95	showed	show	VERB
ijpds-3747	96	96	the	the	DET
ijpds-3747	96	97	major	major	ADJ
ijpds-3747	96	98	effects	effect	NOUN
ijpds-3747	96	99	of	of	ADP
ijpds-3747	96	100	belimumab	belimumab	NOUN
ijpds-3747	96	101	on	on	ADP
ijpds-3747	96	102	the	the	DET
ijpds-3747	96	103	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	96	104	tract	tract	NOUN
ijpds-3747	96	105	,	,	PUNCT
ijpds-3747	96	106	nervous	nervous	ADJ
ijpds-3747	96	107	system	system	NOUN
ijpds-3747	96	108	,	,	PUNCT
ijpds-3747	96	109	and	and	CCONJ
ijpds-3747	96	110	heart	heart	NOUN
ijpds-3747	96	111	.	.	PUNCT
ijpds-3747	97	1	in	in	ADP
ijpds-3747	97	2	some	some	PRON
ijpds-3747	97	3	of	of	ADP
ijpds-3747	97	4	the	the	DET
ijpds-3747	97	5	participants	participant	NOUN
ijpds-3747	97	6	,	,	PUNCT
ijpds-3747	97	7	belimumab	belimumab	NOUN
ijpds-3747	97	8	was	be	AUX
ijpds-3747	97	9	found	find	VERB
ijpds-3747	97	10	associated	associate	VERB
ijpds-3747	97	11	with	with	ADP
ijpds-3747	97	12	depression	depression	NOUN
ijpds-3747	97	13	,	,	PUNCT
ijpds-3747	97	14	suicidal	suicidal	ADJ
ijpds-3747	97	15	thoughts	thought	NOUN
ijpds-3747	97	16	,	,	PUNCT
ijpds-3747	97	17	and	and	CCONJ
ijpds-3747	97	18	changes	change	NOUN
ijpds-3747	97	19	in	in	ADP
ijpds-3747	97	20	sleep	sleep	NOUN
ijpds-3747	97	21	patterns	pattern	NOUN
ijpds-3747	97	22	(	(	PUNCT
ijpds-3747	97	23	insomnia	insomnia	NOUN
ijpds-3747	97	24	)	)	PUNCT
ijpds-3747	97	25	.	.	PUNCT
ijpds-3747	98	1	the	the	DET
ijpds-3747	98	2	positive	positive	ADJ
ijpds-3747	98	3	value	value	NOUN
ijpds-3747	98	4	of	of	ADP
ijpds-3747	98	5	risk	risk	NOUN
ijpds-3747	98	6	difference	difference	NOUN
ijpds-3747	98	7	in	in	ADP
ijpds-3747	98	8	table	table	NOUN
ijpds-3747	98	9	1	1	NUM
ijpds-3747	98	10	indicates	indicate	VERB
ijpds-3747	98	11	that	that	SCONJ
ijpds-3747	98	12	maryam	maryam	PROPN
ijpds-3747	98	13	and	and	CCONJ
ijpds-3747	98	14	ahmad	ahmad	PROPN
ijpds-3747	98	15	safety	safety	PROPN
ijpds-3747	98	16	comparison	comparison	NOUN
ijpds-3747	98	17	of	of	ADP
ijpds-3747	98	18	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	98	19	and	and	CCONJ
ijpds-3747	98	20	belimumab	belimumab	NOUN
ijpds-3747	98	21	vol	vol	NOUN
ijpds-3747	98	22	2	2	NUM
ijpds-3747	98	23	|	|	NOUN
ijpds-3747	98	24	issue	issue	NOUN
ijpds-3747	98	25	1	1	NUM
ijpds-3747	98	26	|	|	ADV
ijpds-3747	98	27	jan	jan	PROPN
ijpds-3747	98	28	–	–	PUNCT
ijpds-3747	98	29	mar	mar	PROPN
ijpds-3747	98	30	2023	2023	NUM
ijpds-3747	98	31	indian	indian	PROPN
ijpds-3747	98	32	j	j	PROPN
ijpds-3747	98	33	pharm	pharm	PROPN
ijpds-3747	98	34	drug	drug	PROPN
ijpds-3747	98	35	studies	study	NOUN
ijpds-3747	98	36	|	|	ADV
ijpds-3747	98	37	8	8	NUM
ijpds-3747	98	38	belimumab	belimumab	NOUN
ijpds-3747	98	39	has	have	VERB
ijpds-3747	98	40	an	an	DET
ijpds-3747	98	41	increased	increase	VERB
ijpds-3747	98	42	risk	risk	NOUN
ijpds-3747	98	43	of	of	ADP
ijpds-3747	98	44	causing	cause	VERB
ijpds-3747	98	45	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	98	46	disorders	disorder	NOUN
ijpds-3747	98	47	,	,	PUNCT
ijpds-3747	98	48	general	general	ADJ
ijpds-3747	98	49	disorders	disorder	NOUN
ijpds-3747	98	50	,	,	PUNCT
ijpds-3747	98	51	nervous	nervous	ADJ
ijpds-3747	98	52	systems	system	NOUN
ijpds-3747	98	53	,	,	PUNCT
ijpds-3747	98	54	and	and	CCONJ
ijpds-3747	98	55	psychiatric	psychiatric	ADJ
ijpds-3747	98	56	disorders	disorder	NOUN
ijpds-3747	98	57	compared	compare	VERB
ijpds-3747	98	58	to	to	ADP
ijpds-3747	98	59	hcq	hcq	NOUN
ijpds-3747	98	60	in	in	ADP
ijpds-3747	98	61	patients	patient	NOUN
ijpds-3747	98	62	.	.	PUNCT
ijpds-3747	99	1	while	while	SCONJ
ijpds-3747	99	2	the	the	DET
ijpds-3747	99	3	negative	negative	ADJ
ijpds-3747	99	4	value	value	NOUN
ijpds-3747	99	5	of	of	ADP
ijpds-3747	99	6	risk	risk	NOUN
ijpds-3747	99	7	difference	difference	NOUN
ijpds-3747	99	8	for	for	ADP
ijpds-3747	99	9	belimumab	belimumab	NOUN
ijpds-3747	99	10	indicates	indicate	VERB
ijpds-3747	99	11	the	the	DET
ijpds-3747	99	12	increased	increase	VERB
ijpds-3747	99	13	risk	risk	NOUN
ijpds-3747	99	14	of	of	ADP
ijpds-3747	99	15	skin	skin	NOUN
ijpds-3747	99	16	disorder	disorder	NOUN
ijpds-3747	99	17	,	,	PUNCT
ijpds-3747	99	18	eye	eye	NOUN
ijpds-3747	99	19	disorders	disorder	NOUN
ijpds-3747	99	20	,	,	PUNCT
ijpds-3747	99	21	immune	immune	ADJ
ijpds-3747	99	22	disorders	disorder	NOUN
ijpds-3747	99	23	,	,	PUNCT
ijpds-3747	99	24	and	and	CCONJ
ijpds-3747	99	25	cardiac	cardiac	ADJ
ijpds-3747	99	26	disorders	disorder	NOUN
ijpds-3747	99	27	by	by	ADP
ijpds-3747	99	28	hcq	hcq	PROPN
ijpds-3747	99	29	.	.	PUNCT
ijpds-3747	100	1	the	the	DET
ijpds-3747	100	2	results	result	NOUN
ijpds-3747	100	3	show	show	VERB
ijpds-3747	100	4	the	the	DET
ijpds-3747	100	5	relative	relative	ADJ
ijpds-3747	100	6	ratio	ratio	NOUN
ijpds-3747	100	7	of	of	ADP
ijpds-3747	100	8	belimumab	belimumab	NOUN
ijpds-3747	100	9	/hcq	/hcq	PUNCT
ijpds-3747	100	10	of	of	ADP
ijpds-3747	100	11	2	2	NUM
ijpds-3747	100	12	for	for	ADP
ijpds-3747	100	13	git	git	NOUN
ijpds-3747	100	14	problems	problem	NOUN
ijpds-3747	100	15	which	which	PRON
ijpds-3747	100	16	indicates	indicate	VERB
ijpds-3747	100	17	that	that	SCONJ
ijpds-3747	100	18	the	the	DET
ijpds-3747	100	19	persons	person	NOUN
ijpds-3747	100	20	taking	take	VERB
ijpds-3747	100	21	belimumab	belimumab	NOUN
ijpds-3747	100	22	are	be	AUX
ijpds-3747	100	23	twice	twice	ADV
ijpds-3747	100	24	as	as	ADV
ijpds-3747	100	25	likely	likely	ADJ
ijpds-3747	100	26	to	to	PART
ijpds-3747	100	27	suffer	suffer	VERB
ijpds-3747	100	28	from	from	ADP
ijpds-3747	100	29	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	100	30	issues	issue	NOUN
ijpds-3747	100	31	as	as	SCONJ
ijpds-3747	100	32	the	the	DET
ijpds-3747	100	33	people	people	NOUN
ijpds-3747	100	34	taking	take	VERB
ijpds-3747	100	35	hcq	hcq	NOUN
ijpds-3747	100	36	.	.	PUNCT
ijpds-3747	101	1	similarly	similarly	ADV
ijpds-3747	101	2	,	,	PUNCT
ijpds-3747	101	3	the	the	DET
ijpds-3747	101	4	relative	relative	ADJ
ijpds-3747	101	5	risk	risk	NOUN
ijpds-3747	101	6	ratio	ratio	NOUN
ijpds-3747	101	7	for	for	ADP
ijpds-3747	101	8	the	the	DET
ijpds-3747	101	9	general	general	ADJ
ijpds-3747	101	10	disorder	disorder	NOUN
ijpds-3747	101	11	is	be	AUX
ijpds-3747	101	12	2	2	NUM
ijpds-3747	101	13	(	(	PUNCT
ijpds-3747	101	14	2x	2x	NUM
ijpds-3747	101	15	risk	risk	NOUN
ijpds-3747	101	16	to	to	PART
ijpds-3747	101	17	suffer	suffer	VERB
ijpds-3747	101	18	from	from	ADP
ijpds-3747	101	19	general	general	ADJ
ijpds-3747	101	20	problems	problem	NOUN
ijpds-3747	101	21	if	if	SCONJ
ijpds-3747	101	22	the	the	DET
ijpds-3747	101	23	person	person	NOUN
ijpds-3747	101	24	is	be	AUX
ijpds-3747	101	25	taking	take	VERB
ijpds-3747	101	26	belimumab	belimumab	NOUN
ijpds-3747	101	27	)	)	PUNCT
ijpds-3747	101	28	,	,	PUNCT
ijpds-3747	101	29	for	for	ADP
ijpds-3747	101	30	nervous	nervous	ADJ
ijpds-3747	101	31	disorders	disorder	NOUN
ijpds-3747	101	32	,	,	PUNCT
ijpds-3747	101	33	the	the	DET
ijpds-3747	101	34	rr	rr	PROPN
ijpds-3747	101	35	ratio	ratio	NOUN
ijpds-3747	101	36	came	come	VERB
ijpds-3747	101	37	out	out	ADP
ijpds-3747	101	38	to	to	PART
ijpds-3747	101	39	be	be	AUX
ijpds-3747	101	40	6.4	6.4	NUM
ijpds-3747	101	41	,	,	PUNCT
ijpds-3747	101	42	and	and	CCONJ
ijpds-3747	101	43	for	for	ADP
ijpds-3747	101	44	psychiatric	psychiatric	ADJ
ijpds-3747	101	45	disorders	disorder	NOUN
ijpds-3747	101	46	,	,	PUNCT
ijpds-3747	101	47	it	it	PRON
ijpds-3747	101	48	is	be	AUX
ijpds-3747	101	49	4.41	4.41	NUM
ijpds-3747	101	50	.	.	PUNCT
ijpds-3747	102	1	skin	skin	NOUN
ijpds-3747	102	2	disorders	disorder	NOUN
ijpds-3747	102	3	show	show	VERB
ijpds-3747	102	4	a	a	DET
ijpds-3747	102	5	relative	relative	ADJ
ijpds-3747	102	6	risk	risk	NOUN
ijpds-3747	102	7	ratio	ratio	NOUN
ijpds-3747	102	8	of	of	ADP
ijpds-3747	102	9	0.78	0.78	NUM
ijpds-3747	102	10	indicating	indicate	VERB
ijpds-3747	102	11	that	that	SCONJ
ijpds-3747	102	12	belimumab	belimumab	NOUN
ijpds-3747	102	13	is	be	AUX
ijpds-3747	102	14	less	less	ADV
ijpds-3747	102	15	likely	likely	ADJ
ijpds-3747	102	16	to	to	PART
ijpds-3747	102	17	cause	cause	VERB
ijpds-3747	102	18	skin	skin	NOUN
ijpds-3747	102	19	problems	problem	NOUN
ijpds-3747	102	20	as	as	ADP
ijpds-3747	102	21	compared	compare	VERB
ijpds-3747	102	22	to	to	ADP
ijpds-3747	102	23	hcq	hcq	PROPN
ijpds-3747	102	24	,	,	PUNCT
ijpds-3747	102	25	in	in	ADP
ijpds-3747	102	26	other	other	ADJ
ijpds-3747	102	27	words	word	NOUN
ijpds-3747	102	28	,	,	PUNCT
ijpds-3747	102	29	hcq	hcq	PROPN
ijpds-3747	102	30	is	be	AUX
ijpds-3747	102	31	1.3	1.3	NUM
ijpds-3747	102	32	times	time	NOUN
ijpds-3747	102	33	more	more	ADV
ijpds-3747	102	34	likely	likely	ADJ
ijpds-3747	102	35	to	to	PART
ijpds-3747	102	36	cause	cause	VERB
ijpds-3747	102	37	skin	skin	NOUN
ijpds-3747	102	38	problems	problem	NOUN
ijpds-3747	102	39	than	than	ADP
ijpds-3747	102	40	belimumab	belimumab	NOUN
ijpds-3747	102	41	.	.	PUNCT
ijpds-3747	103	1	likewise	likewise	ADV
ijpds-3747	103	2	,	,	PUNCT
ijpds-3747	103	3	the	the	DET
ijpds-3747	103	4	rr	rr	PROPN
ijpds-3747	103	5	ratio	ratio	NOUN
ijpds-3747	103	6	for	for	ADP
ijpds-3747	103	7	the	the	DET
ijpds-3747	103	8	cardiac	cardiac	ADJ
ijpds-3747	103	9	disorder	disorder	NOUN
ijpds-3747	103	10	is	be	AUX
ijpds-3747	103	11	0.29	0.29	NUM
ijpds-3747	103	12	showing	show	VERB
ijpds-3747	103	13	3.5	3.5	NUM
ijpds-3747	103	14	times	time	NOUN
ijpds-3747	103	15	increased	increase	VERB
ijpds-3747	103	16	risk	risk	NOUN
ijpds-3747	103	17	of	of	ADP
ijpds-3747	103	18	having	have	VERB
ijpds-3747	103	19	cardiac	cardiac	ADJ
ijpds-3747	103	20	abnormality	abnormality	NOUN
ijpds-3747	103	21	for	for	ADP
ijpds-3747	103	22	people	people	NOUN
ijpds-3747	103	23	taking	take	VERB
ijpds-3747	103	24	hcq	hcq	NOUN
ijpds-3747	103	25	with	with	ADP
ijpds-3747	103	26	dyspnoea	dyspnoea	NOUN
ijpds-3747	103	27	and	and	CCONJ
ijpds-3747	103	28	chest	chest	NOUN
ijpds-3747	103	29	pain	pain	NOUN
ijpds-3747	103	30	as	as	ADP
ijpds-3747	103	31	major	major	ADJ
ijpds-3747	103	32	effects	effect	NOUN
ijpds-3747	103	33	.	.	PUNCT
ijpds-3747	104	1	for	for	ADP
ijpds-3747	104	2	eye	eye	NOUN
ijpds-3747	104	3	disorder	disorder	NOUN
ijpds-3747	104	4	rr	rr	PROPN
ijpds-3747	104	5	ratio	ratio	NOUN
ijpds-3747	104	6	is	be	AUX
ijpds-3747	104	7	0.66	0.66	NUM
ijpds-3747	104	8	showing	show	VERB
ijpds-3747	104	9	a	a	DET
ijpds-3747	104	10	1.5x	1.5x	NUM
ijpds-3747	104	11	risk	risk	NOUN
ijpds-3747	104	12	for	for	ADP
ijpds-3747	104	13	patients	patient	NOUN
ijpds-3747	104	14	taking	take	VERB
ijpds-3747	104	15	hcq	hcq	NOUN
ijpds-3747	104	16	,	,	PUNCT
ijpds-3747	104	17	and	and	CCONJ
ijpds-3747	104	18	the	the	DET
ijpds-3747	104	19	ratio	ratio	NOUN
ijpds-3747	104	20	for	for	ADP
ijpds-3747	104	21	immune	immune	ADJ
ijpds-3747	104	22	disorders	disorder	NOUN
ijpds-3747	104	23	is	be	AUX
ijpds-3747	104	24	surprisingly	surprisingly	ADV
ijpds-3747	104	25	0.92	0.92	NUM
ijpds-3747	104	26	which	which	PRON
ijpds-3747	104	27	somewhat	somewhat	ADV
ijpds-3747	104	28	shows	show	VERB
ijpds-3747	104	29	the	the	DET
ijpds-3747	104	30	equal	equal	ADJ
ijpds-3747	104	31	risk	risk	NOUN
ijpds-3747	104	32	of	of	ADP
ijpds-3747	104	33	getting	get	VERB
ijpds-3747	104	34	an	an	DET
ijpds-3747	104	35	immune	immune	ADJ
ijpds-3747	104	36	disorder	disorder	NOUN
ijpds-3747	104	37	with	with	ADP
ijpds-3747	104	38	the	the	DET
ijpds-3747	104	39	use	use	NOUN
ijpds-3747	104	40	of	of	ADP
ijpds-3747	104	41	hcq	hcq	NOUN
ijpds-3747	104	42	and	and	CCONJ
ijpds-3747	104	43	belimumab	belimumab	NOUN
ijpds-3747	104	44	.	.	PUNCT
ijpds-3747	105	1	moreover	moreover	ADV
ijpds-3747	105	2	,	,	PUNCT
ijpds-3747	105	3	2	2	NUM
ijpds-3747	105	4	cases	case	NOUN
ijpds-3747	105	5	of	of	ADP
ijpds-3747	105	6	mortality	mortality	NOUN
ijpds-3747	105	7	were	be	AUX
ijpds-3747	105	8	observed	observe	VERB
ijpds-3747	105	9	in	in	ADP
ijpds-3747	105	10	patients	patient	NOUN
ijpds-3747	105	11	taking	take	VERB
ijpds-3747	105	12	belimumab	belimumab	NOUN
ijpds-3747	105	13	,	,	PUNCT
ijpds-3747	105	14	while	while	SCONJ
ijpds-3747	105	15	no	no	INTJ
ijpds-3747	105	16	allcause	allcause	INTJ
ijpds-3747	105	17	mortality	mortality	NOUN
ijpds-3747	105	18	was	be	AUX
ijpds-3747	105	19	observed	observe	VERB
ijpds-3747	105	20	when	when	SCONJ
ijpds-3747	105	21	the	the	DET
ijpds-3747	105	22	patients	patient	NOUN
ijpds-3747	105	23	were	be	AUX
ijpds-3747	105	24	administered	administer	VERB
ijpds-3747	105	25	a	a	DET
ijpds-3747	105	26	placebo	placebo	NOUN
ijpds-3747	105	27	or	or	CCONJ
ijpds-3747	105	28	hcq	hcq	NOUN
ijpds-3747	105	29	.	.	PUNCT
ijpds-3747	106	1	then	then	ADV
ijpds-3747	106	2	we	we	PRON
ijpds-3747	106	3	compared	compare	VERB
ijpds-3747	106	4	the	the	DET
ijpds-3747	106	5	adverse	adverse	ADJ
ijpds-3747	106	6	effects	effect	NOUN
ijpds-3747	106	7	of	of	ADP
ijpds-3747	106	8	the	the	DET
ijpds-3747	106	9	drugs	drug	NOUN
ijpds-3747	106	10	belimumab	belimumab	NOUN
ijpds-3747	106	11	and	and	CCONJ
ijpds-3747	106	12	hcq	hcq	NOUN
ijpds-3747	106	13	with	with	ADP
ijpds-3747	106	14	respect	respect	NOUN
ijpds-3747	106	15	to	to	ADP
ijpds-3747	106	16	the	the	DET
ijpds-3747	106	17	placebo	placebo	NOUN
ijpds-3747	106	18	and	and	CCONJ
ijpds-3747	106	19	calculated	calculate	VERB
ijpds-3747	106	20	the	the	DET
ijpds-3747	106	21	odds	odd	NOUN
ijpds-3747	106	22	ratio	ratio	NOUN
ijpds-3747	106	23	.	.	PUNCT
ijpds-3747	107	1	table	table	NOUN
ijpds-3747	107	2	2	2	NUM
ijpds-3747	107	3	shows	show	VERB
ijpds-3747	107	4	the	the	DET
ijpds-3747	107	5	odds	odd	NOUN
ijpds-3747	107	6	-	-	PUNCT
ijpds-3747	107	7	ratio	ratio	NOUN
ijpds-3747	107	8	calculation	calculation	NOUN
ijpds-3747	107	9	for	for	ADP
ijpds-3747	107	10	belimumab	belimumab	NOUN
ijpds-3747	107	11	.	.	PUNCT
ijpds-3747	108	1	table	table	NOUN
ijpds-3747	108	2	2	2	NUM
ijpds-3747	108	3	odd	odd	ADJ
ijpds-3747	108	4	ratio	ratio	NOUN
ijpds-3747	108	5	calculation	calculation	NOUN
ijpds-3747	108	6	for	for	ADP
ijpds-3747	108	7	belimumab	belimumab	NOUN
ijpds-3747	108	8	bel	bel	NOUN
ijpds-3747	108	9	pl	pl	X
ijpds-3747	108	10	or	or	CCONJ
ijpds-3747	108	11	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	108	12	disorders	disorder	NOUN
ijpds-3747	108	13	31.88	31.88	NUM
ijpds-3747	108	14	33.00	33.00	NUM
ijpds-3747	108	15	0.95	0.95	NUM
ijpds-3747	108	16	general	general	ADJ
ijpds-3747	108	17	disorders	disorder	NOUN
ijpds-3747	108	18	10.43	10.43	NUM
ijpds-3747	108	19	10.45	10.45	NUM
ijpds-3747	108	20	1.00	1.00	NUM
ijpds-3747	108	21	nervous	nervous	ADJ
ijpds-3747	108	22	system	system	NOUN
ijpds-3747	108	23	disorder	disorder	NOUN
ijpds-3747	108	24	20.80	20.80	NUM
ijpds-3747	108	25	23.84	23.84	NUM
ijpds-3747	108	26	0.84	0.84	NUM
ijpds-3747	108	27	psychiatric	psychiatric	ADJ
ijpds-3747	108	28	disorders	disorder	NOUN
ijpds-3747	108	29	9.61	9.61	NUM
ijpds-3747	108	30	9.68	9.68	NUM
ijpds-3747	108	31	0.99	0.99	NUM
ijpds-3747	108	32	skin	skin	NOUN
ijpds-3747	108	33	disorders	disorder	NOUN
ijpds-3747	108	34	3.59	3.59	NUM
ijpds-3747	108	35	3.62	3.62	NUM
ijpds-3747	108	36	0.99	0.99	NUM
ijpds-3747	108	37	cardiac	cardiac	ADJ
ijpds-3747	108	38	disorders	disorder	NOUN
ijpds-3747	108	39	1.27	1.27	NUM
ijpds-3747	108	40	1.91	1.91	NUM
ijpds-3747	108	41	0.66	0.66	NUM
ijpds-3747	108	42	eye	eye	NOUN
ijpds-3747	108	43	disorders	disorder	NOUN
ijpds-3747	108	44	0.33	0.33	NUM
ijpds-3747	108	45	0.00	0.00	NUM
ijpds-3747	108	46	0.33	0.33	NUM
ijpds-3747	108	47	immune	immune	ADJ
ijpds-3747	108	48	disorders	disorder	NOUN
ijpds-3747	108	49	0.34	0.34	NUM
ijpds-3747	108	50	0.17	0.17	NUM
ijpds-3747	108	51	2.00	2.00	NUM
ijpds-3747	108	52	*	*	PUNCT
ijpds-3747	108	53	bel	bel	NOUN
ijpds-3747	108	54	–	–	PUNCT
ijpds-3747	108	55	belimumab	belimumab	NOUN
ijpds-3747	108	56	,	,	PUNCT
ijpds-3747	108	57	pl	pl	NOUN
ijpds-3747	108	58	–	–	PUNCT
ijpds-3747	108	59	placebo	placebo	NOUN
ijpds-3747	108	60	,	,	PUNCT
ijpds-3747	108	61	or	or	CCONJ
ijpds-3747	108	62	–	–	PUNCT
ijpds-3747	108	63	odds	odd	NOUN
ijpds-3747	108	64	ratio	ratio	NOUN
ijpds-3747	108	65	the	the	DET
ijpds-3747	108	66	odds	odd	NOUN
ijpds-3747	108	67	ratio	ratio	NOUN
ijpds-3747	108	68	for	for	ADP
ijpds-3747	108	69	belimumab	belimumab	NOUN
ijpds-3747	108	70	showed	show	VERB
ijpds-3747	108	71	the	the	DET
ijpds-3747	108	72	value	value	NOUN
ijpds-3747	108	73	of	of	ADP
ijpds-3747	108	74	1	1	NUM
ijpds-3747	108	75	for	for	ADP
ijpds-3747	108	76	a	a	DET
ijpds-3747	108	77	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	108	78	disorder	disorder	NOUN
ijpds-3747	108	79	,	,	PUNCT
ijpds-3747	108	80	general	general	ADJ
ijpds-3747	108	81	disorder	disorder	NOUN
ijpds-3747	108	82	,	,	PUNCT
ijpds-3747	108	83	psychiatric	psychiatric	ADJ
ijpds-3747	108	84	disorders	disorder	NOUN
ijpds-3747	108	85	,	,	PUNCT
ijpds-3747	108	86	and	and	CCONJ
ijpds-3747	108	87	skin	skin	NOUN
ijpds-3747	108	88	problems	problem	NOUN
ijpds-3747	108	89	.	.	PUNCT
ijpds-3747	109	1	this	this	PRON
ijpds-3747	109	2	predicts	predict	VERB
ijpds-3747	109	3	an	an	DET
ijpds-3747	109	4	equal	equal	ADJ
ijpds-3747	109	5	probability	probability	NOUN
ijpds-3747	109	6	of	of	ADP
ijpds-3747	109	7	belimumab	belimumab	NOUN
ijpds-3747	109	8	and	and	CCONJ
ijpds-3747	109	9	placebo	placebo	NOUN
ijpds-3747	109	10	showing	show	VERB
ijpds-3747	109	11	these	these	DET
ijpds-3747	109	12	disorders	disorder	NOUN
ijpds-3747	109	13	.	.	PUNCT
ijpds-3747	110	1	in	in	ADP
ijpds-3747	110	2	the	the	DET
ijpds-3747	110	3	case	case	NOUN
ijpds-3747	110	4	of	of	ADP
ijpds-3747	110	5	immune	immune	ADJ
ijpds-3747	110	6	disorders	disorder	NOUN
ijpds-3747	110	7	,	,	PUNCT
ijpds-3747	110	8	the	the	DET
ijpds-3747	110	9	odds	odd	NOUN
ijpds-3747	110	10	ratio	ratio	NOUN
ijpds-3747	110	11	is	be	AUX
ijpds-3747	110	12	2	2	NUM
ijpds-3747	110	13	,	,	PUNCT
ijpds-3747	110	14	indicating	indicate	VERB
ijpds-3747	110	15	two	two	NUM
ijpds-3747	110	16	times	time	NOUN
ijpds-3747	110	17	increased	increase	VERB
ijpds-3747	110	18	risk	risk	NOUN
ijpds-3747	110	19	of	of	ADP
ijpds-3747	110	20	belimumab	belimumab	NOUN
ijpds-3747	110	21	to	to	PART
ijpds-3747	110	22	induce	induce	VERB
ijpds-3747	110	23	immune	immune	ADJ
ijpds-3747	110	24	abnormality	abnormality	NOUN
ijpds-3747	110	25	compared	compare	VERB
ijpds-3747	110	26	to	to	ADP
ijpds-3747	110	27	placebo	placebo	NOUN
ijpds-3747	110	28	.	.	PUNCT
ijpds-3747	111	1	0.33	0.33	NUM
ijpds-3747	111	2	odds	odd	NOUN
ijpds-3747	111	3	-	-	PUNCT
ijpds-3747	111	4	ratio	ratio	NOUN
ijpds-3747	111	5	for	for	ADP
ijpds-3747	111	6	eye	eye	NOUN
ijpds-3747	111	7	disorder	disorder	NOUN
ijpds-3747	111	8	,	,	PUNCT
ijpds-3747	111	9	and	and	CCONJ
ijpds-3747	111	10	0.66	0.66	NUM
ijpds-3747	111	11	for	for	ADP
ijpds-3747	111	12	cardiac	cardiac	ADJ
ijpds-3747	111	13	disorder	disorder	NOUN
ijpds-3747	111	14	show	show	VERB
ijpds-3747	111	15	rather	rather	ADV
ijpds-3747	111	16	a	a	DET
ijpds-3747	111	17	protective	protective	ADJ
ijpds-3747	111	18	role	role	NOUN
ijpds-3747	111	19	of	of	ADP
ijpds-3747	111	20	belimumab	belimumab	NOUN
ijpds-3747	111	21	for	for	ADP
ijpds-3747	111	22	these	these	DET
ijpds-3747	111	23	organs	organ	NOUN
ijpds-3747	111	24	compared	compare	VERB
ijpds-3747	111	25	to	to	ADP
ijpds-3747	111	26	placebo	placebo	NOUN
ijpds-3747	111	27	.	.	PUNCT
ijpds-3747	112	1	for	for	ADP
ijpds-3747	112	2	hcq	hcq	NOUN
ijpds-3747	112	3	,	,	PUNCT
ijpds-3747	112	4	in	in	ADP
ijpds-3747	112	5	one	one	NUM
ijpds-3747	112	6	of	of	ADP
ijpds-3747	112	7	the	the	DET
ijpds-3747	112	8	trials	trial	NOUN
ijpds-3747	112	9	we	we	PRON
ijpds-3747	112	10	selected	select	VERB
ijpds-3747	112	11	,	,	PUNCT
ijpds-3747	112	12	the	the	DET
ijpds-3747	112	13	adverse	adverse	ADJ
ijpds-3747	112	14	effects	effect	NOUN
ijpds-3747	112	15	of	of	ADP
ijpds-3747	112	16	hcq	hcq	NOUN
ijpds-3747	112	17	have	have	AUX
ijpds-3747	112	18	been	be	AUX
ijpds-3747	112	19	compared	compare	VERB
ijpds-3747	112	20	with	with	ADP
ijpds-3747	112	21	ascorbic	ascorbic	NOUN
ijpds-3747	112	22	acid	acid	NOUN
ijpds-3747	112	23	so	so	ADV
ijpds-3747	112	24	,	,	PUNCT
ijpds-3747	112	25	for	for	ADP
ijpds-3747	112	26	this	this	DET
ijpds-3747	112	27	trial	trial	NOUN
ijpds-3747	112	28	,	,	PUNCT
ijpds-3747	112	29	the	the	DET
ijpds-3747	112	30	odds	odd	NOUN
ijpds-3747	112	31	ratio	ratio	NOUN
ijpds-3747	112	32	was	be	AUX
ijpds-3747	112	33	compared	compare	VERB
ijpds-3747	112	34	with	with	ADP
ijpds-3747	112	35	ascorbic	ascorbic	NOUN
ijpds-3747	112	36	acid	acid	NOUN
ijpds-3747	112	37	.	.	PUNCT
ijpds-3747	113	1	the	the	DET
ijpds-3747	113	2	results	result	NOUN
ijpds-3747	113	3	of	of	ADP
ijpds-3747	113	4	this	this	PRON
ijpds-3747	113	5	are	be	AUX
ijpds-3747	113	6	illustrated	illustrate	VERB
ijpds-3747	113	7	in	in	ADP
ijpds-3747	113	8	table	table	NOUN
ijpds-3747	113	9	3	3	NUM
ijpds-3747	113	10	.	.	PUNCT
ijpds-3747	114	1	in	in	ADP
ijpds-3747	114	2	the	the	DET
ijpds-3747	114	3	present	present	ADJ
ijpds-3747	114	4	trial	trial	NOUN
ijpds-3747	114	5	,	,	PUNCT
ijpds-3747	114	6	ascorbic	ascorbic	NOUN
ijpds-3747	114	7	acid	acid	NOUN
ijpds-3747	114	8	acted	act	VERB
ijpds-3747	114	9	as	as	ADP
ijpds-3747	114	10	a	a	DET
ijpds-3747	114	11	placebo	placebo	NOUN
ijpds-3747	114	12	equivalent	equivalent	NOUN
ijpds-3747	114	13	.	.	PUNCT
ijpds-3747	115	1	while	while	SCONJ
ijpds-3747	115	2	the	the	DET
ijpds-3747	115	3	second	second	ADJ
ijpds-3747	115	4	trial	trial	NOUN
ijpds-3747	115	5	of	of	ADP
ijpds-3747	115	6	hcq	hcq	NOUN
ijpds-3747	115	7	as	as	ADP
ijpds-3747	115	8	chemoprevention	chemoprevention	NOUN
ijpds-3747	115	9	for	for	ADP
ijpds-3747	115	10	covid-19	covid-19	PROPN
ijpds-3747	115	11	for	for	ADP
ijpds-3747	115	12	high	high	ADJ
ijpds-3747	115	13	-	-	PUNCT
ijpds-3747	115	14	risk	risk	NOUN
ijpds-3747	115	15	healthcare	healthcare	NOUN
ijpds-3747	115	16	workers	worker	NOUN
ijpds-3747	115	17	had	have	VERB
ijpds-3747	115	18	no	no	DET
ijpds-3747	115	19	placebo	placebo	NOUN
ijpds-3747	115	20	as	as	SCONJ
ijpds-3747	115	21	the	the	DET
ijpds-3747	115	22	trial	trial	NOUN
ijpds-3747	115	23	was	be	AUX
ijpds-3747	115	24	during	during	ADP
ijpds-3747	115	25	an	an	DET
ijpds-3747	115	26	ongoing	ongoing	ADJ
ijpds-3747	115	27	pandemic	pandemic	ADJ
ijpds-3747	115	28	situation	situation	NOUN
ijpds-3747	115	29	.	.	PUNCT
ijpds-3747	116	1	the	the	DET
ijpds-3747	116	2	participants	participant	NOUN
ijpds-3747	116	3	enrolled	enrol	VERB
ijpds-3747	116	4	in	in	ADP
ijpds-3747	116	5	the	the	DET
ijpds-3747	116	6	study	study	NOUN
ijpds-3747	116	7	were	be	AUX
ijpds-3747	116	8	on	on	ADP
ijpds-3747	116	9	-	-	PUNCT
ijpds-3747	116	10	duty	duty	NOUN
ijpds-3747	116	11	high	high	ADJ
ijpds-3747	116	12	-	-	PUNCT
ijpds-3747	116	13	risk	risk	NOUN
ijpds-3747	116	14	healthcare	healthcare	NOUN
ijpds-3747	116	15	workers	worker	NOUN
ijpds-3747	116	16	receiving	receive	VERB
ijpds-3747	116	17	hcq	hcq	NOUN
ijpds-3747	116	18	and	and	CCONJ
ijpds-3747	116	19	the	the	DET
ijpds-3747	116	20	placebo	placebo	NOUN
ijpds-3747	116	21	group	group	NOUN
ijpds-3747	116	22	might	might	AUX
ijpds-3747	116	23	increase	increase	VERB
ijpds-3747	116	24	the	the	DET
ijpds-3747	116	25	chance	chance	NOUN
ijpds-3747	116	26	of	of	ADP
ijpds-3747	116	27	covid19	covid19	NOUN
ijpds-3747	116	28	.	.	PUNCT
ijpds-3747	117	1	in	in	ADP
ijpds-3747	117	2	the	the	DET
ijpds-3747	117	3	trial	trial	NOUN
ijpds-3747	117	4	,	,	PUNCT
ijpds-3747	117	5	hcq	hcq	PROPN
ijpds-3747	117	6	did	do	AUX
ijpds-3747	117	7	not	not	PART
ijpds-3747	117	8	show	show	VERB
ijpds-3747	117	9	any	any	DET
ijpds-3747	117	10	risk	risk	NOUN
ijpds-3747	117	11	to	to	ADP
ijpds-3747	117	12	the	the	DET
ijpds-3747	117	13	nervous	nervous	ADJ
ijpds-3747	117	14	system	system	NOUN
ijpds-3747	117	15	and	and	CCONJ
ijpds-3747	117	16	psychiatric	psychiatric	ADJ
ijpds-3747	117	17	related	related	ADJ
ijpds-3747	117	18	disorders	disorder	NOUN
ijpds-3747	117	19	.	.	PUNCT
ijpds-3747	118	1	however	however	ADV
ijpds-3747	118	2	,	,	PUNCT
ijpds-3747	118	3	oddsratio	oddsratio	VERB
ijpds-3747	118	4	for	for	ADP
ijpds-3747	118	5	eye	eye	NOUN
ijpds-3747	118	6	disorder	disorder	NOUN
ijpds-3747	118	7	was	be	AUX
ijpds-3747	118	8	found	find	VERB
ijpds-3747	118	9	to	to	PART
ijpds-3747	118	10	be	be	AUX
ijpds-3747	118	11	98.96	98.96	NUM
ijpds-3747	118	12	,	,	PUNCT
ijpds-3747	118	13	indicating	indicate	VERB
ijpds-3747	118	14	99	99	NUM
ijpds-3747	118	15	times	time	NOUN
ijpds-3747	118	16	increased	increase	VERB
ijpds-3747	118	17	risk	risk	NOUN
ijpds-3747	118	18	of	of	ADP
ijpds-3747	118	19	having	have	VERB
ijpds-3747	118	20	an	an	DET
ijpds-3747	118	21	eye	eye	NOUN
ijpds-3747	118	22	disorder	disorder	NOUN
ijpds-3747	118	23	for	for	ADP
ijpds-3747	118	24	a	a	DET
ijpds-3747	118	25	person	person	NOUN
ijpds-3747	118	26	taking	take	VERB
ijpds-3747	118	27	hcq	hcq	NOUN
ijpds-3747	118	28	as	as	ADP
ijpds-3747	118	29	compared	compare	VERB
ijpds-3747	118	30	to	to	ADP
ijpds-3747	118	31	ascorbic	ascorbic	NOUN
ijpds-3747	118	32	acid	acid	NOUN
ijpds-3747	118	33	.	.	PUNCT
ijpds-3747	119	1	the	the	DET
ijpds-3747	119	2	odds	odd	NOUN
ijpds-3747	119	3	ratios	ratio	NOUN
ijpds-3747	119	4	are	be	AUX
ijpds-3747	119	5	2.5	2.5	NUM
ijpds-3747	119	6	,	,	PUNCT
ijpds-3747	119	7	277.5	277.5	NUM
ijpds-3747	119	8	,	,	PUNCT
ijpds-3747	119	9	and	and	CCONJ
ijpds-3747	119	10	3	3	NUM
ijpds-3747	119	11	for	for	ADP
ijpds-3747	119	12	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	119	13	disorders	disorder	NOUN
ijpds-3747	119	14	,	,	PUNCT
ijpds-3747	119	15	skin	skin	NOUN
ijpds-3747	119	16	disorders	disorder	NOUN
ijpds-3747	119	17	,	,	PUNCT
ijpds-3747	119	18	and	and	CCONJ
ijpds-3747	119	19	immune	immune	ADJ
ijpds-3747	119	20	disorders	disorder	NOUN
ijpds-3747	119	21	respectively	respectively	ADV
ijpds-3747	119	22	showing	show	VERB
ijpds-3747	119	23	a	a	DET
ijpds-3747	119	24	multifold	multifold	ADJ
ijpds-3747	119	25	increase	increase	NOUN
ijpds-3747	119	26	in	in	ADP
ijpds-3747	119	27	the	the	DET
ijpds-3747	119	28	risk	risk	NOUN
ijpds-3747	119	29	of	of	ADP
ijpds-3747	119	30	these	these	DET
ijpds-3747	119	31	disorders	disorder	NOUN
ijpds-3747	119	32	if	if	SCONJ
ijpds-3747	119	33	a	a	DET
ijpds-3747	119	34	patient	patient	NOUN
ijpds-3747	119	35	is	be	AUX
ijpds-3747	119	36	taking	take	VERB
ijpds-3747	119	37	hcq	hcq	NOUN
ijpds-3747	119	38	compared	compare	VERB
ijpds-3747	119	39	to	to	ADP
ijpds-3747	119	40	ascorbic	ascorbic	NOUN
ijpds-3747	119	41	acid	acid	NOUN
ijpds-3747	119	42	.	.	PUNCT
ijpds-3747	120	1	table	table	NOUN
ijpds-3747	120	2	3	3	NUM
ijpds-3747	120	3	–	–	PUNCT
ijpds-3747	120	4	odd	odd	ADJ
ijpds-3747	120	5	ratio	ratio	NOUN
ijpds-3747	120	6	calculation	calculation	NOUN
ijpds-3747	120	7	for	for	ADP
ijpds-3747	120	8	hcq	hcq	PROPN
ijpds-3747	120	9	hcq	hcq	PROPN
ijpds-3747	120	10	aa	aa	NOUN
ijpds-3747	120	11	or	or	CCONJ
ijpds-3747	120	12	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	120	13	disorders	disorder	NOUN
ijpds-3747	120	14	9.58	9.58	NUM
ijpds-3747	120	15	4.03	4.03	NUM
ijpds-3747	120	16	2.52	2.52	NUM
ijpds-3747	120	17	general	general	ADJ
ijpds-3747	120	18	disorders	disorder	NOUN
ijpds-3747	120	19	4.42	4.42	NUM
ijpds-3747	120	20	7.58	7.58	NUM
ijpds-3747	120	21	0.56	0.56	NUM
ijpds-3747	120	22	nervous	nervous	ADJ
ijpds-3747	120	23	system	system	NOUN
ijpds-3747	120	24	disorder	disorder	NOUN
ijpds-3747	120	25	0.01	0.01	NUM
ijpds-3747	120	26	0.01	0.01	NUM
ijpds-3747	120	27	1.00	1.00	NUM
ijpds-3747	120	28	psychiatric	psychiatric	ADJ
ijpds-3747	120	29	disorders	disorder	NOUN
ijpds-3747	120	30	0.01	0.01	NUM
ijpds-3747	120	31	0.01	0.01	NUM
ijpds-3747	120	32	1.00	1.00	NUM
ijpds-3747	120	33	skin	skin	NOUN
ijpds-3747	120	34	disorders	disorder	NOUN
ijpds-3747	120	35	2.7	2.7	NUM
ijpds-3747	120	36	0.01	0.01	NUM
ijpds-3747	120	37	277.46	277.46	NUM
ijpds-3747	120	38	cardiac	cardiac	ADJ
ijpds-3747	120	39	disorders	disorder	NOUN
ijpds-3747	120	40	0.01	0.01	NUM
ijpds-3747	120	41	0.01	0.01	NUM
ijpds-3747	120	42	1.00	1.00	NUM
ijpds-3747	120	43	eye	eye	NOUN
ijpds-3747	120	44	disorders	disorder	NOUN
ijpds-3747	120	45	0.98	0.98	NUM
ijpds-3747	120	46	0.00	0.00	NUM
ijpds-3747	120	47	98.96	98.96	NUM
ijpds-3747	120	48	immune	immune	ADJ
ijpds-3747	120	49	disorders	disorder	NOUN
ijpds-3747	120	50	0.74	0.74	NUM
ijpds-3747	120	51	0.24	0.24	NUM
ijpds-3747	120	52	3.10	3.10	NUM
ijpds-3747	120	53	*	*	PUNCT
ijpds-3747	120	54	hcq	hcq	NOUN
ijpds-3747	120	55	–	–	PUNCT
ijpds-3747	120	56	hydroxychloroquine	hydroxychloroquine	ADJ
ijpds-3747	120	57	,	,	PUNCT
ijpds-3747	120	58	aa	aa	INTJ
ijpds-3747	120	59	–	–	PUNCT
ijpds-3747	120	60	ascorbic	ascorbic	NOUN
ijpds-3747	120	61	acid	acid	NOUN
ijpds-3747	120	62	,	,	PUNCT
ijpds-3747	120	63	or	or	CCONJ
ijpds-3747	120	64	-	-	PUNCT
ijpds-3747	120	65	odds	odd	NOUN
ijpds-3747	120	66	ratio	ratio	NOUN
ijpds-3747	120	67	discussion	discussion	NOUN
ijpds-3747	120	68	the	the	DET
ijpds-3747	120	69	recent	recent	ADJ
ijpds-3747	120	70	advancements	advancement	NOUN
ijpds-3747	120	71	in	in	ADP
ijpds-3747	120	72	the	the	DET
ijpds-3747	120	73	molecular	molecular	ADJ
ijpds-3747	120	74	mechanism	mechanism	NOUN
ijpds-3747	120	75	of	of	ADP
ijpds-3747	120	76	sle	sle	PROPN
ijpds-3747	120	77	and	and	CCONJ
ijpds-3747	120	78	sle	sle	PROPN
ijpds-3747	120	79	’s	’s	PART
ijpds-3747	120	80	association	association	NOUN
ijpds-3747	120	81	with	with	ADP
ijpds-3747	120	82	the	the	DET
ijpds-3747	120	83	immune	immune	ADJ
ijpds-3747	120	84	arm	arm	NOUN
ijpds-3747	120	85	led	lead	VERB
ijpds-3747	120	86	to	to	ADP
ijpds-3747	120	87	the	the	DET
ijpds-3747	120	88	development	development	NOUN
ijpds-3747	120	89	of	of	ADP
ijpds-3747	120	90	novel	novel	ADJ
ijpds-3747	120	91	monoclonal	monoclonal	NOUN
ijpds-3747	120	92	antibodies	antibody	NOUN
ijpds-3747	120	93	against	against	ADP
ijpds-3747	120	94	sle	sle	PROPN
ijpds-3747	120	95	.	.	PUNCT
ijpds-3747	121	1	sle	sle	PROPN
ijpds-3747	121	2	is	be	AUX
ijpds-3747	121	3	an	an	DET
ijpds-3747	121	4	autoimmune	autoimmune	ADJ
ijpds-3747	121	5	disorder	disorder	NOUN
ijpds-3747	121	6	thus	thus	ADV
ijpds-3747	121	7	main	main	ADJ
ijpds-3747	121	8	clinical	clinical	ADJ
ijpds-3747	121	9	strategy	strategy	NOUN
ijpds-3747	121	10	behind	behind	ADP
ijpds-3747	121	11	antibody	antibody	NOUN
ijpds-3747	121	12	design	design	NOUN
ijpds-3747	121	13	is	be	AUX
ijpds-3747	121	14	to	to	PART
ijpds-3747	121	15	target	target	VERB
ijpds-3747	121	16	immune	immune	ADJ
ijpds-3747	121	17	cells	cell	NOUN
ijpds-3747	121	18	to	to	PART
ijpds-3747	121	19	inhibit	inhibit	VERB
ijpds-3747	121	20	the	the	DET
ijpds-3747	121	21	overactivation	overactivation	NOUN
ijpds-3747	121	22	of	of	ADP
ijpds-3747	121	23	the	the	DET
ijpds-3747	121	24	immune	immune	ADJ
ijpds-3747	121	25	system	system	NOUN
ijpds-3747	121	26	and	and	CCONJ
ijpds-3747	121	27	the	the	DET
ijpds-3747	121	28	overproduction	overproduction	NOUN
ijpds-3747	121	29	of	of	ADP
ijpds-3747	121	30	cytokines	cytokine	NOUN
ijpds-3747	121	31	[	[	X
ijpds-3747	121	32	24	24	NUM
ijpds-3747	121	33	]	]	PUNCT
ijpds-3747	121	34	.	.	PUNCT
ijpds-3747	122	1	this	this	DET
ijpds-3747	122	2	critical	critical	ADJ
ijpds-3747	122	3	analysis	analysis	NOUN
ijpds-3747	122	4	was	be	AUX
ijpds-3747	122	5	focused	focus	VERB
ijpds-3747	122	6	on	on	ADP
ijpds-3747	122	7	comparing	compare	VERB
ijpds-3747	122	8	the	the	DET
ijpds-3747	122	9	two	two	NUM
ijpds-3747	122	10	sle	sle	PROPN
ijpds-3747	122	11	drugs	drug	NOUN
ijpds-3747	122	12	belimumab	belimumab	NOUN
ijpds-3747	122	13	and	and	CCONJ
ijpds-3747	122	14	hcq	hcq	NOUN
ijpds-3747	122	15	.	.	PUNCT
ijpds-3747	123	1	there	there	PRON
ijpds-3747	123	2	is	be	VERB
ijpds-3747	123	3	no	no	DET
ijpds-3747	123	4	doubt	doubt	NOUN
ijpds-3747	123	5	that	that	SCONJ
ijpds-3747	123	6	b	b	NOUN
ijpds-3747	123	7	cells	cell	NOUN
ijpds-3747	123	8	are	be	AUX
ijpds-3747	123	9	crucial	crucial	ADJ
ijpds-3747	123	10	to	to	ADP
ijpds-3747	123	11	the	the	DET
ijpds-3747	123	12	development	development	NOUN
ijpds-3747	123	13	of	of	ADP
ijpds-3747	123	14	sle	sle	PROPN
ijpds-3747	123	15	and	and	CCONJ
ijpds-3747	123	16	belimumab	belimumab	NOUN
ijpds-3747	123	17	has	have	VERB
ijpds-3747	123	18	a	a	DET
ijpds-3747	123	19	recognized	recognize	VERB
ijpds-3747	123	20	function	function	NOUN
ijpds-3747	123	21	in	in	ADP
ijpds-3747	123	22	sle	sle	PROPN
ijpds-3747	123	23	treatment	treatment	NOUN
ijpds-3747	123	24	[	[	X
ijpds-3747	123	25	25	25	NUM
ijpds-3747	123	26	]	]	PUNCT
ijpds-3747	123	27	.	.	PUNCT
ijpds-3747	124	1	additionally	additionally	ADV
ijpds-3747	124	2	,	,	PUNCT
ijpds-3747	124	3	clinical	clinical	ADJ
ijpds-3747	124	4	trials	trial	NOUN
ijpds-3747	124	5	have	have	AUX
ijpds-3747	124	6	demonstrated	demonstrate	VERB
ijpds-3747	124	7	the	the	DET
ijpds-3747	124	8	effectiveness	effectiveness	NOUN
ijpds-3747	124	9	of	of	ADP
ijpds-3747	124	10	belimumab	belimumab	NOUN
ijpds-3747	124	11	by	by	ADP
ijpds-3747	124	12	demonstrating	demonstrate	VERB
ijpds-3747	124	13	a	a	DET
ijpds-3747	124	14	beneficial	beneficial	ADJ
ijpds-3747	124	15	improvement	improvement	NOUN
ijpds-3747	124	16	in	in	ADP
ijpds-3747	124	17	disease	disease	NOUN
ijpds-3747	124	18	activity	activity	NOUN
ijpds-3747	124	19	.	.	PUNCT
ijpds-3747	125	1	based	base	VERB
ijpds-3747	125	2	on	on	ADP
ijpds-3747	125	3	its	its	PRON
ijpds-3747	125	4	efficacy	efficacy	NOUN
ijpds-3747	125	5	,	,	PUNCT
ijpds-3747	125	6	food	food	NOUN
ijpds-3747	125	7	and	and	CCONJ
ijpds-3747	125	8	drug	drug	NOUN
ijpds-3747	125	9	administration	administration	NOUN
ijpds-3747	125	10	approved	approve	VERB
ijpds-3747	125	11	it	it	PRON
ijpds-3747	125	12	in	in	ADP
ijpds-3747	125	13	2011	2011	NUM
ijpds-3747	125	14	[	[	X
ijpds-3747	125	15	26	26	NUM
ijpds-3747	125	16	]	]	PUNCT
ijpds-3747	125	17	.	.	PUNCT
ijpds-3747	126	1	whereas	whereas	ADV
ijpds-3747	126	2	,	,	PUNCT
ijpds-3747	126	3	hcq	hcq	PROPN
ijpds-3747	126	4	has	have	VERB
ijpds-3747	126	5	a	a	DET
ijpds-3747	126	6	long	long	ADJ
ijpds-3747	126	7	history	history	NOUN
ijpds-3747	126	8	of	of	ADP
ijpds-3747	126	9	use	use	NOUN
ijpds-3747	126	10	in	in	ADP
ijpds-3747	126	11	sle	sle	PROPN
ijpds-3747	126	12	since	since	SCONJ
ijpds-3747	126	13	it	it	PRON
ijpds-3747	126	14	was	be	AUX
ijpds-3747	126	15	approved	approve	VERB
ijpds-3747	126	16	in	in	ADP
ijpds-3747	126	17	1955	1955	NUM
ijpds-3747	126	18	for	for	ADP
ijpds-3747	126	19	sle	sle	PROPN
ijpds-3747	126	20	treatment	treatment	NOUN
ijpds-3747	126	21	[	[	X
ijpds-3747	126	22	27	27	NUM
ijpds-3747	126	23	]	]	PUNCT
ijpds-3747	126	24	.	.	PUNCT
ijpds-3747	127	1	given	give	VERB
ijpds-3747	127	2	its	its	PRON
ijpds-3747	127	3	broad	broad	ADJ
ijpds-3747	127	4	spectrum	spectrum	NOUN
ijpds-3747	127	5	of	of	ADP
ijpds-3747	127	6	activity	activity	NOUN
ijpds-3747	127	7	,	,	PUNCT
ijpds-3747	127	8	maryam	maryam	PROPN
ijpds-3747	127	9	and	and	CCONJ
ijpds-3747	127	10	ahmad	ahmad	PROPN
ijpds-3747	127	11	safety	safety	PROPN
ijpds-3747	127	12	comparison	comparison	NOUN
ijpds-3747	127	13	of	of	ADP
ijpds-3747	127	14	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	127	15	and	and	CCONJ
ijpds-3747	127	16	belimumab	belimumab	NOUN
ijpds-3747	127	17	vol	vol	NOUN
ijpds-3747	127	18	2	2	NUM
ijpds-3747	127	19	|	|	NOUN
ijpds-3747	127	20	issue	issue	NOUN
ijpds-3747	127	21	1	1	NUM
ijpds-3747	127	22	|	|	ADV
ijpds-3747	127	23	jan	jan	PROPN
ijpds-3747	127	24	–	–	PUNCT
ijpds-3747	127	25	mar	mar	PROPN
ijpds-3747	127	26	2023	2023	NUM
ijpds-3747	127	27	indian	indian	PROPN
ijpds-3747	127	28	j	j	PROPN
ijpds-3747	127	29	pharm	pharm	PROPN
ijpds-3747	127	30	drug	drug	PROPN
ijpds-3747	127	31	studies	study	NOUN
ijpds-3747	127	32	|	|	ADV
ijpds-3747	127	33	9	9	NUM
ijpds-3747	127	34	recently	recently	ADV
ijpds-3747	127	35	,	,	PUNCT
ijpds-3747	127	36	hcq	hcq	PROPN
ijpds-3747	127	37	was	be	AUX
ijpds-3747	127	38	frequently	frequently	ADV
ijpds-3747	127	39	used	use	VERB
ijpds-3747	127	40	as	as	ADP
ijpds-3747	127	41	a	a	DET
ijpds-3747	127	42	protective	protective	ADJ
ijpds-3747	127	43	treatment	treatment	NOUN
ijpds-3747	127	44	for	for	ADP
ijpds-3747	127	45	covid-19	covid-19	PROPN
ijpds-3747	127	46	.	.	PUNCT
ijpds-3747	128	1	the	the	DET
ijpds-3747	128	2	use	use	NOUN
ijpds-3747	128	3	of	of	ADP
ijpds-3747	128	4	this	this	DET
ijpds-3747	128	5	drug	drug	NOUN
ijpds-3747	128	6	globally	globally	ADV
ijpds-3747	128	7	provided	provide	VERB
ijpds-3747	128	8	a	a	DET
ijpds-3747	128	9	golden	golden	ADJ
ijpds-3747	128	10	chance	chance	NOUN
ijpds-3747	128	11	for	for	ADP
ijpds-3747	128	12	clinicians	clinician	NOUN
ijpds-3747	128	13	and	and	CCONJ
ijpds-3747	128	14	researchers	researcher	NOUN
ijpds-3747	128	15	to	to	PART
ijpds-3747	128	16	look	look	VERB
ijpds-3747	128	17	widely	widely	ADV
ijpds-3747	128	18	at	at	ADP
ijpds-3747	128	19	the	the	DET
ijpds-3747	128	20	adverse	adverse	ADJ
ijpds-3747	128	21	events	event	NOUN
ijpds-3747	128	22	associated	associate	VERB
ijpds-3747	128	23	with	with	ADP
ijpds-3747	128	24	hcq	hcq	NOUN
ijpds-3747	128	25	.	.	PUNCT
ijpds-3747	129	1	thus	thus	ADV
ijpds-3747	129	2	,	,	PUNCT
ijpds-3747	129	3	we	we	PRON
ijpds-3747	129	4	performed	perform	VERB
ijpds-3747	129	5	a	a	DET
ijpds-3747	129	6	critical	critical	ADJ
ijpds-3747	129	7	review	review	NOUN
ijpds-3747	129	8	of	of	ADP
ijpds-3747	129	9	the	the	DET
ijpds-3747	129	10	recent	recent	ADJ
ijpds-3747	129	11	clinical	clinical	ADJ
ijpds-3747	129	12	trials	trial	NOUN
ijpds-3747	129	13	conducted	conduct	VERB
ijpds-3747	129	14	on	on	ADP
ijpds-3747	129	15	diverse	diverse	ADJ
ijpds-3747	129	16	populations	population	NOUN
ijpds-3747	129	17	for	for	ADP
ijpds-3747	129	18	hcq	hcq	NOUN
ijpds-3747	129	19	during	during	ADP
ijpds-3747	129	20	the	the	DET
ijpds-3747	129	21	covid-19	covid-19	PROPN
ijpds-3747	129	22	pandemic	pandemic	NOUN
ijpds-3747	129	23	.	.	PUNCT
ijpds-3747	130	1	we	we	PRON
ijpds-3747	130	2	compared	compare	VERB
ijpds-3747	130	3	the	the	DET
ijpds-3747	130	4	adverse	adverse	ADJ
ijpds-3747	130	5	events	event	NOUN
ijpds-3747	130	6	of	of	ADP
ijpds-3747	130	7	hcq	hcq	NOUN
ijpds-3747	130	8	with	with	ADP
ijpds-3747	130	9	a	a	DET
ijpds-3747	130	10	relatively	relatively	ADV
ijpds-3747	130	11	novel	novel	ADJ
ijpds-3747	130	12	monoclonal	monoclonal	NOUN
ijpds-3747	130	13	antibody	antibody	NOUN
ijpds-3747	130	14	belimumab	belimumab	NOUN
ijpds-3747	130	15	by	by	ADP
ijpds-3747	130	16	critically	critically	ADV
ijpds-3747	130	17	analyzing	analyze	VERB
ijpds-3747	130	18	the	the	DET
ijpds-3747	130	19	clinical	clinical	ADJ
ijpds-3747	130	20	trials	trial	NOUN
ijpds-3747	130	21	,	,	PUNCT
ijpds-3747	130	22	and	and	CCONJ
ijpds-3747	130	23	utilizing	utilize	VERB
ijpds-3747	130	24	that	that	DET
ijpds-3747	130	25	data	datum	NOUN
ijpds-3747	130	26	to	to	PART
ijpds-3747	130	27	calculate	calculate	VERB
ijpds-3747	130	28	absolute	absolute	ADJ
ijpds-3747	130	29	risk	risk	NOUN
ijpds-3747	130	30	,	,	PUNCT
ijpds-3747	130	31	relative	relative	ADJ
ijpds-3747	130	32	risk	risk	NOUN
ijpds-3747	130	33	,	,	PUNCT
ijpds-3747	130	34	and	and	CCONJ
ijpds-3747	130	35	odds	odd	VERB
ijpds-3747	130	36	ratio	ratio	NOUN
ijpds-3747	130	37	for	for	ADP
ijpds-3747	130	38	drugs	drug	NOUN
ijpds-3747	130	39	.	.	PUNCT
ijpds-3747	131	1	the	the	DET
ijpds-3747	131	2	trials	trial	NOUN
ijpds-3747	131	3	of	of	ADP
ijpds-3747	131	4	belimumab	belimumab	NOUN
ijpds-3747	131	5	reported	report	VERB
ijpds-3747	131	6	a	a	DET
ijpds-3747	131	7	range	range	NOUN
ijpds-3747	131	8	of	of	ADP
ijpds-3747	131	9	adverse	adverse	ADJ
ijpds-3747	131	10	events	event	NOUN
ijpds-3747	131	11	from	from	ADP
ijpds-3747	131	12	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	131	13	discomforts	discomfort	NOUN
ijpds-3747	131	14	to	to	ADP
ijpds-3747	131	15	serious	serious	ADJ
ijpds-3747	131	16	psychiatric	psychiatric	ADJ
ijpds-3747	131	17	disorders	disorder	NOUN
ijpds-3747	131	18	.	.	PUNCT
ijpds-3747	132	1	however	however	ADV
ijpds-3747	132	2	,	,	PUNCT
ijpds-3747	132	3	the	the	DET
ijpds-3747	132	4	results	result	NOUN
ijpds-3747	132	5	of	of	ADP
ijpds-3747	132	6	the	the	DET
ijpds-3747	132	7	trials	trial	NOUN
ijpds-3747	132	8	observed	observe	VERB
ijpds-3747	132	9	under	under	ADP
ijpds-3747	132	10	the	the	DET
ijpds-3747	132	11	scope	scope	NOUN
ijpds-3747	132	12	of	of	ADP
ijpds-3747	132	13	the	the	DET
ijpds-3747	132	14	study	study	NOUN
ijpds-3747	132	15	were	be	AUX
ijpds-3747	132	16	not	not	PART
ijpds-3747	132	17	in	in	ADP
ijpds-3747	132	18	harmonization	harmonization	NOUN
ijpds-3747	132	19	.	.	PUNCT
ijpds-3747	133	1	the	the	DET
ijpds-3747	133	2	results	result	NOUN
ijpds-3747	133	3	observed	observe	VERB
ijpds-3747	133	4	in	in	ADP
ijpds-3747	133	5	one	one	NUM
ijpds-3747	133	6	of	of	ADP
ijpds-3747	133	7	the	the	DET
ijpds-3747	133	8	trials	trial	NOUN
ijpds-3747	133	9	reported	report	VERB
ijpds-3747	133	10	a	a	DET
ijpds-3747	133	11	41.7	41.7	NUM
ijpds-3747	133	12	%	%	NOUN
ijpds-3747	133	13	risk	risk	NOUN
ijpds-3747	133	14	of	of	ADP
ijpds-3747	133	15	gastrointestinal	gastrointestinal	NOUN
ijpds-3747	133	16	,	,	PUNCT
ijpds-3747	133	17	and	and	CCONJ
ijpds-3747	133	18	28.61	28.61	NUM
ijpds-3747	133	19	%	%	NOUN
ijpds-3747	133	20	risk	risk	NOUN
ijpds-3747	133	21	of	of	ADP
ijpds-3747	133	22	nervous	nervous	ADJ
ijpds-3747	133	23	system	system	NOUN
ijpds-3747	133	24	disorders	disorder	NOUN
ijpds-3747	133	25	.	.	PUNCT
ijpds-3747	134	1	these	these	DET
ijpds-3747	134	2	results	result	NOUN
ijpds-3747	134	3	observed	observe	VERB
ijpds-3747	134	4	were	be	AUX
ijpds-3747	134	5	almost	almost	ADV
ijpds-3747	134	6	double	double	DET
ijpds-3747	134	7	the	the	DET
ijpds-3747	134	8	aes	aes	NOUN
ijpds-3747	134	9	observed	observe	VERB
ijpds-3747	134	10	in	in	ADP
ijpds-3747	134	11	the	the	DET
ijpds-3747	134	12	other	other	ADJ
ijpds-3747	134	13	trial	trial	NOUN
ijpds-3747	134	14	of	of	ADP
ijpds-3747	134	15	the	the	DET
ijpds-3747	134	16	same	same	ADJ
ijpds-3747	134	17	drug	drug	NOUN
ijpds-3747	134	18	.	.	PUNCT
ijpds-3747	135	1	similarly	similarly	ADV
ijpds-3747	135	2	,	,	PUNCT
ijpds-3747	135	3	the	the	DET
ijpds-3747	135	4	risk	risk	NOUN
ijpds-3747	135	5	for	for	ADP
ijpds-3747	135	6	general	general	ADJ
ijpds-3747	135	7	disorders	disorder	NOUN
ijpds-3747	135	8	was	be	AUX
ijpds-3747	135	9	almost	almost	ADV
ijpds-3747	135	10	16	16	NUM
ijpds-3747	135	11	times	time	NOUN
ijpds-3747	135	12	greater	great	ADJ
ijpds-3747	135	13	than	than	ADP
ijpds-3747	135	14	in	in	ADP
ijpds-3747	135	15	another	another	DET
ijpds-3747	135	16	trial	trial	NOUN
ijpds-3747	135	17	for	for	ADP
ijpds-3747	135	18	belimumab	belimumab	NOUN
ijpds-3747	135	19	.	.	PUNCT
ijpds-3747	136	1	however	however	ADV
ijpds-3747	136	2	,	,	PUNCT
ijpds-3747	136	3	the	the	DET
ijpds-3747	136	4	trials	trial	NOUN
ijpds-3747	136	5	presented	present	VERB
ijpds-3747	136	6	an	an	DET
ijpds-3747	136	7	equal	equal	ADJ
ijpds-3747	136	8	percentage	percentage	NOUN
ijpds-3747	136	9	risk	risk	NOUN
ijpds-3747	136	10	for	for	ADP
ijpds-3747	136	11	cardiac	cardiac	ADJ
ijpds-3747	136	12	and	and	CCONJ
ijpds-3747	136	13	eye	eye	NOUN
ijpds-3747	136	14	disorders	disorder	NOUN
ijpds-3747	136	15	.	.	PUNCT
ijpds-3747	137	1	the	the	DET
ijpds-3747	137	2	significant	significant	ADJ
ijpds-3747	137	3	heterogeneity	heterogeneity	NOUN
ijpds-3747	137	4	in	in	ADP
ijpds-3747	137	5	results	result	NOUN
ijpds-3747	137	6	reported	report	VERB
ijpds-3747	137	7	by	by	ADP
ijpds-3747	137	8	the	the	DET
ijpds-3747	137	9	trials	trial	NOUN
ijpds-3747	137	10	can	can	AUX
ijpds-3747	137	11	be	be	AUX
ijpds-3747	137	12	presented	present	VERB
ijpds-3747	137	13	as	as	ADP
ijpds-3747	137	14	the	the	DET
ijpds-3747	137	15	difference	difference	NOUN
ijpds-3747	137	16	in	in	ADP
ijpds-3747	137	17	the	the	DET
ijpds-3747	137	18	number	number	NOUN
ijpds-3747	137	19	of	of	ADP
ijpds-3747	137	20	the	the	DET
ijpds-3747	137	21	study	study	NOUN
ijpds-3747	137	22	group	group	NOUN
ijpds-3747	137	23	and	and	CCONJ
ijpds-3747	137	24	the	the	DET
ijpds-3747	137	25	ethnicity	ethnicity	NOUN
ijpds-3747	137	26	of	of	ADP
ijpds-3747	137	27	the	the	DET
ijpds-3747	137	28	population	population	NOUN
ijpds-3747	137	29	selected	select	VERB
ijpds-3747	137	30	for	for	ADP
ijpds-3747	137	31	the	the	DET
ijpds-3747	137	32	trial	trial	NOUN
ijpds-3747	137	33	as	as	SCONJ
ijpds-3747	137	34	one	one	NUM
ijpds-3747	137	35	trial	trial	NOUN
ijpds-3747	137	36	employed	employ	VERB
ijpds-3747	137	37	americans	americans	PROPN
ijpds-3747	137	38	and	and	CCONJ
ijpds-3747	137	39	the	the	DET
ijpds-3747	137	40	other	other	ADJ
ijpds-3747	137	41	trial	trial	NOUN
ijpds-3747	137	42	was	be	AUX
ijpds-3747	137	43	conducted	conduct	VERB
ijpds-3747	137	44	on	on	ADP
ijpds-3747	137	45	americans	americans	PROPN
ijpds-3747	137	46	,	,	PUNCT
ijpds-3747	137	47	europeans	europeans	PROPN
ijpds-3747	137	48	,	,	PUNCT
ijpds-3747	137	49	and	and	CCONJ
ijpds-3747	137	50	asians	asians	PROPN
ijpds-3747	137	51	.	.	PUNCT
ijpds-3747	138	1	trials	trial	NOUN
ijpds-3747	138	2	for	for	ADP
ijpds-3747	138	3	hcq	hcq	NOUN
ijpds-3747	138	4	showed	show	VERB
ijpds-3747	138	5	a	a	DET
ijpds-3747	138	6	safe	safe	ADJ
ijpds-3747	138	7	profile	profile	NOUN
ijpds-3747	138	8	in	in	ADP
ijpds-3747	138	9	comparison	comparison	NOUN
ijpds-3747	138	10	to	to	ADP
ijpds-3747	138	11	belimumab	belimumab	NOUN
ijpds-3747	138	12	.	.	PUNCT
ijpds-3747	139	1	however	however	ADV
ijpds-3747	139	2	,	,	PUNCT
ijpds-3747	139	3	we	we	PRON
ijpds-3747	139	4	also	also	ADV
ijpds-3747	139	5	observed	observe	VERB
ijpds-3747	139	6	discrepancies	discrepancy	NOUN
ijpds-3747	139	7	in	in	ADP
ijpds-3747	139	8	the	the	DET
ijpds-3747	139	9	results	result	NOUN
ijpds-3747	139	10	of	of	ADP
ijpds-3747	139	11	the	the	DET
ijpds-3747	139	12	hcq	hcq	NOUN
ijpds-3747	139	13	trials	trial	NOUN
ijpds-3747	139	14	.	.	PUNCT
ijpds-3747	140	1	the	the	DET
ijpds-3747	140	2	absolute	absolute	ADJ
ijpds-3747	140	3	risk	risk	NOUN
ijpds-3747	140	4	for	for	ADP
ijpds-3747	140	5	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	140	6	,	,	PUNCT
ijpds-3747	140	7	general	general	ADJ
ijpds-3747	140	8	,	,	PUNCT
ijpds-3747	140	9	and	and	CCONJ
ijpds-3747	140	10	skin	skin	NOUN
ijpds-3747	140	11	disorders	disorder	NOUN
ijpds-3747	140	12	was	be	AUX
ijpds-3747	140	13	found	find	VERB
ijpds-3747	140	14	to	to	PART
ijpds-3747	140	15	be	be	AUX
ijpds-3747	140	16	21.74	21.74	NUM
ijpds-3747	140	17	%	%	NOUN
ijpds-3747	140	18	,	,	PUNCT
ijpds-3747	140	19	8.7	8.7	NUM
ijpds-3747	140	20	%	%	NOUN
ijpds-3747	140	21	,	,	PUNCT
ijpds-3747	140	22	and	and	CCONJ
ijpds-3747	140	23	6.52	6.52	NUM
ijpds-3747	140	24	%	%	NOUN
ijpds-3747	140	25	for	for	ADP
ijpds-3747	140	26	one	one	NUM
ijpds-3747	140	27	trial	trial	NOUN
ijpds-3747	140	28	against	against	ADP
ijpds-3747	140	29	the	the	DET
ijpds-3747	140	30	minute	minute	ADJ
ijpds-3747	140	31	values	value	NOUN
ijpds-3747	140	32	of	of	ADP
ijpds-3747	140	33	9.58	9.58	NUM
ijpds-3747	140	34	%	%	NOUN
ijpds-3747	140	35	,	,	PUNCT
ijpds-3747	140	36	4.42	4.42	NUM
ijpds-3747	140	37	%	%	NOUN
ijpds-3747	140	38	,	,	PUNCT
ijpds-3747	140	39	and	and	CCONJ
ijpds-3747	140	40	2.7	2.7	NUM
ijpds-3747	140	41	%	%	NOUN
ijpds-3747	140	42	for	for	ADP
ijpds-3747	140	43	another	another	PRON
ijpds-3747	140	44	.	.	PUNCT
ijpds-3747	141	1	interestingly	interestingly	ADV
ijpds-3747	141	2	,	,	PUNCT
ijpds-3747	141	3	the	the	DET
ijpds-3747	141	4	trial	trial	NOUN
ijpds-3747	141	5	also	also	ADV
ijpds-3747	141	6	failed	fail	VERB
ijpds-3747	141	7	to	to	PART
ijpds-3747	141	8	provide	provide	VERB
ijpds-3747	141	9	any	any	DET
ijpds-3747	141	10	adverse	adverse	ADJ
ijpds-3747	141	11	effect	effect	NOUN
ijpds-3747	141	12	on	on	ADP
ijpds-3747	141	13	cardiac	cardiac	ADJ
ijpds-3747	141	14	disorders	disorder	NOUN
ijpds-3747	141	15	,	,	PUNCT
ijpds-3747	141	16	the	the	DET
ijpds-3747	141	17	more	more	ADV
ijpds-3747	141	18	pronounced	pronounced	ADJ
ijpds-3747	141	19	effects	effect	NOUN
ijpds-3747	141	20	for	for	ADP
ijpds-3747	141	21	which	which	PRON
ijpds-3747	141	22	hcq	hcq	NOUN
ijpds-3747	141	23	is	be	AUX
ijpds-3747	141	24	famous	famous	ADJ
ijpds-3747	141	25	.	.	PUNCT
ijpds-3747	142	1	again	again	ADV
ijpds-3747	142	2	,	,	PUNCT
ijpds-3747	142	3	this	this	PRON
ijpds-3747	142	4	can	can	AUX
ijpds-3747	142	5	be	be	AUX
ijpds-3747	142	6	attributed	attribute	VERB
ijpds-3747	142	7	to	to	ADP
ijpds-3747	142	8	uneven	uneven	ADJ
ijpds-3747	142	9	sample	sample	NOUN
ijpds-3747	142	10	size	size	NOUN
ijpds-3747	142	11	,	,	PUNCT
ijpds-3747	142	12	differences	difference	NOUN
ijpds-3747	142	13	in	in	ADP
ijpds-3747	142	14	entry	entry	NOUN
ijpds-3747	142	15	requirements	requirement	NOUN
ijpds-3747	142	16	,	,	PUNCT
ijpds-3747	142	17	and	and	CCONJ
ijpds-3747	142	18	the	the	DET
ijpds-3747	142	19	environment	environment	NOUN
ijpds-3747	142	20	in	in	ADP
ijpds-3747	142	21	which	which	PRON
ijpds-3747	142	22	the	the	DET
ijpds-3747	142	23	trials	trial	NOUN
ijpds-3747	142	24	are	be	AUX
ijpds-3747	142	25	being	be	AUX
ijpds-3747	142	26	conducted	conduct	VERB
ijpds-3747	142	27	.	.	PUNCT
ijpds-3747	143	1	belimumab	belimumab	NOUN
ijpds-3747	143	2	caused	cause	VERB
ijpds-3747	143	3	2	2	NUM
ijpds-3747	143	4	mortalities	mortality	NOUN
ijpds-3747	143	5	while	while	SCONJ
ijpds-3747	143	6	hcq	hcq	NOUN
ijpds-3747	143	7	showed	show	VERB
ijpds-3747	143	8	no	no	DET
ijpds-3747	143	9	mortality	mortality	NOUN
ijpds-3747	143	10	.	.	PUNCT
ijpds-3747	144	1	the	the	DET
ijpds-3747	144	2	odds	odd	NOUN
ijpds-3747	144	3	ratio	ratio	NOUN
ijpds-3747	144	4	calculated	calculate	VERB
ijpds-3747	144	5	for	for	ADP
ijpds-3747	144	6	hcq	hcq	NOUN
ijpds-3747	144	7	and	and	CCONJ
ijpds-3747	144	8	belimumab	belimumab	NOUN
ijpds-3747	144	9	trials	trial	NOUN
ijpds-3747	144	10	presented	present	VERB
ijpds-3747	144	11	an	an	DET
ijpds-3747	144	12	abrupt	abrupt	ADJ
ijpds-3747	144	13	trend	trend	NOUN
ijpds-3747	144	14	with	with	ADP
ijpds-3747	144	15	a	a	DET
ijpds-3747	144	16	range	range	NOUN
ijpds-3747	144	17	of	of	ADP
ijpds-3747	144	18	values	value	NOUN
ijpds-3747	144	19	from	from	ADP
ijpds-3747	144	20	0.3	0.3	NUM
ijpds-3747	144	21	to	to	ADP
ijpds-3747	144	22	277	277	NUM
ijpds-3747	144	23	.	.	PUNCT
ijpds-3747	145	1	the	the	DET
ijpds-3747	145	2	odds	odd	NOUN
ijpds-3747	145	3	ratio	ratio	NOUN
ijpds-3747	145	4	for	for	ADP
ijpds-3747	145	5	belimumab	belimumab	NOUN
ijpds-3747	145	6	/	/	SYM
ijpds-3747	145	7	placebo	placebo	NOUN
ijpds-3747	145	8	showed	show	VERB
ijpds-3747	145	9	a	a	DET
ijpds-3747	145	10	value	value	NOUN
ijpds-3747	145	11	of	of	ADP
ijpds-3747	145	12	0.3	0.3	NUM
ijpds-3747	145	13	while	while	SCONJ
ijpds-3747	145	14	98.96	98.96	NUM
ijpds-3747	145	15	for	for	ADP
ijpds-3747	145	16	hcq	hcq	NOUN
ijpds-3747	145	17	/	/	SYM
ijpds-3747	145	18	placebo	placebo	NOUN
ijpds-3747	145	19	for	for	ADP
ijpds-3747	145	20	eye	eye	NOUN
ijpds-3747	145	21	disorders	disorder	NOUN
ijpds-3747	145	22	.	.	PUNCT
ijpds-3747	146	1	0.3	0.3	NUM
ijpds-3747	146	2	indicates	indicate	VERB
ijpds-3747	146	3	three	three	NUM
ijpds-3747	146	4	times	time	NOUN
ijpds-3747	146	5	more	more	ADJ
ijpds-3747	146	6	effect	effect	NOUN
ijpds-3747	146	7	of	of	ADP
ijpds-3747	146	8	placebo	placebo	NOUN
ijpds-3747	146	9	on	on	ADP
ijpds-3747	146	10	eyes	eye	NOUN
ijpds-3747	146	11	and	and	CCONJ
ijpds-3747	146	12	rather	rather	ADV
ijpds-3747	146	13	a	a	DET
ijpds-3747	146	14	protective	protective	ADJ
ijpds-3747	146	15	role	role	NOUN
ijpds-3747	146	16	of	of	ADP
ijpds-3747	146	17	belimumab	belimumab	NOUN
ijpds-3747	146	18	for	for	ADP
ijpds-3747	146	19	eyes	eye	NOUN
ijpds-3747	146	20	.	.	PUNCT
ijpds-3747	147	1	on	on	ADP
ijpds-3747	147	2	the	the	DET
ijpds-3747	147	3	other	other	ADJ
ijpds-3747	147	4	hand	hand	NOUN
ijpds-3747	147	5	,	,	PUNCT
ijpds-3747	147	6	98.96	98.96	NUM
ijpds-3747	147	7	for	for	ADP
ijpds-3747	147	8	hcq	hcq	NOUN
ijpds-3747	147	9	/	/	SYM
ijpds-3747	147	10	placebo	placebo	NOUN
ijpds-3747	147	11	showed	show	VERB
ijpds-3747	147	12	99	99	NUM
ijpds-3747	147	13	times	time	NOUN
ijpds-3747	147	14	increased	increase	VERB
ijpds-3747	147	15	tendency	tendency	NOUN
ijpds-3747	147	16	of	of	ADP
ijpds-3747	147	17	hcq	hcq	NOUN
ijpds-3747	147	18	to	to	PART
ijpds-3747	147	19	cause	cause	VERB
ijpds-3747	147	20	eye	eye	NOUN
ijpds-3747	147	21	ailments	ailment	NOUN
ijpds-3747	147	22	.	.	PUNCT
ijpds-3747	148	1	the	the	DET
ijpds-3747	148	2	most	most	ADV
ijpds-3747	148	3	common	common	ADJ
ijpds-3747	148	4	cardiac	cardiac	ADJ
ijpds-3747	148	5	effects	effect	NOUN
ijpds-3747	148	6	reported	report	VERB
ijpds-3747	148	7	in	in	ADP
ijpds-3747	148	8	our	our	PRON
ijpds-3747	148	9	study	study	NOUN
ijpds-3747	148	10	by	by	ADP
ijpds-3747	148	11	hcq	hcq	NOUN
ijpds-3747	148	12	include	include	VERB
ijpds-3747	148	13	chest	chest	NOUN
ijpds-3747	148	14	pain	pain	NOUN
ijpds-3747	148	15	,	,	PUNCT
ijpds-3747	148	16	dyspnoea	dyspnoea	NOUN
ijpds-3747	148	17	,	,	PUNCT
ijpds-3747	148	18	qt	qt	NOUN
ijpds-3747	148	19	prolongation	prolongation	NOUN
ijpds-3747	148	20	,	,	PUNCT
ijpds-3747	148	21	and	and	CCONJ
ijpds-3747	148	22	qt	qt	NOUN
ijpds-3747	148	23	syndrome	syndrome	NOUN
ijpds-3747	148	24	.	.	PUNCT
ijpds-3747	149	1	these	these	DET
ijpds-3747	149	2	results	result	NOUN
ijpds-3747	149	3	for	for	ADP
ijpds-3747	149	4	hcq	hcq	NOUN
ijpds-3747	149	5	are	be	AUX
ijpds-3747	149	6	in	in	ADP
ijpds-3747	149	7	concordance	concordance	NOUN
ijpds-3747	149	8	with	with	ADP
ijpds-3747	149	9	previous	previous	ADJ
ijpds-3747	149	10	studies	study	NOUN
ijpds-3747	149	11	as	as	SCONJ
ijpds-3747	149	12	the	the	DET
ijpds-3747	149	13	previous	previous	ADJ
ijpds-3747	149	14	studies	study	NOUN
ijpds-3747	149	15	conducted	conduct	VERB
ijpds-3747	149	16	for	for	ADP
ijpds-3747	149	17	hcq	hcq	NOUN
ijpds-3747	149	18	showed	show	VERB
ijpds-3747	149	19	the	the	DET
ijpds-3747	149	20	increased	increase	VERB
ijpds-3747	149	21	probability	probability	NOUN
ijpds-3747	149	22	of	of	ADP
ijpds-3747	149	23	the	the	DET
ijpds-3747	149	24	drug	drug	NOUN
ijpds-3747	149	25	for	for	ADP
ijpds-3747	149	26	cardiomyopathy	cardiomyopathy	ADJ
ijpds-3747	149	27	,	,	PUNCT
ijpds-3747	149	28	eye	eye	NOUN
ijpds-3747	149	29	disorders	disorder	NOUN
ijpds-3747	149	30	,	,	PUNCT
ijpds-3747	149	31	and	and	CCONJ
ijpds-3747	149	32	skin	skin	NOUN
ijpds-3747	149	33	hyperpigmentation	hyperpigmentation	NOUN
ijpds-3747	149	34	[	[	X
ijpds-3747	149	35	28	28	NUM
ijpds-3747	149	36	]	]	PUNCT
ijpds-3747	149	37	.	.	PUNCT
ijpds-3747	150	1	in	in	ADP
ijpds-3747	150	2	addition	addition	NOUN
ijpds-3747	150	3	to	to	ADP
ijpds-3747	150	4	corneal	corneal	ADJ
ijpds-3747	150	5	deposits	deposit	NOUN
ijpds-3747	150	6	,	,	PUNCT
ijpds-3747	150	7	dysfunction	dysfunction	NOUN
ijpds-3747	150	8	in	in	ADP
ijpds-3747	150	9	the	the	DET
ijpds-3747	150	10	ciliary	ciliary	ADJ
ijpds-3747	150	11	body	body	NOUN
ijpds-3747	150	12	,	,	PUNCT
ijpds-3747	150	13	posterior	posterior	ADJ
ijpds-3747	150	14	subcapsular	subcapsular	ADJ
ijpds-3747	150	15	lens	lens	NOUN
ijpds-3747	150	16	opacity	opacity	NOUN
ijpds-3747	150	17	,	,	PUNCT
ijpds-3747	150	18	uneven	uneven	ADJ
ijpds-3747	150	19	macular	macular	ADJ
ijpds-3747	150	20	pigmentation	pigmentation	NOUN
ijpds-3747	150	21	,	,	PUNCT
ijpds-3747	150	22	and	and	CCONJ
ijpds-3747	150	23	hydroxychloroquine	hydroxychloroquine	PROPN
ijpds-3747	150	24	can	can	AUX
ijpds-3747	150	25	result	result	VERB
ijpds-3747	150	26	in	in	ADP
ijpds-3747	150	27	side	side	NOUN
ijpds-3747	150	28	effects	effect	NOUN
ijpds-3747	150	29	including	include	VERB
ijpds-3747	150	30	a	a	DET
ijpds-3747	150	31	ring	ring	NOUN
ijpds-3747	150	32	of	of	ADP
ijpds-3747	150	33	macular	macular	ADJ
ijpds-3747	150	34	pigment	pigment	NOUN
ijpds-3747	150	35	dropout	dropout	NOUN
ijpds-3747	150	36	.	.	PUNCT
ijpds-3747	151	1	additionally	additionally	ADV
ijpds-3747	151	2	,	,	PUNCT
ijpds-3747	151	3	the	the	DET
ijpds-3747	151	4	hcq	hcq	NOUN
ijpds-3747	151	5	manufacturers	manufacturer	NOUN
ijpds-3747	151	6	claim	claim	VERB
ijpds-3747	151	7	that	that	SCONJ
ijpds-3747	151	8	hcq	hcq	NOUN
ijpds-3747	151	9	is	be	AUX
ijpds-3747	151	10	contraindicated	contraindicate	VERB
ijpds-3747	151	11	in	in	ADP
ijpds-3747	151	12	already	already	ADV
ijpds-3747	151	13	existing	exist	VERB
ijpds-3747	151	14	maculopathy	maculopathy	ADJ
ijpds-3747	151	15	conditions	condition	NOUN
ijpds-3747	151	16	[	[	X
ijpds-3747	151	17	29	29	NUM
ijpds-3747	151	18	]	]	PUNCT
ijpds-3747	151	19	.	.	PUNCT
ijpds-3747	152	1	in	in	ADP
ijpds-3747	152	2	some	some	DET
ijpds-3747	152	3	studies	study	NOUN
ijpds-3747	152	4	,	,	PUNCT
ijpds-3747	152	5	for	for	ADP
ijpds-3747	152	6	example	example	NOUN
ijpds-3747	152	7	,	,	PUNCT
ijpds-3747	152	8	hcq	hcq	NOUN
ijpds-3747	152	9	-	-	PUNCT
ijpds-3747	152	10	induced	induce	VERB
ijpds-3747	152	11	retinopathy	retinopathy	NOUN
ijpds-3747	152	12	was	be	AUX
ijpds-3747	152	13	found	find	VERB
ijpds-3747	152	14	to	to	PART
ijpds-3747	152	15	be	be	AUX
ijpds-3747	152	16	more	more	ADV
ijpds-3747	152	17	common	common	ADJ
ijpds-3747	152	18	in	in	ADP
ijpds-3747	152	19	those	those	PRON
ijpds-3747	152	20	who	who	PRON
ijpds-3747	152	21	used	use	VERB
ijpds-3747	152	22	the	the	DET
ijpds-3747	152	23	drug	drug	NOUN
ijpds-3747	152	24	for	for	ADP
ijpds-3747	152	25	longer	long	ADJ
ijpds-3747	152	26	than	than	ADP
ijpds-3747	152	27	five	five	NUM
ijpds-3747	152	28	years	year	NOUN
ijpds-3747	152	29	,	,	PUNCT
ijpds-3747	152	30	with	with	ADP
ijpds-3747	152	31	a	a	DET
ijpds-3747	152	32	prevalence	prevalence	NOUN
ijpds-3747	152	33	of	of	ADP
ijpds-3747	152	34	7.5	7.5	NUM
ijpds-3747	152	35	%	%	NOUN
ijpds-3747	152	36	,	,	PUNCT
ijpds-3747	152	37	and	and	CCONJ
ijpds-3747	152	38	between	between	ADP
ijpds-3747	152	39	20	20	NUM
ijpds-3747	152	40	and	and	CCONJ
ijpds-3747	152	41	50	50	NUM
ijpds-3747	152	42	%	%	NOUN
ijpds-3747	152	43	in	in	ADP
ijpds-3747	152	44	people	people	NOUN
ijpds-3747	152	45	who	who	PRON
ijpds-3747	152	46	used	use	VERB
ijpds-3747	152	47	it	it	PRON
ijpds-3747	152	48	for	for	ADP
ijpds-3747	152	49	longer	long	ADJ
ijpds-3747	152	50	than	than	ADP
ijpds-3747	152	51	twenty	twenty	NUM
ijpds-3747	152	52	years	year	NOUN
ijpds-3747	153	1	[	[	X
ijpds-3747	153	2	28	28	NUM
ijpds-3747	153	3	]	]	PUNCT
ijpds-3747	153	4	.	.	PUNCT
ijpds-3747	154	1	the	the	DET
ijpds-3747	154	2	results	result	NOUN
ijpds-3747	154	3	of	of	ADP
ijpds-3747	154	4	our	our	PRON
ijpds-3747	154	5	clinical	clinical	ADJ
ijpds-3747	154	6	trials	trial	NOUN
ijpds-3747	154	7	’	'	PUNCT
ijpds-3747	154	8	analysis	analysis	NOUN
ijpds-3747	154	9	revealed	reveal	VERB
ijpds-3747	154	10	that	that	SCONJ
ijpds-3747	154	11	belimumab	belimumab	NOUN
ijpds-3747	154	12	has	have	VERB
ijpds-3747	154	13	the	the	DET
ijpds-3747	154	14	highest	high	ADJ
ijpds-3747	154	15	drug	drug	NOUN
ijpds-3747	154	16	-	-	PUNCT
ijpds-3747	154	17	related	relate	VERB
ijpds-3747	154	18	adverse	adverse	ADJ
ijpds-3747	154	19	effects	effect	NOUN
ijpds-3747	154	20	that	that	PRON
ijpds-3747	154	21	range	range	VERB
ijpds-3747	154	22	from	from	ADP
ijpds-3747	154	23	gastrointestinal	gastrointestinal	ADJ
ijpds-3747	154	24	disorders	disorder	NOUN
ijpds-3747	154	25	,	,	PUNCT
ijpds-3747	154	26	and	and	CCONJ
ijpds-3747	154	27	general	general	ADJ
ijpds-3747	154	28	disorders	disorder	NOUN
ijpds-3747	154	29	,	,	PUNCT
ijpds-3747	154	30	to	to	ADP
ijpds-3747	154	31	more	more	ADV
ijpds-3747	154	32	serious	serious	ADJ
ijpds-3747	154	33	events	event	NOUN
ijpds-3747	154	34	in	in	ADP
ijpds-3747	154	35	nervous	nervous	ADJ
ijpds-3747	154	36	systems	system	NOUN
ijpds-3747	154	37	,	,	PUNCT
ijpds-3747	154	38	and	and	CCONJ
ijpds-3747	154	39	psychiatric	psychiatric	ADJ
ijpds-3747	154	40	disorders	disorder	NOUN
ijpds-3747	154	41	.	.	PUNCT
ijpds-3747	155	1	belimumab	belimumab	NOUN
ijpds-3747	155	2	treatment	treatment	NOUN
ijpds-3747	155	3	presented	present	VERB
ijpds-3747	155	4	one	one	NUM
ijpds-3747	155	5	case	case	NOUN
ijpds-3747	155	6	of	of	ADP
ijpds-3747	155	7	a	a	DET
ijpds-3747	155	8	successful	successful	ADJ
ijpds-3747	155	9	suicidal	suicidal	ADJ
ijpds-3747	155	10	attempt	attempt	NOUN
ijpds-3747	155	11	and	and	CCONJ
ijpds-3747	155	12	2	2	NUM
ijpds-3747	155	13	cases	case	NOUN
ijpds-3747	155	14	of	of	ADP
ijpds-3747	155	15	mortality	mortality	NOUN
ijpds-3747	155	16	.	.	PUNCT
ijpds-3747	156	1	the	the	DET
ijpds-3747	156	2	results	result	NOUN
ijpds-3747	156	3	of	of	ADP
ijpds-3747	156	4	our	our	PRON
ijpds-3747	156	5	study	study	NOUN
ijpds-3747	156	6	resonate	resonate	VERB
ijpds-3747	156	7	with	with	ADP
ijpds-3747	156	8	the	the	DET
ijpds-3747	156	9	belimumab	belimumab	NOUN
ijpds-3747	156	10	assessment	assessment	NOUN
ijpds-3747	156	11	of	of	ADP
ijpds-3747	156	12	safety	safety	NOUN
ijpds-3747	156	13	study	study	NOUN
ijpds-3747	156	14	(	(	PUNCT
ijpds-3747	156	15	base	base	NOUN
ijpds-3747	156	16	)	)	PUNCT
ijpds-3747	156	17	trial	trial	NOUN
ijpds-3747	156	18	and	and	CCONJ
ijpds-3747	156	19	medicines	medicine	NOUN
ijpds-3747	156	20	and	and	CCONJ
ijpds-3747	156	21	healthcare	healthcare	NOUN
ijpds-3747	156	22	products	product	NOUN
ijpds-3747	156	23	regulatory	regulatory	ADJ
ijpds-3747	156	24	agency	agency	NOUN
ijpds-3747	156	25	uk	uk	PROPN
ijpds-3747	156	26	drug	drug	NOUN
ijpds-3747	156	27	update	update	NOUN
ijpds-3747	156	28	who	who	PRON
ijpds-3747	156	29	suggested	suggest	VERB
ijpds-3747	156	30	the	the	DET
ijpds-3747	156	31	increase	increase	NOUN
ijpds-3747	156	32	in	in	ADP
ijpds-3747	156	33	psychiatric	psychiatric	ADJ
ijpds-3747	156	34	disorders	disorder	NOUN
ijpds-3747	156	35	and	and	CCONJ
ijpds-3747	156	36	mortality	mortality	NOUN
ijpds-3747	156	37	rate	rate	NOUN
ijpds-3747	156	38	.	.	PUNCT
ijpds-3747	157	1	after	after	ADP
ijpds-3747	157	2	the	the	DET
ijpds-3747	157	3	critical	critical	ADJ
ijpds-3747	157	4	analysis	analysis	NOUN
ijpds-3747	157	5	of	of	ADP
ijpds-3747	157	6	the	the	DET
ijpds-3747	157	7	results	result	NOUN
ijpds-3747	157	8	,	,	PUNCT
ijpds-3747	157	9	we	we	PRON
ijpds-3747	157	10	concluded	conclude	VERB
ijpds-3747	157	11	that	that	SCONJ
ijpds-3747	157	12	except	except	SCONJ
ijpds-3747	157	13	for	for	ADP
ijpds-3747	157	14	the	the	DET
ijpds-3747	157	15	effects	effect	NOUN
ijpds-3747	157	16	of	of	ADP
ijpds-3747	157	17	hcq	hcq	NOUN
ijpds-3747	157	18	on	on	ADP
ijpds-3747	157	19	heart	heart	NOUN
ijpds-3747	157	20	and	and	CCONJ
ijpds-3747	157	21	retinopathy	retinopathy	ADJ
ijpds-3747	157	22	,	,	PUNCT
ijpds-3747	157	23	hcq	hcq	PROPN
ijpds-3747	157	24	was	be	AUX
ijpds-3747	157	25	found	find	VERB
ijpds-3747	157	26	to	to	PART
ijpds-3747	157	27	be	be	AUX
ijpds-3747	157	28	safer	safe	ADJ
ijpds-3747	157	29	than	than	ADP
ijpds-3747	157	30	belimumab	belimumab	NOUN
ijpds-3747	157	31	.	.	PUNCT
ijpds-3747	158	1	previous	previous	ADJ
ijpds-3747	158	2	studies	study	NOUN
ijpds-3747	158	3	also	also	ADV
ijpds-3747	158	4	confirm	confirm	VERB
ijpds-3747	158	5	the	the	DET
ijpds-3747	158	6	safety	safety	NOUN
ijpds-3747	158	7	of	of	ADP
ijpds-3747	158	8	hcq	hcq	NOUN
ijpds-3747	158	9	[	[	X
ijpds-3747	158	10	17	17	NUM
ijpds-3747	158	11	]	]	PUNCT
ijpds-3747	158	12	.	.	PUNCT
ijpds-3747	159	1	the	the	DET
ijpds-3747	159	2	safe	safe	ADJ
ijpds-3747	159	3	safety	safety	NOUN
ijpds-3747	159	4	profile	profile	NOUN
ijpds-3747	159	5	of	of	ADP
ijpds-3747	159	6	hcq	hcq	NOUN
ijpds-3747	159	7	can	can	AUX
ijpds-3747	159	8	be	be	AUX
ijpds-3747	159	9	due	due	ADJ
ijpds-3747	159	10	to	to	ADP
ijpds-3747	159	11	the	the	DET
ijpds-3747	159	12	tolerability	tolerability	NOUN
ijpds-3747	159	13	of	of	ADP
ijpds-3747	159	14	the	the	DET
ijpds-3747	159	15	drug	drug	NOUN
ijpds-3747	159	16	attributed	attribute	VERB
ijpds-3747	159	17	to	to	ADP
ijpds-3747	159	18	the	the	DET
ijpds-3747	159	19	well	well	ADV
ijpds-3747	159	20	-	-	PUNCT
ijpds-3747	159	21	established	establish	VERB
ijpds-3747	159	22	and	and	CCONJ
ijpds-3747	159	23	long	long	ADJ
ijpds-3747	159	24	-	-	PUNCT
ijpds-3747	159	25	term	term	NOUN
ijpds-3747	159	26	use	use	NOUN
ijpds-3747	159	27	of	of	ADP
ijpds-3747	159	28	hcq	hcq	NOUN
ijpds-3747	159	29	in	in	ADP
ijpds-3747	159	30	the	the	DET
ijpds-3747	159	31	general	general	ADJ
ijpds-3747	159	32	population	population	NOUN
ijpds-3747	159	33	while	while	SCONJ
ijpds-3747	159	34	belimumab	belimumab	NOUN
ijpds-3747	159	35	in	in	ADP
ijpds-3747	159	36	turn	turn	NOUN
ijpds-3747	159	37	is	be	AUX
ijpds-3747	159	38	a	a	DET
ijpds-3747	159	39	novel	novel	ADJ
ijpds-3747	159	40	agent	agent	NOUN
ijpds-3747	159	41	.	.	PUNCT
ijpds-3747	160	1	however	however	ADV
ijpds-3747	160	2	,	,	PUNCT
ijpds-3747	160	3	a	a	DET
ijpds-3747	160	4	critical	critical	ADJ
ijpds-3747	160	5	point	point	NOUN
ijpds-3747	160	6	here	here	ADV
ijpds-3747	160	7	is	be	AUX
ijpds-3747	160	8	that	that	SCONJ
ijpds-3747	160	9	the	the	DET
ijpds-3747	160	10	trials	trial	NOUN
ijpds-3747	160	11	conducted	conduct	VERB
ijpds-3747	160	12	for	for	ADP
ijpds-3747	160	13	belimumab	belimumab	NOUN
ijpds-3747	160	14	also	also	ADV
ijpds-3747	160	15	showed	show	VERB
ijpds-3747	160	16	adverse	adverse	ADJ
ijpds-3747	160	17	effects	effect	NOUN
ijpds-3747	160	18	with	with	ADP
ijpds-3747	160	19	placebo	placebo	NOUN
ijpds-3747	160	20	.	.	PUNCT
ijpds-3747	161	1	thus	thus	ADV
ijpds-3747	161	2	,	,	PUNCT
ijpds-3747	161	3	the	the	DET
ijpds-3747	161	4	odds	odd	NOUN
ijpds-3747	161	5	-	-	PUNCT
ijpds-3747	161	6	ratio	ratio	NOUN
ijpds-3747	161	7	calculated	calculate	VERB
ijpds-3747	161	8	for	for	ADP
ijpds-3747	161	9	belimumab	belimumab	NOUN
ijpds-3747	161	10	showed	showed	AUX
ijpds-3747	161	11	neglected	neglect	VERB
ijpds-3747	161	12	adverse	adverse	ADJ
ijpds-3747	161	13	effects	effect	NOUN
ijpds-3747	161	14	with	with	ADP
ijpds-3747	161	15	belimumab	belimumab	NOUN
ijpds-3747	161	16	except	except	SCONJ
ijpds-3747	161	17	for	for	ADP
ijpds-3747	161	18	the	the	DET
ijpds-3747	161	19	immune	immune	ADJ
ijpds-3747	161	20	system	system	NOUN
ijpds-3747	161	21	disorder	disorder	NOUN
ijpds-3747	161	22	that	that	PRON
ijpds-3747	161	23	is	be	AUX
ijpds-3747	161	24	again	again	ADV
ijpds-3747	161	25	the	the	DET
ijpds-3747	161	26	known	known	ADJ
ijpds-3747	161	27	ae	ae	PROPN
ijpds-3747	161	28	of	of	ADP
ijpds-3747	161	29	belimumab	belimumab	NOUN
ijpds-3747	161	30	.	.	PUNCT
ijpds-3747	162	1	however	however	ADV
ijpds-3747	162	2	,	,	PUNCT
ijpds-3747	162	3	contrary	contrary	ADV
ijpds-3747	162	4	to	to	ADP
ijpds-3747	162	5	hcq	hcq	NOUN
ijpds-3747	162	6	,	,	PUNCT
ijpds-3747	162	7	belimumab	belimumab	NOUN
ijpds-3747	162	8	was	be	AUX
ijpds-3747	162	9	found	find	VERB
ijpds-3747	162	10	associated	associate	VERB
ijpds-3747	162	11	with	with	ADP
ijpds-3747	162	12	suicidal	suicidal	ADJ
ijpds-3747	162	13	attempts	attempt	NOUN
ijpds-3747	162	14	and	and	CCONJ
ijpds-3747	162	15	depression	depression	NOUN
ijpds-3747	162	16	cases	case	NOUN
ijpds-3747	162	17	which	which	PRON
ijpds-3747	162	18	makes	make	VERB
ijpds-3747	162	19	hcq	hcq	NOUN
ijpds-3747	162	20	a	a	DET
ijpds-3747	162	21	safer	safe	ADJ
ijpds-3747	162	22	drug	drug	NOUN
ijpds-3747	162	23	than	than	ADP
ijpds-3747	162	24	belimumab	belimumab	NOUN
ijpds-3747	162	25	.	.	PUNCT
ijpds-3747	163	1	conclusion	conclusion	NOUN
ijpds-3747	163	2	the	the	DET
ijpds-3747	163	3	critical	critical	ADJ
ijpds-3747	163	4	analysis	analysis	NOUN
ijpds-3747	163	5	of	of	ADP
ijpds-3747	163	6	the	the	DET
ijpds-3747	163	7	adverse	adverse	ADJ
ijpds-3747	163	8	effects	effect	NOUN
ijpds-3747	163	9	of	of	ADP
ijpds-3747	163	10	the	the	DET
ijpds-3747	163	11	drugs	drug	NOUN
ijpds-3747	163	12	,	,	PUNCT
ijpds-3747	163	13	belimumab	belimumab	NOUN
ijpds-3747	163	14	and	and	CCONJ
ijpds-3747	163	15	hcq	hcq	NOUN
ijpds-3747	163	16	showed	show	VERB
ijpds-3747	163	17	the	the	DET
ijpds-3747	163	18	safe	safe	ADJ
ijpds-3747	163	19	profile	profile	NOUN
ijpds-3747	163	20	of	of	ADP
ijpds-3747	163	21	both	both	DET
ijpds-3747	163	22	drugs	drug	NOUN
ijpds-3747	163	23	.	.	PUNCT
ijpds-3747	164	1	like	like	ADP
ijpds-3747	164	2	the	the	DET
ijpds-3747	164	3	previous	previous	ADJ
ijpds-3747	164	4	studies	study	NOUN
ijpds-3747	164	5	,	,	PUNCT
ijpds-3747	164	6	hcq	hcq	PROPN
ijpds-3747	164	7	showed	show	VERB
ijpds-3747	164	8	major	major	ADJ
ijpds-3747	164	9	adverse	adverse	ADJ
ijpds-3747	164	10	effects	effect	NOUN
ijpds-3747	164	11	on	on	ADP
ijpds-3747	164	12	the	the	DET
ijpds-3747	164	13	heart	heart	NOUN
ijpds-3747	164	14	and	and	CCONJ
ijpds-3747	164	15	eyes	eye	NOUN
ijpds-3747	164	16	,	,	PUNCT
ijpds-3747	164	17	while	while	SCONJ
ijpds-3747	164	18	belimumab	belimumab	NOUN
ijpds-3747	164	19	was	be	AUX
ijpds-3747	164	20	found	find	VERB
ijpds-3747	164	21	associated	associate	VERB
ijpds-3747	164	22	with	with	ADP
ijpds-3747	164	23	immune	immune	ADJ
ijpds-3747	164	24	system	system	NOUN
ijpds-3747	164	25	disorders	disorder	NOUN
ijpds-3747	164	26	.	.	PUNCT
ijpds-3747	165	1	though	though	SCONJ
ijpds-3747	165	2	both	both	DET
ijpds-3747	165	3	drugs	drug	NOUN
ijpds-3747	165	4	were	be	AUX
ijpds-3747	165	5	found	find	VERB
ijpds-3747	165	6	to	to	PART
ijpds-3747	165	7	be	be	AUX
ijpds-3747	165	8	safe	safe	ADJ
ijpds-3747	165	9	for	for	ADP
ijpds-3747	165	10	anti	anti	ADJ
ijpds-3747	165	11	-	-	ADJ
ijpds-3747	165	12	sle	sle	ADJ
ijpds-3747	165	13	treatment	treatment	NOUN
ijpds-3747	165	14	because	because	SCONJ
ijpds-3747	165	15	of	of	ADP
ijpds-3747	165	16	their	their	PRON
ijpds-3747	165	17	long	long	ADJ
ijpds-3747	165	18	-	-	PUNCT
ijpds-3747	165	19	term	term	NOUN
ijpds-3747	165	20	use	use	NOUN
ijpds-3747	165	21	,	,	PUNCT
ijpds-3747	165	22	hcq	hcq	PROPN
ijpds-3747	165	23	was	be	AUX
ijpds-3747	165	24	found	find	VERB
ijpds-3747	165	25	to	to	PART
ijpds-3747	165	26	be	be	AUX
ijpds-3747	165	27	safer	safe	ADJ
ijpds-3747	165	28	,	,	PUNCT
ijpds-3747	165	29	having	have	VERB
ijpds-3747	165	30	less	less	ADV
ijpds-3747	165	31	serious	serious	ADJ
ijpds-3747	165	32	adverse	adverse	ADJ
ijpds-3747	165	33	effects	effect	NOUN
ijpds-3747	165	34	than	than	ADP
ijpds-3747	165	35	belimumab	belimumab	NOUN
ijpds-3747	165	36	.	.	PUNCT
ijpds-3747	166	1	thus	thus	ADV
ijpds-3747	166	2	,	,	PUNCT
ijpds-3747	166	3	based	base	VERB
ijpds-3747	166	4	on	on	ADP
ijpds-3747	166	5	the	the	DET
ijpds-3747	166	6	results	result	NOUN
ijpds-3747	166	7	and	and	CCONJ
ijpds-3747	166	8	observed	observe	VERB
ijpds-3747	166	9	heterogeneity	heterogeneity	NOUN
ijpds-3747	166	10	in	in	ADP
ijpds-3747	166	11	the	the	DET
ijpds-3747	166	12	results	result	NOUN
ijpds-3747	166	13	,	,	PUNCT
ijpds-3747	166	14	it	it	PRON
ijpds-3747	166	15	can	can	AUX
ijpds-3747	166	16	be	be	AUX
ijpds-3747	166	17	concluded	conclude	VERB
ijpds-3747	166	18	that	that	SCONJ
ijpds-3747	166	19	for	for	ADP
ijpds-3747	166	20	result	result	NOUN
ijpds-3747	166	21	homogeneity	homogeneity	NOUN
ijpds-3747	166	22	and	and	CCONJ
ijpds-3747	166	23	to	to	PART
ijpds-3747	166	24	further	far	ADV
ijpds-3747	166	25	evaluate	evaluate	VERB
ijpds-3747	166	26	the	the	DET
ijpds-3747	166	27	safety	safety	NOUN
ijpds-3747	166	28	and	and	CCONJ
ijpds-3747	166	29	efficacy	efficacy	NOUN
ijpds-3747	166	30	of	of	ADP
ijpds-3747	166	31	belimumab	belimumab	NOUN
ijpds-3747	166	32	,	,	PUNCT
ijpds-3747	166	33	high	high	ADJ
ijpds-3747	166	34	-	-	PUNCT
ijpds-3747	166	35	quality	quality	NOUN
ijpds-3747	166	36	randomized	randomize	VERB
ijpds-3747	166	37	controlled	control	VERB
ijpds-3747	166	38	clinical	clinical	ADJ
ijpds-3747	166	39	trials	trial	NOUN
ijpds-3747	166	40	on	on	ADP
ijpds-3747	166	41	larger	large	ADJ
ijpds-3747	166	42	population	population	NOUN
ijpds-3747	166	43	sizes	size	NOUN
ijpds-3747	166	44	are	be	AUX
ijpds-3747	166	45	needed	need	VERB
ijpds-3747	166	46	.	.	PUNCT
ijpds-3747	167	1	references	reference	NOUN
ijpds-3747	167	2	1	1	NUM
ijpds-3747	167	3	.	.	PUNCT
ijpds-3747	167	4	fava	fava	PROPN
ijpds-3747	167	5	a	a	PRON
ijpds-3747	167	6	,	,	PUNCT
ijpds-3747	167	7	petri	petri	ADJ
ijpds-3747	167	8	m.	m.	NOUN
ijpds-3747	167	9	sle	sle	PROPN
ijpds-3747	167	10	.	.	PUNCT
ijpds-3747	168	1	diagnosis	diagnosis	NOUN
ijpds-3747	168	2	and	and	CCONJ
ijpds-3747	168	3	clinical	clinical	ADJ
ijpds-3747	168	4	management	management	NOUN
ijpds-3747	168	5	.	.	PUNCT
ijpds-3747	169	1	physiol	physiol	PROPN
ijpds-3747	169	2	behav	behav	PROPN
ijpds-3747	169	3	.	.	PUNCT
ijpds-3747	170	1	2020;176(3	2020;176(3	NUM
ijpds-3747	170	2	)	)	PUNCT
ijpds-3747	170	3	.	.	PUNCT
ijpds-3747	171	1	maryam	maryam	PROPN
ijpds-3747	171	2	and	and	CCONJ
ijpds-3747	171	3	ahmad	ahmad	PROPN
ijpds-3747	171	4	safety	safety	PROPN
ijpds-3747	171	5	comparison	comparison	NOUN
ijpds-3747	171	6	of	of	ADP
ijpds-3747	171	7	hydroxychloroquine	hydroxychloroquine	NOUN
ijpds-3747	171	8	and	and	CCONJ
ijpds-3747	171	9	belimumab	belimumab	NOUN
ijpds-3747	171	10	vol	vol	NOUN
ijpds-3747	171	11	2	2	NUM
ijpds-3747	171	12	|	|	NOUN
ijpds-3747	171	13	issue	issue	NOUN
ijpds-3747	171	14	1	1	NUM
ijpds-3747	171	15	|	|	ADV
ijpds-3747	171	16	jan	jan	PROPN
ijpds-3747	171	17	–	–	PUNCT
ijpds-3747	171	18	mar	mar	PROPN
ijpds-3747	171	19	2023	2023	NUM
ijpds-3747	171	20	indian	indian	PROPN
ijpds-3747	171	21	j	j	PROPN
ijpds-3747	171	22	pharm	pharm	PROPN
ijpds-3747	171	23	drug	drug	PROPN
ijpds-3747	171	24	studies	study	NOUN
ijpds-3747	171	25	|	|	ADV
ijpds-3747	171	26	10	10	NUM
ijpds-3747	171	27	2	2	NUM
ijpds-3747	171	28	.	.	PUNCT
ijpds-3747	172	1	thompson	thompson	PROPN
ijpds-3747	172	2	ra	ra	PROPN
ijpds-3747	172	3	,	,	PUNCT
ijpds-3747	172	4	haeney	haeney	PROPN
ijpds-3747	172	5	m	m	PROPN
ijpds-3747	172	6	,	,	PUNCT
ijpds-3747	172	7	reid	reid	PROPN
ijpds-3747	172	8	kbm	kbm	PROPN
ijpds-3747	172	9	,	,	PUNCT
ijpds-3747	172	10	et	et	PROPN
ijpds-3747	172	11	al	al	PROPN
ijpds-3747	172	12	,	,	PUNCT
ijpds-3747	172	13	white	white	PROPN
ijpds-3747	172	14	rhr	rhr	PROPN
ijpds-3747	172	15	,	,	PUNCT
ijpds-3747	172	16	cameron	cameron	PROPN
ijpds-3747	172	17	ah	ah	INTJ
ijpds-3747	172	18	.	.	PUNCT
ijpds-3747	173	1	a	a	DET
ijpds-3747	173	2	genetic	genetic	ADJ
ijpds-3747	173	3	defect	defect	NOUN
ijpds-3747	173	4	of	of	ADP
ijpds-3747	173	5	the	the	DET
ijpds-3747	173	6	c1q	c1q	NOUN
ijpds-3747	173	7	subcomponent	subcomponent	NOUN
ijpds-3747	173	8	of	of	ADP
ijpds-3747	173	9	complement	complement	NOUN
ijpds-3747	173	10	associated	associate	VERB
ijpds-3747	173	11	with	with	ADP
ijpds-3747	173	12	childhood	childhood	NOUN
ijpds-3747	173	13	(	(	PUNCT
ijpds-3747	173	14	immune	immune	ADJ
ijpds-3747	173	15	complex	complex	NOUN
ijpds-3747	173	16	)	)	PUNCT
ijpds-3747	173	17	nephritis	nephritis	NOUN
ijpds-3747	173	18	.	.	PUNCT
ijpds-3747	174	1	n	n	PROPN
ijpds-3747	174	2	engl	engl	PROPN
ijpds-3747	174	3	j	j	PROPN
ijpds-3747	174	4	med	med	PROPN
ijpds-3747	174	5	.	.	PUNCT
ijpds-3747	174	6	1980	1980	NUM
ijpds-3747	174	7	;	;	PUNCT
ijpds-3747	174	8	303(1	303(1	NUM
ijpds-3747	174	9	)	)	PUNCT
ijpds-3747	174	10	.	.	PUNCT
ijpds-3747	175	1	3	3	X
ijpds-3747	175	2	.	.	X
ijpds-3747	175	3	casciola	casciola	PROPN
ijpds-3747	175	4	-	-	PUNCT
ijpds-3747	175	5	rosen	rosen	PROPN
ijpds-3747	175	6	l	l	PROPN
ijpds-3747	175	7	,	,	PUNCT
ijpds-3747	175	8	rosen	rosen	PROPN
ijpds-3747	175	9	a	a	PRON
ijpds-3747	175	10	,	,	PUNCT
ijpds-3747	175	11	petri	petri	ADJ
ijpds-3747	175	12	m	m	PROPN
ijpds-3747	175	13	,	,	PUNCT
ijpds-3747	175	14	et	et	PROPN
ijpds-3747	175	15	al	al	PROPN
ijpds-3747	175	16	.	.	PROPN
ijpds-3747	175	17	surface	surface	PROPN
ijpds-3747	175	18	blebs	blebs	PROPN
ijpds-3747	175	19	on	on	ADP
ijpds-3747	175	20	apoptotic	apoptotic	ADJ
ijpds-3747	175	21	cells	cell	NOUN
ijpds-3747	175	22	are	be	AUX
ijpds-3747	175	23	sites	site	NOUN
ijpds-3747	175	24	of	of	ADP
ijpds-3747	175	25	enhanced	enhanced	ADJ
ijpds-3747	175	26	procoagulant	procoagulant	NOUN
ijpds-3747	175	27	activity	activity	NOUN
ijpds-3747	175	28	:	:	PUNCT
ijpds-3747	175	29	implications	implication	NOUN
ijpds-3747	175	30	for	for	ADP
ijpds-3747	175	31	coagulation	coagulation	NOUN
ijpds-3747	175	32	events	event	NOUN
ijpds-3747	175	33	and	and	CCONJ
ijpds-3747	175	34	antigenic	antigenic	ADJ
ijpds-3747	175	35	spread	spread	NOUN
ijpds-3747	175	36	in	in	ADP
ijpds-3747	175	37	systemic	systemic	ADJ
ijpds-3747	175	38	lupus	lupus	PROPN
ijpds-3747	175	39	erythematosus	erythematosus	PROPN
ijpds-3747	175	40	.	.	PUNCT
ijpds-3747	176	1	proc	proc	PROPN
ijpds-3747	176	2	natl	natl	PROPN
ijpds-3747	176	3	acad	acad	PROPN
ijpds-3747	176	4	sci	sci	PROPN
ijpds-3747	176	5	u	u	PROPN
ijpds-3747	176	6	s	s	NOUN
ijpds-3747	176	7	a.	a.	NOUN
ijpds-3747	176	8	1996	1996	NUM
ijpds-3747	176	9	;	;	PUNCT
ijpds-3747	176	10	93(4	93(4	NUM
ijpds-3747	176	11	)	)	PUNCT
ijpds-3747	176	12	.	.	PUNCT
ijpds-3747	177	1	4	4	X
ijpds-3747	177	2	.	.	X
ijpds-3747	177	3	guiducci	guiducci	PROPN
ijpds-3747	177	4	c	c	PROPN
ijpds-3747	177	5	,	,	PUNCT
ijpds-3747	177	6	gong	gong	PROPN
ijpds-3747	177	7	m	m	PROPN
ijpds-3747	177	8	,	,	PUNCT
ijpds-3747	177	9	xu	xu	PROPN
ijpds-3747	177	10	zg	zg	PROPN
ijpds-3747	177	11	,	,	PUNCT
ijpds-3747	177	12	et	et	PROPN
ijpds-3747	177	13	al	al	PROPN
ijpds-3747	177	14	.	.	PUNCT
ijpds-3747	178	1	tlr	tlr	PROPN
ijpds-3747	178	2	recognition	recognition	PROPN
ijpds-3747	178	3	of	of	ADP
ijpds-3747	178	4	self	self	NOUN
ijpds-3747	178	5	-	-	PUNCT
ijpds-3747	178	6	nucleic	nucleic	ADJ
ijpds-3747	178	7	acids	acid	NOUN
ijpds-3747	178	8	hampers	hamper	NOUN
ijpds-3747	178	9	glucocorticoid	glucocorticoid	ADJ
ijpds-3747	178	10	activity	activity	NOUN
ijpds-3747	178	11	in	in	ADP
ijpds-3747	178	12	lupus	lupus	NOUN
ijpds-3747	178	13	.	.	PUNCT
ijpds-3747	179	1	nature	nature	NOUN
ijpds-3747	179	2	.	.	PUNCT
ijpds-3747	180	1	2010	2010	NUM
ijpds-3747	180	2	;	;	PUNCT
ijpds-3747	180	3	465(7300	465(7300	NUM
ijpds-3747	180	4	)	)	PUNCT
ijpds-3747	180	5	.	.	PUNCT
ijpds-3747	181	1	5	5	X
ijpds-3747	181	2	.	.	X
ijpds-3747	181	3	lehmann	lehmann	PROPN
ijpds-3747	181	4	p	p	PROPN
ijpds-3747	181	5	,	,	PUNCT
ijpds-3747	181	6	homey	homey	PROPN
ijpds-3747	181	7	b.	b.	PROPN
ijpds-3747	181	8	clinic	clinic	PROPN
ijpds-3747	181	9	and	and	CCONJ
ijpds-3747	181	10	pathophysiology	pathophysiology	NOUN
ijpds-3747	181	11	of	of	ADP
ijpds-3747	181	12	photosensitivity	photosensitivity	NOUN
ijpds-3747	181	13	in	in	ADP
ijpds-3747	181	14	lupus	lupus	PROPN
ijpds-3747	181	15	erythematosus	erythematosus	NOUN
ijpds-3747	181	16	.	.	PUNCT
ijpds-3747	182	1	autoimmunity	autoimmunity	NOUN
ijpds-3747	182	2	reviews	review	NOUN
ijpds-3747	182	3	.	.	PUNCT
ijpds-3747	183	1	2009	2009	NUM
ijpds-3747	183	2	;	;	PUNCT
ijpds-3747	183	3	8	8	NUM
ijpds-3747	183	4	.	.	NOUN
ijpds-3747	184	1	6	6	NUM
ijpds-3747	184	2	.	.	X
ijpds-3747	185	1	xiong	xiong	PROPN
ijpds-3747	185	2	w	w	PROPN
ijpds-3747	185	3	,	,	PUNCT
ijpds-3747	185	4	lahita	lahita	PROPN
ijpds-3747	185	5	rg	rg	PROPN
ijpds-3747	185	6	.	.	PROPN
ijpds-3747	185	7	pragmatic	pragmatic	ADJ
ijpds-3747	185	8	approaches	approach	NOUN
ijpds-3747	185	9	to	to	ADP
ijpds-3747	185	10	therapy	therapy	NOUN
ijpds-3747	185	11	for	for	ADP
ijpds-3747	185	12	systemic	systemic	ADJ
ijpds-3747	185	13	lupus	lupus	PROPN
ijpds-3747	185	14	erythematosus	erythematosus	PROPN
ijpds-3747	185	15	.	.	PUNCT
ijpds-3747	186	1	nature	nature	PROPN
ijpds-3747	186	2	rev	rev	VERB
ijpds-3747	186	3	rheumatol	rheumatol	NOUN
ijpds-3747	186	4	.	.	PUNCT
ijpds-3747	186	5	2014	2014	NUM
ijpds-3747	186	6	;	;	PUNCT
ijpds-3747	186	7	10	10	NUM
ijpds-3747	186	8	.	.	X
ijpds-3747	187	1	7	7	X
ijpds-3747	187	2	.	.	X
ijpds-3747	187	3	danchenko	danchenko	PROPN
ijpds-3747	187	4	n	n	NUM
ijpds-3747	187	5	,	,	PUNCT
ijpds-3747	187	6	satia	satia	PROPN
ijpds-3747	187	7	ja	ja	PROPN
ijpds-3747	187	8	,	,	PUNCT
ijpds-3747	187	9	anthony	anthony	PROPN
ijpds-3747	187	10	ms	ms	PROPN
ijpds-3747	187	11	.	.	PROPN
ijpds-3747	187	12	epidemiology	epidemiology	NOUN
ijpds-3747	187	13	of	of	ADP
ijpds-3747	187	14	systemic	systemic	ADJ
ijpds-3747	187	15	lupus	lupus	PROPN
ijpds-3747	187	16	erythematosus	erythematosus	NOUN
ijpds-3747	187	17	:	:	PUNCT
ijpds-3747	187	18	a	a	DET
ijpds-3747	187	19	comparison	comparison	NOUN
ijpds-3747	187	20	of	of	ADP
ijpds-3747	187	21	worldwide	worldwide	ADJ
ijpds-3747	187	22	disease	disease	NOUN
ijpds-3747	187	23	burden	burden	NOUN
ijpds-3747	187	24	.	.	PUNCT
ijpds-3747	188	1	lupus	lupus	NOUN
ijpds-3747	188	2	.	.	PUNCT
ijpds-3747	189	1	2006	2006	NUM
ijpds-3747	189	2	;	;	PUNCT
ijpds-3747	189	3	15	15	NUM
ijpds-3747	189	4	.	.	NOUN
ijpds-3747	189	5	8	8	NUM
ijpds-3747	189	6	.	.	X
ijpds-3747	189	7	pons	pon	NOUN
ijpds-3747	189	8	-	-	PUNCT
ijpds-3747	189	9	estel	estel	PROPN
ijpds-3747	189	10	gj	gj	PROPN
ijpds-3747	189	11	,	,	PUNCT
ijpds-3747	189	12	alarcón	alarcón	PROPN
ijpds-3747	189	13	gs	gs	PROPN
ijpds-3747	189	14	,	,	PUNCT
ijpds-3747	189	15	scofield	scofield	PROPN
ijpds-3747	189	16	l	l	PROPN
ijpds-3747	189	17	,	,	PUNCT
ijpds-3747	189	18	et	et	PROPN
ijpds-3747	189	19	al	al	PROPN
ijpds-3747	189	20	.	.	PUNCT
ijpds-3747	190	1	understanding	understand	VERB
ijpds-3747	190	2	the	the	DET
ijpds-3747	190	3	epidemiology	epidemiology	NOUN
ijpds-3747	190	4	and	and	CCONJ
ijpds-3747	190	5	progression	progression	NOUN
ijpds-3747	190	6	of	of	ADP
ijpds-3747	190	7	systemic	systemic	ADJ
ijpds-3747	190	8	lupus	lupus	PROPN
ijpds-3747	190	9	erythematosus	erythematosus	PROPN
ijpds-3747	190	10	.	.	PUNCT
ijpds-3747	191	1	sem	sem	ADJ
ijpds-3747	191	2	arthritis	arthritis	NOUN
ijpds-3747	191	3	rheumatism	rheumatism	NOUN
ijpds-3747	191	4	.	.	PUNCT
ijpds-3747	192	1	2010	2010	NUM
ijpds-3747	192	2	;	;	PUNCT
ijpds-3747	192	3	39	39	NUM
ijpds-3747	192	4	.	.	NOUN
ijpds-3747	193	1	9	9	X
ijpds-3747	193	2	.	.	X
ijpds-3747	194	1	ferucci	ferucci	ADP
ijpds-3747	194	2	ed	ed	PROPN
ijpds-3747	194	3	,	,	PUNCT
ijpds-3747	194	4	johnston	johnston	PROPN
ijpds-3747	194	5	jm	jm	PROPN
ijpds-3747	194	6	,	,	PUNCT
ijpds-3747	194	7	gaddy	gaddy	PROPN
ijpds-3747	194	8	jr	jr	PROPN
ijpds-3747	194	9	,	,	PUNCT
ijpds-3747	194	10	et	et	PROPN
ijpds-3747	194	11	al	al	PROPN
ijpds-3747	194	12	.	.	PUNCT
ijpds-3747	195	1	prevalence	prevalence	NOUN
ijpds-3747	195	2	and	and	CCONJ
ijpds-3747	195	3	incidence	incidence	NOUN
ijpds-3747	195	4	of	of	ADP
ijpds-3747	195	5	systemic	systemic	ADJ
ijpds-3747	195	6	lupus	lupus	NOUN
ijpds-3747	195	7	erythematosus	erythematosus	NOUN
ijpds-3747	195	8	in	in	ADP
ijpds-3747	195	9	a	a	DET
ijpds-3747	195	10	populationbased	populationbase	VERB
ijpds-3747	195	11	registry	registry	NOUN
ijpds-3747	195	12	of	of	ADP
ijpds-3747	195	13	american	american	PROPN
ijpds-3747	195	14	indian	indian	PROPN
ijpds-3747	195	15	and	and	CCONJ
ijpds-3747	195	16	alaska	alaska	PROPN
ijpds-3747	195	17	native	native	ADJ
ijpds-3747	195	18	people	people	NOUN
ijpds-3747	195	19	,	,	PUNCT
ijpds-3747	195	20	2007	2007	NUM
ijpds-3747	195	21	-	-	SYM
ijpds-3747	195	22	2009	2009	NUM
ijpds-3747	195	23	.	.	PUNCT
ijpds-3747	196	1	arthritis	arthritis	NOUN
ijpds-3747	196	2	rheumatol	rheumatol	NOUN
ijpds-3747	196	3	.	.	PUNCT
ijpds-3747	197	1	2014	2014	NUM
ijpds-3747	197	2	;	;	PUNCT
ijpds-3747	197	3	66(9	66(9	NUM
ijpds-3747	197	4	)	)	PUNCT
ijpds-3747	197	5	.	.	PUNCT
ijpds-3747	198	1	10	10	NUM
ijpds-3747	198	2	.	.	PUNCT
ijpds-3747	198	3	helmick	helmick	PROPN
ijpds-3747	198	4	cg	cg	PROPN
ijpds-3747	198	5	,	,	PUNCT
ijpds-3747	198	6	felson	felson	NOUN
ijpds-3747	198	7	dt	dt	PROPN
ijpds-3747	198	8	,	,	PUNCT
ijpds-3747	198	9	lawrence	lawrence	PROPN
ijpds-3747	198	10	rc	rc	PROPN
ijpds-3747	198	11	,	,	PUNCT
ijpds-3747	198	12	et	et	PROPN
ijpds-3747	198	13	al	al	PROPN
ijpds-3747	198	14	.	.	PROPN
ijpds-3747	198	15	estimates	estimate	NOUN
ijpds-3747	198	16	of	of	ADP
ijpds-3747	198	17	the	the	DET
ijpds-3747	198	18	prevalence	prevalence	NOUN
ijpds-3747	198	19	of	of	ADP
ijpds-3747	198	20	arthritis	arthritis	NOUN
ijpds-3747	198	21	and	and	CCONJ
ijpds-3747	198	22	other	other	ADJ
ijpds-3747	198	23	rheumatic	rheumatic	ADJ
ijpds-3747	198	24	conditions	condition	NOUN
ijpds-3747	198	25	in	in	ADP
ijpds-3747	198	26	the	the	DET
ijpds-3747	198	27	united	united	PROPN
ijpds-3747	198	28	states	states	PROPN
ijpds-3747	198	29	.	.	PUNCT
ijpds-3747	199	1	part	part	PROPN
ijpds-3747	199	2	i.	i.	PROPN
ijpds-3747	199	3	arthritis	arthritis	PROPN
ijpds-3747	199	4	rheum	rheum	PROPN
ijpds-3747	199	5	.	.	PUNCT
ijpds-3747	200	1	2008	2008	NUM
ijpds-3747	200	2	;	;	PUNCT
ijpds-3747	201	1	58(1	58(1	X
ijpds-3747	201	2	)	)	PUNCT
ijpds-3747	201	3	.	.	PUNCT
ijpds-3747	202	1	11	11	NUM
ijpds-3747	202	2	.	.	PUNCT
ijpds-3747	203	1	parodis	parodi	NOUN
ijpds-3747	203	2	i	i	PRON
ijpds-3747	203	3	,	,	PUNCT
ijpds-3747	203	4	axelsson	axelsson	PROPN
ijpds-3747	203	5	m	m	PROPN
ijpds-3747	203	6	,	,	PUNCT
ijpds-3747	203	7	gunnarsson	gunnarsson	PROPN
ijpds-3747	203	8	i.	i.	PROPN
ijpds-3747	203	9	belimumab	belimumab	NOUN
ijpds-3747	203	10	for	for	ADP
ijpds-3747	203	11	systemic	systemic	ADJ
ijpds-3747	203	12	lupus	lupus	PROPN
ijpds-3747	203	13	erythematosus	erythematosus	NOUN
ijpds-3747	203	14	:	:	PUNCT
ijpds-3747	203	15	a	a	DET
ijpds-3747	203	16	practice	practice	NOUN
ijpds-3747	203	17	-	-	PUNCT
ijpds-3747	203	18	based	base	VERB
ijpds-3747	203	19	view	view	NOUN
ijpds-3747	203	20	.	.	PUNCT
ijpds-3747	204	1	lupus	lupus	NOUN
ijpds-3747	204	2	.	.	PUNCT
ijpds-3747	205	1	2013	2013	NUM
ijpds-3747	205	2	;	;	PUNCT
ijpds-3747	205	3	22(4	22(4	NUM
ijpds-3747	205	4	)	)	PUNCT
ijpds-3747	205	5	.	.	PUNCT
ijpds-3747	206	1	12	12	NUM
ijpds-3747	206	2	.	.	PUNCT
ijpds-3747	207	1	ss	ss	PROPN
ijpds-3747	208	1	k	k	PROPN
ijpds-3747	208	2	,	,	PUNCT
ijpds-3747	208	3	ka	ka	PROPN
ijpds-3747	209	1	k	k	PROPN
ijpds-3747	209	2	,	,	PUNCT
ijpds-3747	209	3	d	d	X
ijpds-3747	209	4	e	e	NOUN
ijpds-3747	209	5	belimumab	belimumab	NOUN
ijpds-3747	209	6	in	in	ADP
ijpds-3747	209	7	systemic	systemic	ADJ
ijpds-3747	209	8	lupus	lupus	PROPN
ijpds-3747	209	9	erythematosus	erythematosus	NOUN
ijpds-3747	209	10	:	:	PUNCT
ijpds-3747	209	11	an	an	DET
ijpds-3747	209	12	update	update	NOUN
ijpds-3747	209	13	for	for	ADP
ijpds-3747	209	14	clinicians	clinician	NOUN
ijpds-3747	209	15	.	.	PUNCT
ijpds-3747	210	1	tacd	tacd	NOUN
ijpds-3747	210	2	.	.	PROPN
ijpds-3747	210	3	2012	2012	NUM
ijpds-3747	210	4	;	;	PUNCT
ijpds-3747	210	5	3(1	3(1	NUM
ijpds-3747	210	6	)	)	PUNCT
ijpds-3747	210	7	.	.	PUNCT
ijpds-3747	211	1	13	13	NUM
ijpds-3747	211	2	.	.	X
ijpds-3747	211	3	petri	petri	PROPN
ijpds-3747	211	4	m	m	PROPN
ijpds-3747	211	5	,	,	PUNCT
ijpds-3747	211	6	stohl	stohl	PROPN
ijpds-3747	211	7	w	w	PROPN
ijpds-3747	211	8	,	,	PUNCT
ijpds-3747	211	9	chatham	chatham	PROPN
ijpds-3747	211	10	w	w	PROPN
ijpds-3747	211	11	,	,	PUNCT
ijpds-3747	211	12	et	et	PROPN
ijpds-3747	211	13	al	al	PROPN
ijpds-3747	211	14	.	.	PROPN
ijpds-3747	211	15	association	association	PROPN
ijpds-3747	211	16	of	of	ADP
ijpds-3747	211	17	plasma	plasma	PROPN
ijpds-3747	211	18	b	b	PROPN
ijpds-3747	211	19	lymphocyte	lymphocyte	ADJ
ijpds-3747	211	20	stimulator	stimulator	NOUN
ijpds-3747	211	21	levels	level	NOUN
ijpds-3747	211	22	and	and	CCONJ
ijpds-3747	211	23	disease	disease	NOUN
ijpds-3747	211	24	activity	activity	NOUN
ijpds-3747	211	25	in	in	ADP
ijpds-3747	211	26	systemic	systemic	ADJ
ijpds-3747	211	27	lupus	lupus	PROPN
ijpds-3747	211	28	erythematosus	erythematosus	PROPN
ijpds-3747	211	29	.	.	PUNCT
ijpds-3747	212	1	arthritis	arthritis	NOUN
ijpds-3747	212	2	rheum	rheum	NOUN
ijpds-3747	212	3	.	.	PUNCT
ijpds-3747	213	1	2008;58(8	2008;58(8	NUM
ijpds-3747	213	2	)	)	PUNCT
ijpds-3747	213	3	.	.	PUNCT
ijpds-3747	214	1	14	14	NUM
ijpds-3747	214	2	.	.	PUNCT
ijpds-3747	215	1	vana	vana	PROPN
ijpds-3747	215	2	dr	dr	PROPN
ijpds-3747	215	3	.	.	PROPN
ijpds-3747	215	4	belimumab	belimumab	PROPN
ijpds-3747	215	5	:	:	PUNCT
ijpds-3747	215	6	therapeutic	therapeutic	ADJ
ijpds-3747	215	7	mechanism	mechanism	NOUN
ijpds-3747	215	8	and	and	CCONJ
ijpds-3747	215	9	current	current	ADJ
ijpds-3747	215	10	status	status	NOUN
ijpds-3747	215	11	of	of	ADP
ijpds-3747	215	12	clinical	clinical	ADJ
ijpds-3747	215	13	trials	trial	NOUN
ijpds-3747	215	14	.	.	PUNCT
ijpds-3747	215	15	biomed	biome	VERB
ijpds-3747	215	16	res	re	NOUN
ijpds-3747	215	17	.	.	PUNCT
ijpds-3747	215	18	2018;29(16	2018;29(16	NUM
ijpds-3747	215	19	)	)	PUNCT
ijpds-3747	215	20	.	.	PUNCT
ijpds-3747	216	1	15	15	X
ijpds-3747	216	2	.	.	PUNCT
ijpds-3747	217	1	fda	fda	PROPN
ijpds-3747	217	2	.	.	PUNCT
ijpds-3747	218	1	highlights	highlight	NOUN
ijpds-3747	218	2	of	of	ADP
ijpds-3747	218	3	prescribing	prescribe	VERB
ijpds-3747	218	4	information	information	NOUN
ijpds-3747	218	5	these	these	DET
ijpds-3747	218	6	highlights	highlight	NOUN
ijpds-3747	218	7	do	do	AUX
ijpds-3747	218	8	not	not	PART
ijpds-3747	218	9	include	include	VERB
ijpds-3747	218	10	all	all	DET
ijpds-3747	218	11	the	the	DET
ijpds-3747	218	12	information	information	NOUN
ijpds-3747	218	13	needed	need	VERB
ijpds-3747	218	14	to	to	PART
ijpds-3747	218	15	use	use	VERB
ijpds-3747	218	16	benlysta	benlysta	NOUN
ijpds-3747	218	17	safely	safely	ADV
ijpds-3747	218	18	and	and	CCONJ
ijpds-3747	218	19	effectively	effectively	ADV
ijpds-3747	218	20	.	.	PUNCT
ijpds-3747	219	1	see	see	VERB
ijpds-3747	219	2	full	full	ADJ
ijpds-3747	219	3	prescribing	prescribing	NOUN
ijpds-3747	219	4	information	information	NOUN
ijpds-3747	219	5	for	for	ADP
ijpds-3747	219	6	benlysta	benlysta	NOUN
ijpds-3747	219	7	.	.	PUNCT
ijpds-3747	220	1	benlysta	benlysta	NOUN
ijpds-3747	220	2	(	(	PUNCT
ijpds-3747	220	3	belimumab	belimumab	NOUN
ijpds-3747	220	4	)	)	PUNCT
ijpds-3747	220	5	for	for	ADP
ijpds-3747	220	6	injection	injection	NOUN
ijpds-3747	220	7	,	,	PUNCT
ijpds-3747	220	8	for	for	ADP
ijpds-3747	220	9	intravenous	intravenous	ADJ
ijpds-3747	220	10	use	use	NOUN
ijpds-3747	220	11	benlysta	benlysta	NOUN
ijpds-3747	220	12	(	(	PUNCT
ijpds-3747	220	13	belimumab	belimumab	NOUN
ijpds-3747	220	14	)	)	PUNCT
ijpds-3747	220	15	injection	injection	NOUN
ijpds-3747	220	16	,	,	PUNCT
ijpds-3747	220	17	for	for	ADP
ijpds-3747	220	18	subcutaneous	subcutaneous	ADJ
ijpds-3747	220	19	use	use	NOUN
ijpds-3747	220	20	.	.	PUNCT
ijpds-3747	221	1	2022;15(12	2022;15(12	NUM
ijpds-3747	221	2	)	)	PUNCT
ijpds-3747	222	1	;	;	PUNCT
ijpds-3747	222	2	available	available	ADJ
ijpds-3747	222	3	from	from	ADP
ijpds-3747	222	4	:	:	PUNCT
ijpds-3747	222	5	www.fda.gov/medwatch	www.fda.gov/medwatch	PROPN
ijpds-3747	222	6	16	16	NUM
ijpds-3747	222	7	.	.	PUNCT
ijpds-3747	222	8	benlysta	benlysta	NOUN
ijpds-3747	222	9	|	|	CCONJ
ijpds-3747	222	10	ema	ema	PROPN
ijpds-3747	222	11	.	.	PUNCT
ijpds-3747	223	1	2022	2022	NUM
ijpds-3747	223	2	;	;	PUNCT
ijpds-3747	223	3	15(12	15(12	NUM
ijpds-3747	223	4	)	)	PUNCT
ijpds-3747	223	5	.	.	PUNCT
ijpds-3747	224	1	available	available	ADJ
ijpds-3747	224	2	from	from	ADP
ijpds-3747	224	3	:	:	PUNCT
ijpds-3747	224	4	https://www	https://www	PROPN
ijpds-3747	224	5	.	.	PUNCT
ijpds-3747	225	1	ema.europa.eu/en/medicines/human/epar/benlysta	ema.europa.eu/en/medicines/human/epar/benlysta	PROPN
ijpds-3747	225	2	17	17	NUM
ijpds-3747	225	3	.	.	PUNCT
ijpds-3747	226	1	ponticelli	ponticelli	PROPN
ijpds-3747	226	2	c	c	PROPN
ijpds-3747	226	3	,	,	PUNCT
ijpds-3747	226	4	moroni	moroni	PROPN
ijpds-3747	226	5	g.	g.	PROPN
ijpds-3747	226	6	hydroxychloroquine	hydroxychloroquine	PROPN
ijpds-3747	226	7	in	in	ADP
ijpds-3747	226	8	systemic	systemic	ADJ
ijpds-3747	226	9	lupus	lupus	NOUN
ijpds-3747	226	10	erythematosus	erythematosus	NOUN
ijpds-3747	226	11	(	(	PUNCT
ijpds-3747	226	12	sle	sle	PROPN
ijpds-3747	226	13	)	)	PUNCT
ijpds-3747	226	14	.	.	PUNCT
ijpds-3747	227	1	expert	expert	ADJ
ijpds-3747	227	2	opinion	opinion	NOUN
ijpds-3747	227	3	on	on	ADP
ijpds-3747	227	4	drug	drug	NOUN
ijpds-3747	227	5	safety	safety	NOUN
ijpds-3747	227	6	.	.	PUNCT
ijpds-3747	228	1	2017	2017	NUM
ijpds-3747	228	2	;	;	PUNCT
ijpds-3747	229	1	16	16	NUM
ijpds-3747	229	2	.	.	NOUN
ijpds-3747	230	1	18	18	NUM
ijpds-3747	230	2	.	.	PUNCT
ijpds-3747	231	1	james	james	PROPN
ijpds-3747	231	2	ja	ja	PROPN
ijpds-3747	231	3	,	,	PUNCT
ijpds-3747	231	4	kim	kim	PROPN
ijpds-3747	231	5	-	-	PUNCT
ijpds-3747	231	6	howard	howard	PROPN
ijpds-3747	231	7	xr	xr	PROPN
ijpds-3747	231	8	,	,	PUNCT
ijpds-3747	231	9	bruner	bruner	PROPN
ijpds-3747	231	10	bf	bf	PROPN
ijpds-3747	231	11	,	,	PUNCT
ijpds-3747	231	12	et	et	PROPN
ijpds-3747	231	13	al	al	PROPN
ijpds-3747	231	14	.	.	PROPN
ijpds-3747	231	15	hydroxychloroquine	hydroxychloroquine	PROPN
ijpds-3747	231	16	sulfate	sulfate	NOUN
ijpds-3747	231	17	treatment	treatment	NOUN
ijpds-3747	231	18	is	be	AUX
ijpds-3747	231	19	associated	associate	VERB
ijpds-3747	231	20	with	with	ADP
ijpds-3747	231	21	later	later	ADJ
ijpds-3747	231	22	onset	onset	NOUN
ijpds-3747	231	23	of	of	ADP
ijpds-3747	231	24	systemic	systemic	ADJ
ijpds-3747	231	25	lupus	lupus	PROPN
ijpds-3747	231	26	erythematosus	erythematosus	NOUN
ijpds-3747	231	27	.	.	PUNCT
ijpds-3747	232	1	lupus	lupus	NOUN
ijpds-3747	232	2	.	.	PUNCT
ijpds-3747	233	1	2007;16(6	2007;16(6	NUM
ijpds-3747	233	2	)	)	PUNCT
ijpds-3747	233	3	.	.	PUNCT
ijpds-3747	234	1	19	19	NUM
ijpds-3747	234	2	.	.	PUNCT
ijpds-3747	234	3	kaiser	kaiser	PROPN
ijpds-3747	234	4	r	r	PROPN
ijpds-3747	234	5	,	,	PUNCT
ijpds-3747	234	6	cleveland	cleveland	PROPN
ijpds-3747	234	7	cm	cm	PROPN
ijpds-3747	234	8	,	,	PUNCT
ijpds-3747	234	9	criswell	criswell	PROPN
ijpds-3747	234	10	la	la	PROPN
ijpds-3747	234	11	.	.	PUNCT
ijpds-3747	235	1	risk	risk	NOUN
ijpds-3747	235	2	and	and	CCONJ
ijpds-3747	235	3	protective	protective	ADJ
ijpds-3747	235	4	factors	factor	NOUN
ijpds-3747	235	5	for	for	ADP
ijpds-3747	235	6	thrombosis	thrombosis	NOUN
ijpds-3747	235	7	in	in	ADP
ijpds-3747	235	8	systemic	systemic	ADJ
ijpds-3747	235	9	lupus	lupus	PROPN
ijpds-3747	235	10	erythematosus	erythematosus	NOUN
ijpds-3747	235	11	:	:	PUNCT
ijpds-3747	235	12	results	result	VERB
ijpds-3747	235	13	from	from	ADP
ijpds-3747	235	14	a	a	DET
ijpds-3747	235	15	large	large	ADJ
ijpds-3747	235	16	,	,	PUNCT
ijpds-3747	235	17	multi	multi	ADJ
ijpds-3747	235	18	-	-	ADJ
ijpds-3747	235	19	ethnic	ethnic	ADJ
ijpds-3747	235	20	cohort	cohort	NOUN
ijpds-3747	235	21	.	.	PUNCT
ijpds-3747	236	1	ann	ann	PROPN
ijpds-3747	236	2	rheum	rheum	PROPN
ijpds-3747	236	3	dis	dis	PROPN
ijpds-3747	236	4	.	.	PUNCT
ijpds-3747	237	1	2009;68(2	2009;68(2	NUM
ijpds-3747	237	2	)	)	PUNCT
ijpds-3747	237	3	.	.	PUNCT
ijpds-3747	238	1	20	20	NUM
ijpds-3747	238	2	.	.	PUNCT
ijpds-3747	239	1	ruiz	ruiz	NOUN
ijpds-3747	239	2	-	-	PUNCT
ijpds-3747	239	3	irastorza	irastorza	PROPN
ijpds-3747	239	4	g	g	PROPN
ijpds-3747	239	5	,	,	PUNCT
ijpds-3747	239	6	ramos	ramo	NOUN
ijpds-3747	239	7	-	-	NOUN
ijpds-3747	239	8	casals	casal	NOUN
ijpds-3747	239	9	m	m	PROPN
ijpds-3747	239	10	,	,	PUNCT
ijpds-3747	239	11	brito	brito	PROPN
ijpds-3747	239	12	-	-	PROPN
ijpds-3747	239	13	zeron	zeron	PROPN
ijpds-3747	239	14	p	p	PROPN
ijpds-3747	239	15	,	,	PUNCT
ijpds-3747	239	16	et	et	PROPN
ijpds-3747	239	17	al	al	PROPN
ijpds-3747	239	18	.	.	PROPN
ijpds-3747	240	1	clinical	clinical	ADJ
ijpds-3747	240	2	efficacy	efficacy	NOUN
ijpds-3747	240	3	and	and	CCONJ
ijpds-3747	240	4	side	side	NOUN
ijpds-3747	240	5	effects	effect	NOUN
ijpds-3747	240	6	of	of	ADP
ijpds-3747	240	7	antimalarials	antimalarial	NOUN
ijpds-3747	240	8	in	in	ADP
ijpds-3747	240	9	systemic	systemic	ADJ
ijpds-3747	240	10	lupus	lupus	PROPN
ijpds-3747	240	11	erythematosus	erythematosus	NOUN
ijpds-3747	240	12	:	:	PUNCT
ijpds-3747	240	13	a	a	DET
ijpds-3747	240	14	systematic	systematic	ADJ
ijpds-3747	240	15	review	review	NOUN
ijpds-3747	240	16	.	.	PUNCT
ijpds-3747	241	1	69	69	NUM
ijpds-3747	241	2	,	,	PUNCT
ijpds-3747	241	3	annals	annal	NOUN
ijpds-3747	241	4	of	of	ADP
ijpds-3747	241	5	the	the	DET
ijpds-3747	241	6	rheumatic	rheumatic	ADJ
ijpds-3747	241	7	diseases	disease	NOUN
ijpds-3747	241	8	.	.	PUNCT
ijpds-3747	242	1	2010	2010	NUM
ijpds-3747	242	2	.	.	PUNCT
ijpds-3747	243	1	21	21	NUM
ijpds-3747	243	2	.	.	PUNCT
ijpds-3747	243	3	akarsu	akarsu	PROPN
ijpds-3747	243	4	s.	s.	PROPN
ijpds-3747	243	5	hydroxychloroquine	hydroxychloroquine	PROPN
ijpds-3747	243	6	:	:	PUNCT
ijpds-3747	243	7	from	from	ADP
ijpds-3747	243	8	pharmacological	pharmacological	ADJ
ijpds-3747	243	9	profile	profile	NOUN
ijpds-3747	243	10	to	to	PART
ijpds-3747	243	11	neglected	neglect	VERB
ijpds-3747	243	12	adverse	adverse	ADJ
ijpds-3747	243	13	reactions	reaction	NOUN
ijpds-3747	243	14	.	.	PUNCT
ijpds-3747	244	1	j	j	PROPN
ijpds-3747	244	2	basic	basic	ADJ
ijpds-3747	244	3	clin	clin	PROPN
ijpds-3747	244	4	heal	heal	PROPN
ijpds-3747	244	5	sci	sci	PROPN
ijpds-3747	244	6	j	j	PROPN
ijpds-3747	244	7	basic	basic	ADJ
ijpds-3747	244	8	clin	clin	PROPN
ijpds-3747	244	9	heal	heal	PROPN
ijpds-3747	244	10	sci	sci	PROPN
ijpds-3747	244	11	.	.	PROPN
ijpds-3747	244	12	2020	2020	NUM
ijpds-3747	244	13	;	;	PUNCT
ijpds-3747	244	14	4	4	NUM
ijpds-3747	244	15	:	:	PUNCT
ijpds-3747	244	16	205–11	205–11	NUM
ijpds-3747	244	17	.	.	PROPN
ijpds-3747	244	18	22	22	NUM
ijpds-3747	244	19	.	.	PUNCT
ijpds-3747	245	1	szumilas	szumila	NOUN
ijpds-3747	245	2	m.	m.	NOUN
ijpds-3747	245	3	explaining	explain	VERB
ijpds-3747	245	4	odds	odd	NOUN
ijpds-3747	245	5	ratios	ratio	NOUN
ijpds-3747	245	6	.	.	PUNCT
ijpds-3747	246	1	j	j	PROPN
ijpds-3747	246	2	can	can	AUX
ijpds-3747	246	3	acad	acad	VERB
ijpds-3747	246	4	child	child	NOUN
ijpds-3747	246	5	adolesc	adolesc	NOUN
ijpds-3747	246	6	psychiatry	psychiatry	NOUN
ijpds-3747	246	7	.	.	PUNCT
ijpds-3747	247	1	2010	2010	NUM
ijpds-3747	247	2	;	;	PUNCT
ijpds-3747	247	3	19(3	19(3	NUM
ijpds-3747	247	4	):	):	PUNCT
ijpds-3747	247	5	227	227	NUM
ijpds-3747	247	6	.	.	NUM
ijpds-3747	247	7	23	23	NUM
ijpds-3747	247	8	.	.	PUNCT
ijpds-3747	248	1	wang	wang	PROPN
ijpds-3747	248	2	h	h	PROPN
ijpds-3747	248	3	,	,	PUNCT
ijpds-3747	248	4	chow	chow	PROPN
ijpds-3747	248	5	sc	sc	PROPN
ijpds-3747	248	6	,	,	PUNCT
ijpds-3747	248	7	li	li	PROPN
ijpds-3747	248	8	g.	g.	PROPN
ijpds-3747	248	9	on	on	ADP
ijpds-3747	248	10	sample	sample	NOUN
ijpds-3747	248	11	size	size	NOUN
ijpds-3747	248	12	calculation	calculation	NOUN
ijpds-3747	248	13	based	base	VERB
ijpds-3747	248	14	on	on	ADP
ijpds-3747	248	15	odds	odd	NOUN
ijpds-3747	248	16	ratio	ratio	NOUN
ijpds-3747	248	17	in	in	ADP
ijpds-3747	248	18	clinical	clinical	ADJ
ijpds-3747	248	19	trials	trial	NOUN
ijpds-3747	248	20	.	.	PUNCT
ijpds-3747	249	1	j	j	PROPN
ijpds-3747	249	2	biopharm	biopharm	PROPN
ijpds-3747	249	3	stat	stat	PROPN
ijpds-3747	249	4	.	.	PUNCT
ijpds-3747	250	1	2002	2002	NUM
ijpds-3747	250	2	;	;	PUNCT
ijpds-3747	250	3	12(4	12(4	NUM
ijpds-3747	250	4	):	):	PUNCT
ijpds-3747	250	5	471	471	NUM
ijpds-3747	250	6	–	–	PUNCT
ijpds-3747	250	7	83	83	NUM
ijpds-3747	250	8	.	.	X
ijpds-3747	251	1	24	24	NUM
ijpds-3747	251	2	.	.	PUNCT
ijpds-3747	252	1	davis	davis	PROPN
ijpds-3747	252	2	ls	ls	PROPN
ijpds-3747	252	3	,	,	PUNCT
ijpds-3747	252	4	hutcheson	hutcheson	PROPN
ijpds-3747	252	5	j	j	PROPN
ijpds-3747	252	6	,	,	PUNCT
ijpds-3747	252	7	mohan	mohan	PROPN
ijpds-3747	252	8	c.	c.	PROPN
ijpds-3747	252	9	the	the	DET
ijpds-3747	252	10	role	role	NOUN
ijpds-3747	252	11	of	of	ADP
ijpds-3747	252	12	cytokines	cytokine	NOUN
ijpds-3747	252	13	in	in	ADP
ijpds-3747	252	14	the	the	DET
ijpds-3747	252	15	pathogenesis	pathogenesis	NOUN
ijpds-3747	252	16	and	and	CCONJ
ijpds-3747	252	17	treatment	treatment	NOUN
ijpds-3747	252	18	of	of	ADP
ijpds-3747	252	19	systemic	systemic	ADJ
ijpds-3747	252	20	lupus	lupus	PROPN
ijpds-3747	252	21	erythematosus	erythematosus	PROPN
ijpds-3747	252	22	.	.	PUNCT
ijpds-3747	253	1	j	j	PROPN
ijpds-3747	253	2	interf	interf	PROPN
ijpds-3747	253	3	cytokine	cytokine	NOUN
ijpds-3747	253	4	res	re	NOUN
ijpds-3747	253	5	.	.	PUNCT
ijpds-3747	253	6	2011	2011	NUM
ijpds-3747	253	7	;	;	PUNCT
ijpds-3747	253	8	31(10	31(10	NUM
ijpds-3747	253	9	):	):	PUNCT
ijpds-3747	253	10	781	781	NUM
ijpds-3747	253	11	.	.	NUM
ijpds-3747	254	1	25	25	NUM
ijpds-3747	254	2	.	.	PUNCT
ijpds-3747	255	1	wise	wise	PROPN
ijpds-3747	255	2	lm	lm	PROPN
ijpds-3747	255	3	,	,	PUNCT
ijpds-3747	255	4	stohl	stohl	NOUN
ijpds-3747	255	5	w.	w.	NOUN
ijpds-3747	255	6	belimumab	belimumab	NOUN
ijpds-3747	255	7	and	and	CCONJ
ijpds-3747	255	8	rituximab	rituximab	NOUN
ijpds-3747	255	9	in	in	ADP
ijpds-3747	255	10	systemic	systemic	ADJ
ijpds-3747	255	11	lupus	lupus	PROPN
ijpds-3747	255	12	erythematosus	erythematosus	NOUN
ijpds-3747	255	13	:	:	PUNCT
ijpds-3747	255	14	a	a	DET
ijpds-3747	255	15	tale	tale	NOUN
ijpds-3747	255	16	of	of	ADP
ijpds-3747	255	17	two	two	NUM
ijpds-3747	255	18	b	b	NOUN
ijpds-3747	255	19	cell	cell	NOUN
ijpds-3747	255	20	-	-	PUNCT
ijpds-3747	255	21	targeting	target	VERB
ijpds-3747	255	22	agents	agent	NOUN
ijpds-3747	255	23	.	.	PUNCT
ijpds-3747	256	1	front	front	PROPN
ijpds-3747	256	2	med	med	PROPN
ijpds-3747	256	3	.	.	PUNCT
ijpds-3747	256	4	2020	2020	NUM
ijpds-3747	256	5	;	;	PUNCT
ijpds-3747	256	6	7	7	X
ijpds-3747	256	7	.	.	NOUN
ijpds-3747	256	8	26	26	NUM
ijpds-3747	256	9	.	.	PUNCT
ijpds-3747	256	10	dubey	dubey	PROPN
ijpds-3747	256	11	ak	ak	PROPN
ijpds-3747	256	12	,	,	PUNCT
ijpds-3747	256	13	handu	handu	PROPN
ijpds-3747	256	14	ss	ss	PROPN
ijpds-3747	256	15	,	,	PUNCT
ijpds-3747	256	16	dubey	dubey	PROPN
ijpds-3747	256	17	s	s	PROPN
ijpds-3747	256	18	,	,	PUNCT
ijpds-3747	256	19	et	et	PROPN
ijpds-3747	256	20	al	al	PROPN
ijpds-3747	256	21	.	.	PROPN
ijpds-3747	256	22	belimumab	belimumab	PROPN
ijpds-3747	256	23	:	:	PUNCT
ijpds-3747	256	24	first	first	ADJ
ijpds-3747	256	25	targeted	target	VERB
ijpds-3747	256	26	biological	biological	ADJ
ijpds-3747	256	27	treatment	treatment	NOUN
ijpds-3747	256	28	for	for	ADP
ijpds-3747	256	29	systemic	systemic	ADJ
ijpds-3747	256	30	lupus	lupus	PROPN
ijpds-3747	256	31	erythematosus	erythematosus	PROPN
ijpds-3747	256	32	.	.	PUNCT
ijpds-3747	257	1	j	j	PROPN
ijpds-3747	257	2	pharmacol	pharmacol	PROPN
ijpds-3747	257	3	pharmacother	pharmacother	PROPN
ijpds-3747	257	4	.	.	PUNCT
ijpds-3747	258	1	2011	2011	NUM
ijpds-3747	258	2	;	;	PUNCT
ijpds-3747	258	3	2(4	2(4	NUM
ijpds-3747	258	4	):	):	PUNCT
ijpds-3747	259	1	317	317	NUM
ijpds-3747	259	2	.	.	NUM
ijpds-3747	259	3	27	27	NUM
ijpds-3747	259	4	.	.	PUNCT
ijpds-3747	260	1	dima	dima	PROPN
ijpds-3747	260	2	a	a	PRON
ijpds-3747	260	3	,	,	PUNCT
ijpds-3747	260	4	jurcut	jurcut	ADJ
ijpds-3747	260	5	c	c	NOUN
ijpds-3747	260	6	,	,	PUNCT
ijpds-3747	260	7	chasset	chasset	ADJ
ijpds-3747	260	8	f	f	NOUN
ijpds-3747	260	9	,	,	PUNCT
ijpds-3747	260	10	et	et	PROPN
ijpds-3747	260	11	al	al	PROPN
ijpds-3747	260	12	.	.	PROPN
ijpds-3747	260	13	hydroxychloroquine	hydroxychloroquine	PROPN
ijpds-3747	260	14	in	in	ADP
ijpds-3747	260	15	systemic	systemic	ADJ
ijpds-3747	260	16	lupus	lupus	PROPN
ijpds-3747	260	17	erythematosus	erythematosus	NOUN
ijpds-3747	260	18	:	:	PUNCT
ijpds-3747	260	19	overview	overview	NOUN
ijpds-3747	260	20	of	of	ADP
ijpds-3747	260	21	current	current	ADJ
ijpds-3747	260	22	knowledge	knowledge	NOUN
ijpds-3747	260	23	.	.	PUNCT
ijpds-3747	261	1	ther	ther	INTJ
ijpds-3747	261	2	adv	adv	INTJ
ijpds-3747	261	3	musculoskelet	musculoskelet	NOUN
ijpds-3747	261	4	dis	dis	PROPN
ijpds-3747	261	5	.	.	PUNCT
ijpds-3747	262	1	2022	2022	NUM
ijpds-3747	262	2	;	;	PUNCT
ijpds-3747	263	1	14	14	NUM
ijpds-3747	263	2	.	.	NOUN
ijpds-3747	263	3	28	28	NUM
ijpds-3747	263	4	.	.	PUNCT
ijpds-3747	264	1	frederick	frederick	PROPN
ijpds-3747	264	2	w	w	PROPN
ijpds-3747	264	3	,	,	PUNCT
ijpds-3747	264	4	marmor	marmor	NOUN
ijpds-3747	264	5	mf	mf	NOUN
ijpds-3747	264	6	.	.	PROPN
ijpds-3747	264	7	rates	rate	NOUN
ijpds-3747	264	8	and	and	CCONJ
ijpds-3747	264	9	predictors	predictor	NOUN
ijpds-3747	264	10	of	of	ADP
ijpds-3747	264	11	hydroxychloroquine	hydroxychloroquine	ADJ
ijpds-3747	264	12	retinal	retinal	ADJ
ijpds-3747	264	13	toxicity	toxicity	NOUN
ijpds-3747	264	14	in	in	ADP
ijpds-3747	264	15	patients	patient	NOUN
ijpds-3747	264	16	with	with	ADP
ijpds-3747	264	17	rheumatoid	rheumatoid	NOUN
ijpds-3747	264	18	arthritis	arthritis	NOUN
ijpds-3747	264	19	and	and	CCONJ
ijpds-3747	264	20	systemic	systemic	ADJ
ijpds-3747	264	21	lupus	lupus	PROPN
ijpds-3747	264	22	erythematosus	erythematosus	PROPN
ijpds-3747	264	23	.	.	PUNCT
ijpds-3747	265	1	arthritis	arthritis	NOUN
ijpds-3747	265	2	care	care	NOUN
ijpds-3747	265	3	res	re	NOUN
ijpds-3747	265	4	(	(	PUNCT
ijpds-3747	265	5	hoboken	hoboken	PROPN
ijpds-3747	265	6	)	)	PUNCT
ijpds-3747	265	7	.	.	PUNCT
ijpds-3747	266	1	2010	2010	NUM
ijpds-3747	266	2	;	;	PUNCT
ijpds-3747	267	1	62(6	62(6	NUM
ijpds-3747	267	2	):	):	PUNCT
ijpds-3747	267	3	775–84	775–84	NOUN
ijpds-3747	267	4	.	.	PUNCT
ijpds-3747	268	1	29	29	NUM
ijpds-3747	268	2	.	.	PUNCT
ijpds-3747	269	1	yusuf	yusuf	PROPN
ijpds-3747	269	2	ih	ih	PROPN
ijpds-3747	269	3	,	,	PUNCT
ijpds-3747	269	4	sharma	sharma	PROPN
ijpds-3747	269	5	s	s	PROPN
ijpds-3747	269	6	,	,	PUNCT
ijpds-3747	269	7	luqmani	luqmani	ADJ
ijpds-3747	269	8	r	r	NOUN
ijpds-3747	269	9	,	,	PUNCT
ijpds-3747	269	10	et	et	PROPN
ijpds-3747	269	11	al	al	PROPN
ijpds-3747	269	12	.	.	PROPN
ijpds-3747	269	13	hydroxychloroquine	hydroxychloroquine	PROPN
ijpds-3747	269	14	retinopathy	retinopathy	NOUN
ijpds-3747	269	15	.	.	PUNCT
ijpds-3747	270	1	eye	eye	NOUN
ijpds-3747	270	2	(	(	PUNCT
ijpds-3747	270	3	lond	lond	PROPN
ijpds-3747	270	4	)	)	PUNCT
ijpds-3747	270	5	.	.	PUNCT
ijpds-3747	271	1	2017	2017	NUM
ijpds-3747	271	2	;	;	PUNCT
ijpds-3747	271	3	31(6	31(6	NUM
ijpds-3747	271	4	):	):	PUNCT
ijpds-3747	271	5	828–45	828–45	NUM
ijpds-3747	271	6	.	.	PUNCT
ijpds-3747	272	1	how	how	SCONJ
ijpds-3747	272	2	to	to	PART
ijpds-3747	272	3	cite	cite	VERB
ijpds-3747	272	4	this	this	DET
ijpds-3747	272	5	article	article	NOUN
ijpds-3747	272	6	:	:	PUNCT
ijpds-3747	272	7	maryam	maryam	PROPN
ijpds-3747	272	8	z	z	PROPN
ijpds-3747	272	9	,	,	PUNCT
ijpds-3747	272	10	ahmad	ahmad	PROPN
ijpds-3747	272	11	a.	a.	PROPN
ijpds-3747	272	12	comprehensive	comprehensive	ADJ
ijpds-3747	272	13	analysis	analysis	NOUN
ijpds-3747	272	14	and	and	CCONJ
ijpds-3747	272	15	critical	critical	ADJ
ijpds-3747	272	16	review	review	NOUN
ijpds-3747	272	17	of	of	ADP
ijpds-3747	272	18	randomized	randomized	ADJ
ijpds-3747	272	19	clinical	clinical	ADJ
ijpds-3747	272	20	trials	trial	NOUN
ijpds-3747	272	21	on	on	ADP
ijpds-3747	272	22	safety	safety	NOUN
ijpds-3747	272	23	profiling	profiling	NOUN
ijpds-3747	272	24	of	of	ADP
ijpds-3747	272	25	hcq	hcq	NOUN
ijpds-3747	272	26	and	and	CCONJ
ijpds-3747	272	27	belimumab	belimumab	NOUN
ijpds-3747	272	28	.	.	PUNCT
ijpds-3747	273	1	indian	indian	PROPN
ijpds-3747	273	2	j	j	PROPN
ijpds-3747	273	3	pharm	pharm	PROPN
ijpds-3747	273	4	drug	drug	PROPN
ijpds-3747	273	5	studies	study	NOUN
ijpds-3747	273	6	.	.	PUNCT
ijpds-3747	274	1	2023	2023	NUM
ijpds-3747	274	2	;	;	PUNCT
ijpds-3747	274	3	2(1	2(1	NUM
ijpds-3747	274	4	)	)	PUNCT
ijpds-3747	274	5	5	5	NUM
ijpds-3747	274	6	-	-	SYM
ijpds-3747	274	7	10	10	NUM
ijpds-3747	274	8	.	.	PUNCT
ijpds-3747	275	1	funding	funding	NOUN
ijpds-3747	275	2	:	:	PUNCT
ijpds-3747	275	3	none	none	NOUN
ijpds-3747	275	4	conflict	conflict	NOUN
ijpds-3747	275	5	of	of	ADP
ijpds-3747	275	6	interest	interest	NOUN
ijpds-3747	275	7	:	:	PUNCT
ijpds-3747	275	8	none	none	NOUN
ijpds-3747	275	9	stated	state	VERB
ijpds-3747	275	10	http://www.fda.gov/medwatch	http://www.fda.gov/medwatch	NOUN